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Editorial on the Research Topic
C1q: A Molecular Bridge to Innate and Adaptive Immunity
Human C1q is the first recognition molecule of the classical pathway of the complement system.
C1q has a characteristic tulip-like overall structure where N-terminal collagenous stalk (CLR) is
followed by a heterotrimeric C-terminal globular (gC1q) domain (1). After recognizing IgG- and
IgM-containing immune complexes, C1q, in association with C1r and C1s complexes that yields
C1 molecule, triggers the classical pathway activation. However, C1q is not always dependent
on the binding of IgG or IgM to target ligands, primarily pathogens, in order to perform its
duty as a potent innate immune molecule. In addition to being the key molecule of the classical
pathway, C1q has a broad range of functions that includes clearance of apoptotic and necrotic cells,
sustenance of pregnancy, recognition of pathogens in an antibody-independent manner, immune
cell modulation, and pruning of excess synapse during development (2, 3). The importance of C1q
in human health has been highlighted by its involvement in a number of pathological conditions
including lupus nephritis, a number of inflammatory disorders, Alzheimer’s disease, prion disease,
and cancer.
During the course of last two decades, a number of proteins of diverse origin have been shown
to contain at least gC1q-like domain, and hence, identification of a C1q family (4). The structural
analysis of one of such C1q family member, adiponectin, revealed that the three dimensional
structure of gC1q domain was remarkably conserved and overlapped with tumor necrosis factor
(TNF) and related molecules, hence, recognition of a C1q-TNF superfamily (2, 5–7).
Although the main source of the local synthesis of C1q has been attributed to the potent antigen
presenting cells such as monocyte/macrophages and dendritic cells, various types of proliferating
and non-proliferating cells including malignant cells can also be included in the list of C1q
producers (8). Thus, there are a number of functions assigned to C1q that are not reliant on
complement activation mediated by C1q (non-complement functions of C1q) (3).
In this volume, which highlights the structural and functional complexities of human C1q, Reid,
one of the pioneers in the field, has elegantly provided a historical account of the field, together
with many unanswered questions and what the future holds for this truly remarkable complement
protein. Another review by Lu and Kishore examines important features of C1 complex that can
perform exciting and unexpected functions without involving complement activation (9). For
instance, C1q, when bound to the Frizzled receptors, leads to activation of C1s, which cleaves
lipoprotein receptor-related protein (LRP) 6 to trigger aging-associated Wnt receptor signaling
(10). C1q binds to apoptotic cells and the activated C1 proteases cleave nuclear antigens (11).
The diversity of C1q ligands and C1 protease substrates makes C1q as well as C1 complex quite
a versatile recognition and effector machinery beyond the territory of complement activation. In
the continuing theme of structural and functional versatility of C1q, Ghebrehiwet et al. emphasize
the modular organization of the gC1q domain, revealing the ‘secret of this functional diversity’,
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based on the modularity within each chain of gC1q domain
i.e., ghA, ghB, and ghC modules (12). Within the gC1q
domain, which is composed of the C-terminal ends of A,
B and C chains, this review makes arguments for the
A-chain (ghA) to be most versatile module in terms of
ligand binding (11).
C1q binding to the CH2 domain of antigen-bound IgG
and subsequent classical pathway activation depends on its
close proximity to the Fc region of adjacent IgG; C1q does
not bind (or binds with very weak affinity to) circulating IgG
monomers. Crucially, IgG CH2 domains contain Asp-297 N-
linked glycan amenable to extension by terminal galactose and
sialic acid residues. Using recombinant variants of CD20-specific
monoclonal antibody, rituximab, Perschke et al. demonstrate
that Fc-galactose enhances complement fixation, but only for
IgG1 and IgG4, proposing a novel strategy to manipulate
complement fixing ability of therapeutic antibodies. Following
up on the C1q-IgG subclass interaction, Lilienthal et al.
have examined the parallel between murine IgG1 and human
IgG4 subclasses (both capable of inhibiting hexamerisation of
IgG1 and IgG3 and subsequent C1q binding and classical
pathway activation). The authors show that murine IgG1
suppresses IgG2a-mediated classical pathway activation. Since
IgG subclass is of great importance in pathophysiology, galactose
and sialic acid manipulation has therapeutic implications
(Lilienthal et al.). It is worthwhile to note that allergen-based
immunotherapy in allergic patients can give rise to increased
IgG4 levels while dampening specific IgE production; thus, IgG4
subclass polarization also circumvents the classical pathways
activation in allergen-desensitized patients (13). Moving on from
immunoglobulin interaction of C1q to non-immune ligands,
Donat et al. examined the implications of C1q binding to
cholesterol crystals as well as von Willebrand factor (vWF)
with respect to cholesterol crystal clearance by macrophages.
Curiously, vWF bound cholesterol crystals via C1q, and
the tripartite complex upregulated phagocytic and sensing
receptors, such as MerTK, LRP-1, SR-A1, CD14, LAIR1, and
PD-L1. vWF seems to interfere with the phagocytosis of
cholesterol crystals and C1q complex. An assessment of pro-
inflammatory cytokines revealed that vWF binding to C1q
suppresses inflammatory response by macrophages, which may
be relevant in atherosclerosis. El-Shamy et al. have reviewed
the role of complement (and C1q) in chronic hepatitis C virus
(HCV) infection and cryoglobulinemia since HCV-triggered
complement activation is involved in liver fibrosis and type
II cryoglobulinemia.
The last two papers, from Roberta Bulla group, in the
volume allude to the fascinating involvement of C1q in tumor
(Agostinis et al.; Mangogna et al.). C1q is expressed in the
microenvironment of various types of human tumors, including
melanoma, prostate, mesothelioma, and ovarian cancers. C1q
promotes tumor by encouraging their adhesion, migration, and
proliferation in addition to angiogenesis and metastasis (14).
Agostinis et al. now report that C1q is found in good amounts
in the tumor microenvironment of asbestos-induced malignant
pleural mesothelioma (MPM), where it can interact with
hyaluronic acid (HA), an abundant tumor microenvironment
component. C1q-HA interaction seems to work in favor of
MPM cells, suggesting that C1q can be exploited by tumor
for its progression and invasion. In another study, Mangogna
et al. have used Oncomine and UALCAN database in order
to ascertain whether the transcriptional expression of the C1q
three chains has a prognostic relevance for glioma. C1q is
known to be expressed in the central nervous system and is
considered a precipitation factor for neurodegeneration and
neuroinflammation (9). The study reveals a positive correlation
between higher levels of C1q expression and unfavorable
prognosis in a diverse grade of gliomas, thus, giving a new
dimension to C1q research. How C1q interacts with brain tumor
cells as well as microglia and astrocytes in the context of gliomas
needs further investigation.
In conclusion, C1q remains an ever important molecule of
complement and innate immunity. Its versatility and modularity
seem to offer enormous physiological potential; sometimes,
it can be exploited by pathogens and tumor to their end.
Future research in the area of cancer, pregnancy, aging and
neuroinflammation is going to throw many pleasant surprises.
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complement component c1q: 
Historical Perspective of a 
Functionally versatile, and 
structurally Unusual, serum  
Protein
Kenneth B. M. Reid*
Green Templeton College, University of Oxford, Oxford, United Kingdom
Complement component C1q plays an important recognition role in adaptive, and 
innate, immunity through its ability to interact, via its six globular head regions, with 
both immunoglobulin and non-immunoglobulin activators of the complement system, 
and also in the clearance of cell debris, and by playing a role in regulation of cellular 
events by interacting with a wide range of cell surface molecules. The presence of 
collagen-like triple-helical structures within C1q appears crucial to the presentation, and 
multivalent binding, of the globular heads of C1q to targets, and also to its association 
with the proenzyme complex of C1r2–C1s2, to yield the C1 complex. The possible role 
that movement of these collagen-like structures may play in the activation of the C1 
complex is a controversial area, with there still being no definitive answer as to how the 
first C1r proenzyme molecule becomes activated within the C1 complex, thus allowing 
it to activate proenzyme C1s, and initiate and the consequent cascade of events in the 
activation of the classical pathway of complement. The globular heads of C1q are similar 
to domains found within the tumor necrosis factor (TNF) superfamily of proteins, and 
have been shown to bind to a very wide range of ligands. In addition to its well-defined 
roles in infection and immunity, a variety of other functions associated with C1q include 
possible roles, in the development of problems in the central nervous system, which 
occur with aging, and perhaps in the regulation of tumor growth.
Keywords: c1 activation, c1q, collagen-like structure, globular heads, tumor, aging
iNtrODUctiON
Prior to the formal proof of there being collagen triple helical coils present in the C1q molecule 
(1), it was considered that any such protein, containing that feature, would most likely play a 
structural role in the extracellular matrix, rather than being involved in the activation of the serum 
complement system. However, it was recognized by the end of the 1980s (2) that several other 
serum proteins, besides subcomponent C1q, also contained collagen-like regions, and were likely 
to be involved in innate immune effector systems. These included the C-type lectins, mannose 
binding lectin (MBL), bovine conglutinin, and lung surfactant protein A. Indeed, conglutinin was 
the first vertebrate lectin to be characterized by virtue of its function to promote the agglutination of 
Abbreviations: CTRP, C1q/TNF-related protein; MBL, mannose binding lectin; MASP, MBL-associated serine protease; CRP, 
C-reactive protein; CUB, complement C1r/C1s; EGF, epidermal growth factor.
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erythrocytes coated with activated complement components (3). 
It is now known that there are several other lectins, such as lung 
surfactant protein D, the ficolins, bovine serum lectin (CL-43), 
in a growing family of proteins, containing collagen-like regions, 
which are involved in immune defense. These proteins display a 
wide range of binding properties, via both their globular head 
regions and collagen-like triple-helical regions, toward both 
immune targets and cell surface receptors, and participate as a 
bridge between innate and adaptive immunity. The relationship 
between structure and function with respect to the many bind-
ing, and triggering, properties shown by C1q should now be able 
to be even more fully explored, by generation of point mutation 
variants, as a result of the major achievement of expression of the 
functionally fully active recombinant form of this structurally 
complicated protein, composed of three different polypeptide 
chains, in a mammalian cell system (4).
eArLY cHArActerisAtiON OF c1q AND 
DeterMiNAtiON OF its strUctUre
The C1q protein was first, accurately, described, in 1961, as a 
“11s thermolabile serum protein which precipitates γ-globulin 
aggregates and participates in immune hemolysis” (5), thus 
highlighting interesting features about its large size (460 kDa) 
and its binding properties (to immunoglobulin complexes) and 
its function (participation in complement-mediated hemolysis 
of antibody-coated red cells). In 1963 (6), Lepow et al. showed 
that the euglobulin fraction of human serum (proteins precipi-
tated in low ionic strength buffer, at pH 5.5), which contained 
the then defined C1component of the complement system, 
could be fractionated, by ion-exchange chromatography into 
three subcomponents, which were defined, based on their elu-
tion positions, from an ion-exchange column, as C1q, C1r, and 
C1s (the nomenclature a, b, and c…, was not used, in order 
to avoid confusion with “C1a” being used for activated C1, at 
that time). It was shown that all three subcomponents were 
required to reconstitute the original C1 hemolytic activity. The 
use of further, new at the time, techniques, such as gel-filtration 
and affinity chromatography, allowed the isolation of highly 
purified C1q to perform detailed structural and functional 
studies.
Early chemical studies of human and rabbit C1q (7–9) pro-
vided indirect evidence, that there may be collagen-like struc-
tures within C1q, since it was reported to have an unusually high 
glycine content, to contain hydroxylysine and hydroxyproline 
residues and disaccharide units of glucosylgalactose, linked to 
the hyroxylysine, and it had a great susceptibility to collagenase. 
The first direct evidence for the presence of collagen-like amino 
acid sequence, in the A-chain of C1q, was obtained in 1974 (10).
It was then shown that the preparation of the collagen-like 
regions of C1q could be achieved by limited proteolysis of the 
native intact molecule with pepsin at pH 4.45, when the globular 
head regions are digested to small peptides leaving the large, 
190  kDa, collagen-like region intact (1, 11). When viewed in 
the electron microscope, C1q was seen to be composed of six 
peripheral globular “head” regions, which are each joined by a 
collagen-like connecting strand to a fibril-like central portion/
stalk (1, 12, 13).
All these studies allowed the proposal in 1976 (14) of a 
molecular model for subcomponent C1q (Figure 1), which has 
stood the test of time, in which there are 18 polypeptide chains 
(6 A-, 6 B-, and 6 C-chains), with disulfide bonds between the A- 
and B- chains and between pairs of C-chains, thus yielding nine 
dimers, i.e., six A–B dimers and three C–C dimers. The complete 
derived amino acid sequence, along with the characterization and 
organization of the genes encoding all three polypeptide chains of 
C1q, was completed in 1991 (15).
The use of large fragments of C1q, produced by limited pro-
teolysis with either collagenase or pepsin, allowed direct analysis 
of the primary functions of the two, very different, regions of the 
C1q molecule. The globular head regions of C1q can be prepared 
by digestion with collagenase at pH 7.4, which results in a rapid 
loss of C1q function (9, 16). These preparations, of globular 
subunits, with a molecular weight of 47 kDa, were shown (16) to 
be able to inhibit the binding of C1q to IgG immune complexes, 
thus directly illustrating the role of the peripheral globular 
head units in binding to IgG. The determination of the crystal 
structure globular head region of C1q (17), also prepared by 
collagenase digestion, has shown that it is an almost spherical 
heterotrimeric assembly (formed from the C-terminals regions 
of the A-, B-, and C-chains). This allowed molecular modeling 
with two of its well-defined targets, IgG and C-reactive protein 
(CRP), providing a good illustration of the versatility in binding 
shown by the globular heads of C1q. It was found that the large 
pepsin-resistant fragment of C1q, composed almost entirely of 
the collagen-like regions of the molecule, could act as an effective 
inhibitor of the reconstitution of whole C1 hemolytic activity, 
when intact C1q was mixed with C1r2–C1s2 (18). It has also 
been found that the pepsin-resistant fragment of C1q bound the 
unactivated C1r2–C1s2 with approximately the same strength 
as that of the intact C1q molecule (19). These studies provided 
strong functional evidence that the C1r2–C1s2 interacted primar-
ily with the collagen-like regions of C1q, and was in agreement 
with electron microscopy studies of the whole C1 complex 
(20) which suggested that the C1r2–C1s2 binding site is in the 
middle of the triple helical collagen-like regions, close to where 
the collagen-like strands diverge out from the central fibril-like 
region (Figure 1).
strUctUrAL MODeL OF tHe 
cOLLAGeN-LiKe reGiON OF c1q,  
its iNterActiON WitH c1r2–c1s2  
AND POssiBLe iNvOLveMeNt iN 
ActivAtiON OF tHe c1 cOMPLeX
It is clear from electron microscopy, and all the protein struc-
tural data available, that the 460  kDa C1q molecule adopts 
a bouquet of flowers shape, comprising six heterotrimeric 
collagen-like triple helices that associate in their N-terminal 
half to form a fibril-like structure, then diverge at a bend, or 
“kink,” approximately half-way along the collagen-like region to 
form six individual “stalks,” each terminating in a C-terminal 
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FiGUre 1 | Proposed model of human subcomponent C1q. Initial diagram, drawn up in 1975, of the first published molecular model proposed for C1q (14). It was 
based on the electron microscopy measurements (12, 13), the amino acid sequencing and physical chemistry results of the studies on the 190 kDa pepsin-resistant 
fragment of C1q (1, 11), and the assumption that the collagen-like regions in the A-, B-, and C-chains of C1q form a triple helical collagen-type structure (denoted 
by the solid, broken, and wavy lines), and the C-terminal approximately 140 amino acid residues, in each of the A-, B-, and C-chains, form a globular heterotrimeric 
structure of 47.8 kDa (which should, more correctly, be shown as globular units, rather than the tulip-flower shapes as shown in the initial diagram). From the 
dimensions shown, which are averages of those given in the electron microscopy studies (12), the following comparisons can be made: length of collagen-like  
fiber plus fibril-like end piece = 115 + 112 = 227 Å. Length of triple helix proposed from amino acid sequences = 78 × 2.9 = 226 Å (2.9 Å is the rise of collagen 
helix per residue, and there are 78 residues, over the collagen-like regions, in each of the three chains of C1q).
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heterotrimeric globular domain (Figure 1). Other serum pro-
teins (MBLs, Ficolins) have an overall structural similarity to 
C1q, and also interact with their associated proteases via their 
collagen-like regions. It was noted that, on alignment of all 
the known, collagen-like sequences, present in various chains 
of C1q, MBL, and Ficolin, from several species, that there is a 
conserved amino acid sequence (-Hyp-Gly-Lys-Xaa-Gly-Pro-) 
in which it was shown, by site-directed mutagenesis of Ficolin 
A, that the lysine is the critical residue involved in interaction 
with its associated protease, MASP (21). This conserved site, 
also present in each of the three chains of C1q, is six Gly-Xaa-
Yaa- triplets C-terminal to the link region of C1q, and it was, 
therefore, postulated that this is likely to be the major binding 
site for C1r2–C1s2 on the stalks of C1q (21). The importance of 
these lysine residues, in the B- and C- chains, and lesser extent 
the A-chain, for the interaction, and activation, of C1r2–C1s2 was 
elegantly formally proved by their mutation to alanine residues, 
with consequent loss-of-function. Further studies, involving 
the determination of the crystal structure of the CUB1-EGF-
CUB2 region of C1s bound to a short triple helical collagen-like 
peptide, containing the important conserved lysine, provided 
strong direct structural evidence for the proposed, precise 
interaction site between C1q and C1r2–C1s2 (22).
c1q tArGets AND recePtOrs
The structural studies on globular head region of C1q show that 
it is member of the growing TNF superfamily (17, 23) and func-
tional studies indicate that the C1q heads can bind a wide range 
of self and non-self ligands.
Primary targets for the six globular heads of C1q are the mul-
tiple Fc regions presented within immune complexes, contain-
ing IgG or IgM antibodies. Well-defined non-immunoglobulin 
tar gets, for the C1q heads, include CRP (24) and pentraxin 3, 
as well as lipopolysaccharides and bacterial porins. Apoptotic 
cells also form a major target (25–28), probably via C1q binding 
to phosphatidylserine and double-stranded DNA, thus allow-
ing for opsonization and effective phagocytosis of cell debris 
(28, 29), and enhancement of the immunosuppressive nature 
of the apoptotic cells.
One of the first molecules to be proposed as a receptor, for 
the globular heads of C1q, is gC1qR/p33 (30), but this molecule, 
although found at the surface of a wide variety of cells, has been 
shown to be present mainly in mitochondria. Since it does not 
possess a transmembrane domain, or a lipid anchor, it appears 
that it must always have to interact with other cell surface mol-
ecules, in order to modulate intracellular functions.
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After activation of the C1 complex, control of the activated 
C1r and C1s is mediated by C1-inhibitor which forms covalent 
complexes with both the activated C1r and C1s, rapidly remov-
ing them from the C1 complex, leaving the entire collagen-like 
region of C1q free to interact with potential cell-surface recep-
tors. One such putative receptor was a 60 kDa molecule isolated 
from Raji cell membranes (31) and to bind to the collagen 
region of C1q (and thus became to be defined as cC1qR). The 
NH2-terminal amino acid sequence of this molecule, isolated 
from endothelial cells (32) was found to be identical to that 
of C1qR, isolated from tonsil lymphocytes, and also to that of 
calreticulin (33) The C1qR preparation was shown to bind to 
the collagen-like regions of C1q and several other collagen-like 
proteins (34). Although cC1qR/C1qR/calreticulin can be found 
at the surfaces of many cell types, it is primarily found in the 
endoplasmic reticulum, and lacks a transmembrane domain. 
Thus care must be taken to define both gC1qR and cC1qR as 
“C1q-binding proteins,” rather than as true “transmembrane 
receptors.”
A wide range of other cell surface molecules have now been 
shown to interact with the either the heads, or collagen-like 
regions, of C1q, and occasionally with both. This area has recently 
been thoroughly and critically reviewed (35). The putative recep-
tors were neatly placed in four main groups, based on the nature 
of their extracellular domains: (i) large multi-modular ectodo-
mains involved in interaction with multiple ligands (CR1, LRP1, 
and the scavenger receptors SR-F1 and SR-F3); (ii) integrins 
(α2-β1 and CR3/αM-β2); (iii) Ig-like receptors (RAGE, LAIR-1, 
and CD33); and (iv) the C-type lectin receptors, DC-SIGN and 
DC-SIGNR.
cUrreNt vieWs As tO tHe 
MecHANisM OF ActivAtiON  
OF tHe c1 cOMPLeX
There are two recent publications (36, 37), which address the 
possible mechanism by which it is considered the first steps of 
activation of proenzyme C1r, within the C1 complex, may take 
place, and they come to significantly different conclusions.
One view, the intramolecular view (36), is that the proenzyme 
C1r domains must be linked together at the center of the hetero-
tetramer C1r2–C1s2, and that autoactivation of proenzyme C1r 
occurs as soon as the contacts between the catalytic domains 
are broken, possibly by flexibility of the collagen-like stems of 
C1q, on contact of the globular heads with targets. These con-
clusions derive from previous observations and are associated 
with studies on the interactions, in solution, of fragments (the 
CUB1-EGF-CUB2 fragments) of the C1r and C1s involved in 
binding to C1q, and also the crystal structure of a complex of 
these two fragments, allowing a close analysis of the C1s–C1r 
interface.
The other view, the intermolecular view (37), is that the C1 
complex cross-activates by interacting with neighboring C1 
complexes. This model is based on synchrotron small-angle 
X-ray scattering and electron microscopy studies and concludes 
that there is cleavage of proenzyme C1r in one C1 complex by 
C1r in a neighboring complex. The two models differ in the 
precise manner in which the C1r2–C1s2 complex is aligned, at 
the now generally agreed position, within the collagenous stems 
of C1q. The intramolecular view (36) does appear to be consist-
ent with the first-order kinetics, reported by several groups, as 
regards activation of C1, but does rely upon contacts between 
the catalytic domains being broken, presumably by flexibility 
within the collagen-like stems on binding to a target, and this has 
not yet been formally proven. However, although collagen-like 
structures are seen as structures with only limited flexibility, all 
observations, made on C1q, suggest flexible hinge movements 
at the level of the “kink,” which can modulate the positions of 
the six globular domains. The intermolecular model (37), in 
which the serine protease domains are considered to be located 
at the periphery of the C1r2–C1s2 complex is consistent with the 
fact that C1 can bind to a structurally diverse range of activa-
tors and allows intermolecular activation between neighboring 
complexes. In a very recent study (38), cryo-electron microscopy 
was used to examine C1 bound to monoclonal antibodies, and 
the authors observed heterogeneous structures of single and 
clustered C1-IgG1 hexamer complexes. This structural data was 
interpreted as showing that, upon antibody binding, the C1q 
arms condense, thus inducing rearrangements of the C1r2–C1s2 
complex and tilting the C1q’s cone-shaped stalk. Thus, it was 
concluded that C1r perhaps could activate C1s within single, 
strained C1 complexes, or between neighboring C1 complexes 
on surfaces (38).
Final general acceptance of one, or other, or indeed a combina-
tion, of these models of C1 activation awaits further study.
BiOsYNtHesis OF c1q, LeveLs OF 
serUM c1q, AND DeFicieNcY OF c1q
Unlike most of the other complement proteins, which are mainly 
liver-derived, C1q is synthesized primarily by macrophages, 
as demonstrated by the fact that bone marrow transplantation 
from wild-type mice into C1q-deficient (C1qa−/−) mice was able 
to restore the normal serum levels of C1q (39). This finding has 
prompted the use of hematopoietic stem cell transplantation 
in the remarkable, and successful, treatment of genetic human 
C1q deficiency (40), a condition where the complete absence of 
C1q function results in an exceptionally high risk of severe lupus 
erythematosus, and complications with skin and renal diseases.
In normal healthy human sera, C1q has a concentration of 
around 80 µg/ml (0.17 µM in serum) and thus is present in an 
approximately equimolar concentration to that of the C1r2–C1s2 
complex (50 µg/ml of each of C1r and C1s, thus 0.15 µM C1r2–
C1s2). The concentration of C1q rises quite steeply with aging, 
reaching 161  µg/ml, in the 60–81, years old, age group (41). 
It is of interest that the high serum level of C1q could surprisingly 
be reduced by a simple exercise regime, down to almost normal 
levels, which may be of significance to health in old age. An even 
more dramatic (10- to 300-fold) increase in C1q levels in the cen-
tral nervous system (42) has been reported in mouse and human 
brains, with the highest levels being seen in close pro ximity to 
synapses and central regions of the brain. Interestingly, aged 
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C1q-deficient (C1qa−/−) mice showed less cognitive and memory 
decline in hippocampus-dependent behavior tests compared to 
their wild-type litter mates (42), thus suggesting that C1q may 
play a role in the development of problems, during aging, that 
are seen in the central nervous system.
Another connection between C1q and aging has emerged 
from studies that there is elevated Wnt signaling in aging mice, 
where muscle stem cells have an increased tendency to fibro-
blastic differentiation (43). This appears to be due to the binding 
by one, or more, serum factors, to the Frizzled family of cell 
surface receptors, thus causing Wnt receptor signaling, and one 
Frizzled-binding protein has been identified to be C1q (44). It 
has been proposed that when C1q, within the C1 complex, binds 
to Frizzled then activated C1s cleaves lipoprotein receptor 6, 
which is a Wnt co-receptor, thus causing canonical Wnt signaling 
and accelerated aging. Thus abnormally high, or low, C1q levels 
could possibly play a role in various disease states caused by 
increased, or decreased, Wnt signaling.
There is growing evidence that C1q binding, leading to activa-
tion of C1r and C1s, may trigger other functions via activated 
C1s, unexpectedly, cleaving nuclear antigens, MHC class I 
antigens and other proteins, as well as lipoprotein receptor 6 
(45), thus opening up many other biological pathways, besides 
complement, that may be triggered by C1q binding.
A recent study has indicated that non-bone marrow derived, 
locally synthesized, C1q may play a role in enhancing tumor 
progression by facilitating cancer cell seeding and promoting 
angiogenesis (46). This view is consistent with the finding of 
increased expression of the genes of the chains of C1q correlating 
with a poor prognosis in breast cancers (47). However, other 
studies indicate that C1q may possibly play a protective role, as 
judged by C1q-enhanced apoptosis in an ovarian cancer cell line 
(48) and activation of a tumor suppressor to induce apoptosis in 
prostate cancer cells (49).
cONcLUsiON
There have been many publications concerned with the possible 
functions mediated via C1q, since its first description in 1961 
(5), and perhaps more the use of the well-defined, globular, 
and collagen-like, fragments of C1q, monoclonal antibodies 
against these regions, or mutation of specific residues within 
the expressed whole recombinant molecule (4), will aid under-
standing of how exactly C1q is interacting with the large number 
of targets (in the region of 100, to date) to which it has been 
reported to bind. The use of a short synthetic triple helical pep-
tide, corresponding to the binding site on C1q for the C1r2–C1s2 
complex (22), to define the precise region on C1q involved in 
that interaction shows there are possibly many other innovative 
ways, utilizing protein fragments or synthetic peptides, which 
will allow the exploration, at the molecular level, of the functions 
of this versatile molecule.
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Complement C1 is the defining component of the classical pathway. Within the 
C1qC1r2C1s2 complex, C1q functions as a molecular scaffold for C1r2C1s2 and C1q 
binding to its ligands activates these two serine proteases. The classic C1q ligands are 
antigen-bound antibodies and activated C1s cleaves C4 and C2 to initiate the comple-
ment cascade. Recent studies suggest broad C1 functions beyond the complement 
system. C1q binds to the Frizzled receptors to activate C1s, which cleaves lipoprotein 
receptor-related protein 6 to trigger aging-associated Wnt receptor signaling. C1q binds 
to apoptotic cells and the activated C1 proteases cleave nuclear antigens. C1s also 
cleaves MHC class I molecule and potentially numerous other proteins. The diversity of 
C1q ligands and C1 protease substrates renders C1 complex versatile and modular so 
that it can adapt to multiple molecular and cellular processes besides the complement 
system.
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iNTRODUCTiON
In invertebrates, complement takes primitive forms represented only by a few ancestral proteins 
and lacks the specificity and sophisticated regulatory mechanisms of the modern vertebrate comple-
ment system (1–4). In mammals and other higher vertebrates, the complement system is a complex 
protein network consisting of nearly 30 plasma proteins. Depending on the target ligands, the 
complement system can be activated via the classical, alternative, or lectin pathway (5, 6). In the 
case of microbial pathogens, each complement pathway is triggered through a specific mechanism 
of ligand recognition, and collectively, the three pathways empower this humoral system to defend 
against a broad range of microorganisms. Like the blood coagulation system, the complement 
system is orchestrated around serine proteases, which are sequentially activated and then cleave 
specific downstream complement proteins so as to amplify a cascade of reactions (2, 7, 8). These 
reactions generate proteolytic or lytic complexes, opsonins, and peptide anaphylatoxins leading to 
lysis, inflammation, and clearance of opsonized microorganisms (Figure 1) (5, 6). The complement 
serine proteases exhibit conserved active sites (2). However, these proteases are highly specific for 
substrate within the complement network, and this appears vital for the directional amplification of 
each pathway.
Abbreviations: IGFBP5, insulin-like growth factor-binding protein 5; MBL, mannose-binding lectin; MASP, MBL-associated 
serine protease; SLE, systemic lupus erythematosus; LRP6, low-density lipoprotein receptor-related protein 6; CRP, C-reactive 
protein; DC, dendritic cell; NPM1, nucleophosmin-1; CTRP, C1q/TNF-related protein.
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FigURe 1 | The complement protein and protease network. The complement system operates via three target recognition pathways: the classical, alternative, 
and lectin pathways. All pathways recognize microorganisms and apoptotic cells and the recognition subcomponents are in green. Upon its triggering via any of the 
three pathways, the complement acts through three effector reactions: the C8-C9 lytic or membrane attack complex, the soluble C3a and C5a anaphylatoxins (blue 
color), and surface-bound C3b, C4b, and further proteolytic fragment opsonins (orange color with green asterisk). All three pathways converge at the C3 component 
and complement reactions are essentially amplified through cascades of serine proteases (red color). MBL, mannose-binding lectin; MASPs, MBL-associated serine 
proteases; fB, factor B; fD, factor D; fI, factor I; fH, factor H. Homozygous deficiency of C1q, C1r/C1s, or C4 is causally associated with systemic lupus 
erythematosus (SLE) pathogenesis. Genetic C2 deficiency also increases risk for SLE and some other autoimmune diseases.
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The complement system is commonly intended for host defense 
against microbial infections. Recent data suggest that various non-
microbial exogenous and endogenous structures, such as apop-
totic cells, may also trigger the complement pathways (Figure 1) 
(9–15). The effects of complement activation may also be delivered 
through a segment of the system rather than in its entirety. For 
example, the C1s protease apparently cleaves non-complement 
proteins including MHC class I molecule, insulin-like growth 
factor binding protein 5 (IGFBP5), Wnt receptor, and nuclear 
autoantigens (16–21). This suggests that, besides its well-defined 
roles in host defense, the C1 complex functions broadly, e.g., in 
tissue homeostasis and immune tolerance. In fact, invertebrates 
also utilize their limited repertoire of complement components to 
clear damaged cells as well as invading microorganisms (22, 23).
THe CLASSiCAL PATHwAY iS A  
MODeRN PATHwAY
During evolution from invertebrates leading up to higher verte-
brates, animals experienced major genomic expansion through 
gene duplication and recombination, with higher vertebrates 
acquiring increased complexity in genomic composition, body 
plans, and physiological processes (24). The expansion of the 
complement system in higher vertebrates includes at least two 
aspects: the generation of paralogous complement elements and 
the formation of a new classical pathway. In invertebrates, ancestral 
complement elements were only found that were equivalent to the 
alternative and lectin pathways, including ancestral C3, factor B, 
mannose-binding lectin (MBL), ficolins, and MBL-associated 
serine proteases (MASPs) (3, 22). The modern C1 complex, 
i.e., the C1qC1r2C1s2 pentamer that defines the recognition 
component of the classical pathway, only appeared from jawed 
vertebrates when adaptive immunity also emerged.
Complement gene duplication and recombination are evident 
in higher vertebrates, e.g., factor B/C2, C3/C4/C5, and C6/C7/
C8/C9 (3). Evidence that the C1r and C1s genes are relatively 
modern duplications is also suggested by their close genomic 
proximity and structural similarity (8, 25). This is even more 
striking with the three C1q subunit genes, i.e., C1qA, C1qB, 
and C1qC, which are clustered within a 30-kb genomic region 
separated by short intergenic sequences (26, 27) (Figure 2). The 
closest C1q-related protein in invertebrates is encoded by a single 
gene and the C1q-like protein recognizes carbohydrates rather 
14
FigURe 2 | Schematic illustration of the cellular origin of C1q, its assembly, and three distinct modular functions of C1 complex. C1q is an abundant 
plasma protein. It can be produced broadly in tissues by macrophages and DCs, which also produce C1r/C1s. C1q is formed from three similar but distinct 
subunits, i.e., A, B, and C, and the order of assembly is illustrated. Inter-subunit disulfide bonds (purple bars) and the collagen-like helices defines the sorting of the 
three subunits within the C1q polypeptide. In the serum, C1q is associated with the serine protease proenzyme tetramer C1r2C1s2 to form the C1 complex. In this 
complex, C1q binds to diverse targets that activate the serine proteases and the proteases trigger effector reactions by cleaving specific substrate. Three 
physiological contexts are highlighted in which the C1 complex is known to play a role. When C1q binds to antibodies on microbial pathogens, the activated C1s 
cleaves complement C4 and C2 to initiate the proteolytic cascade. When C1q binds to Frizzled, activated C1s cleaves lipoprotein receptor-related protein 6 to 
cause canonical Wnt signaling and accelerated aging. When C1q binds to apoptotic cells, the activated C1s cleaves apoptotic cellular antigens to reduce 
autoimmunogenicity. The red arrows indicate C1s cleavage of the specific substrate.
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than immunoglobulins (4). The emergence of the C1 complex 
or the classical pathway in higher vertebrates, which coincided 
with the appearance of the adaptive immune system, makes it a 
“modern” arm of the complement system that responds to anti-
bodies and other self, non-self, and altered self targets.
C1q DeFiCieNCY iS A STRONg CAUSe 
OF SYSTeMiC LUPUS eRYTHeMATOSUS 
(SLe) PATHOgeNeSiS
Genetic deficiency has been identified for many complement 
proteins and, in most cases, this increases susceptibility to 
infections (28, 29). Deficiency in some complement proteins is 
also associated with other pathological conditions and particu-
larly strong associations were found between deficiencies in the 
early components of the complement classical pathway and the 
autoimmune disease SLE (29–34). The association is especially 
strong with homozygous C1 and C4 deficiencies. Functionally, 
C1q binding to ligands causes C1r and then C1s activation and 
the activated C1s cleaves C4 and then C2 to initiate the further 
downstream complement cascade (5, 6). C2 deficiency is more 
prevalent than C1 and C4 deficiencies, but it has substantially 
less effect and is also associated with other autoimmune diseases 
(31, 32). However, C1q, C1r/C1s, and C4 deficiencies cause 
predominantly SLE-like conditions.
15
FigURe 3 | Schematic illustration of C1q gene organization, gene transcription, and multimeric C1q assembly. (A) The three human C1q genes span 
approximately 25 kb on human chromosome 1. The intergenic regions are 4.0 and 5.1 kb, respectively, which are not distinguishable in size from regular introns in 
the C1q genes. Each of the three C1q genes contains three exons and the transcribed peptides form disulfide-linked A-B hererodimers and C-C homodimers. Each 
C chain in the homodimer forms a collagen triple-helix with an A-B heterodimer, and hence, two triple-helices linked by the disulfide bond in the C-C dimer. Three 
such ABC-CBA twin helices associate non-covalently over the N-terminal ends to form the 18-polypeptide C1q molecule. The gC1q domains are often the 
ligand-binding sites for C1q and the collagen triple-helices associate with the C1r2C1s2 serine protease tetramer. (B) Conservation of the C1q gene organization in 
eight different animal species. The three C1q genes in chimpanzee occupied the largest genomic space which is approx. 27 kb. In chickens, the three C1q genes 
occupied merely 7.7 kb with intergenic sequences of 0.7 and 1.3 kb, respectively.
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In C1 and C4 deficiencies, the disease manifestations also 
deviate from that found in the larger SLE patient population. 
Typically, this specific group of SLE patients exhibit early disease 
onset and equal disease risks from both genders (30, 31, 35). 
SLE is otherwise a chronic disease that affects predominantly 
females at childbearing ages (36). How deficiency in each of 
these intimately related complement proteins, which define the 
classical pathway (Figure 1), causes SLE remains incompletely 
understood.
SYSTeMiC LUPUS eRYTHeMATOSUS
Clinical documentation of SLE disease has existed for more than 
a century. In 1948, Hargraves pioneered the mechanistic investi-
gation of this disease by reporting the L.E. cell phenomenon, i.e., 
SLE patient serum caused polymorphnuclear leukocytes to bind 
or clump around autologous amorphous nuclear materials (37). 
The serum activity was later attributed to the γ-globulin fraction 
of the patient serum, presently known as autoantibodies reactive 
with chromatin or DNA (38–40). A pathogenic role for these 
autoantibodies became apparent when Tan et  al. reported the 
asymptomatic appearance of anti-DNA autoantibodies, which 
disappeared during the ensuing disease flare when serum DNA 
antigen surged to complex with these autoantibodies (41). These 
autoantibodies are hallmarks in SLE pathogenesis and deposit in 
tissues leading to inflammatory tissue injury (42–44).
For a large majority of SLE patients, there is no definitive 
genetic explanation for the disease despite more than 50 SLE risk 
genes that have been identified (45). Most of these susceptibility 
genes are not specific for SLE and individually each risk gene has 
low-to-moderate effect on the disease (32). Known exceptions 
are genetic deficiencies of the intracellular exonuclease Trex1, 
and complement C1 and C4 (30–32). How deficiency in each of 
these complement proteins overrides the complex mechanisms 
governing host immunity and tolerance to cause this complex 
autoimmune disease is not fully understood. As anti-nuclear 
autoantibodies are pathogenic in SLE, understanding how these 
deficiencies cause anti-nuclear autoimmunity can provide greater 
insights into the underlying pathogenic mechanisms.
PLASMA C1q ACCUMULATiON iS 
ASSOCiATeD wiTH ACCeLeRATeD 
AgiNg
While C1q deficiency causes autoimmunity, its elevated plasma 
levels signify accelerated aging. Aging is marked by a decline in 
tissue regeneration and repair, and in the number and dynamics 
of tissue stem or progenitor cells (46). At the molecular level, one 
observation is that progenitor cells exhibit elevated Wnt signaling 
in the aging tissue environment (47, 48). In aged mice, muscle 
stem cells exhibit increased tendency to fibroblastic differentia-
tion (48). This was found to be conferred by a serum factor(s) in 
aged mice binding to the Frizzled family of cell surface receptors 
and causing Wnt receptor signaling (48). This Frizzled-binding 
protein was identified as C1q (48). Its serum level increased 
threefold (from 90 to 280  µg/ml) in old mice (20  months) as 
compared with young mice (2 months) (19).
Mechanistically, C1q binding to the Frizzled receptors causes 
C1s activation and activated C1s cleaves the Wnt receptor pro-
tein low-density lipoprotein receptor-related protein 6 (LRP6) 
to trigger canonical Wnt receptor signaling (19) (Figure  3). 
The involvement of C4 and further downstream complement 
16
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components are not defined. Nonetheless, this emphasizes the 
rather less-studied aspect of C1-mediated cleavage of proteins 
outside the complement network. C1s similarly cleaves MHC 
class I molecule, although the C1q ligands are not defined in this 
context (16, 17). It appears that activation of the complement 
classical pathway, which involves C1s cleavage of C4 and C2, is 
merely one of a number of effector mechanisms downstream of 
the C1 complex (Figure 3).
Besides a distinct decline in tissue regeneration and repair, 
aging is also characterized by systemic elevation of the inflam-
matory status (49, 50). In the elderly population, plasma pro-
inflammatory cytokines, IL-6 and TNF-α, and the acute phase 
C-reactive protein (CRP) are chronically elevated. When young 
(<40 years) and aged (60–81 years) populations were compared 
in a series of age-related parameters, including muscle mass, 
plasma C1q, as well as plasma IL-6, TNF-α, and CRP, the young 
population had clearly lower plasma C1q (80.5 µg/ml) than the 
aged population (161 µg/ml) (51). Interestingly, after 12 weeks 
of supervised resistance training intervention, plasma C1q in 
the elderly group decreased substantially (89.3  µg/ml) with 
muscle mass being significantly increased, revealing an inverse 
correlation between plasma C1q level and muscle mass (51). 
The cause for plasma C1q accumulation in the elderly group 
and its reduction after training is unclear in this study and a 
causal relationship between plasma C1q and muscle mass was 
also not established (51). The overall conclusion was, however, 
in line with C1q contribution to accelerated aging as reported 
in mice (19).
MeCHANiSM OF C1 FUNCTiONAL 
DiveRSiTY
The mechanisms for C1 complex function in the context of 
com plement activation and Wnt receptor signaling have been 
clearly documented. However, mechanistic understanding of 
its involvement in SLE pathogenesis remains fragmentary 
(Figure 3). Genetic deficiencies in complement proteins generally 
increase susceptibility to infections but mostly lack the type of 
strong association with SLE pathogenesis that is observed with 
deficiencies of C1 and its immediate substrate C4 (28). This raises 
the possibility that SLE pathogenesis may be related to a modular 
C1 activity. Depending on what C1q recognizes, C1 may have 
effects through the C1r/C1s proteases on various molecular/
cellular processes besides the complement system. C1 activation 
of Wnt receptor signaling is a good example of such a modular 
activity (19). The degradation of apoptotic cell debris is appar-
ently another process involving a modular C1 complex function 
(Figure 3) (9).
Since the discovery of C1q binding to apoptotic cells (9), a 
significant body of work has been published revolving mostly 
around C1q opsonization of apoptotic cells and its regulation 
of immune tolerance. First, C1q binding to apoptotic cells 
opsonizes the cell debris for effective phagocytosis (10). Second, 
C1q binding contributes to the immunosuppressive nature of 
apoptotic cells (52, 53). Third, C1q modulates dendritic cell (DC) 
development to induce more prominent tolerogenic features in 
these antigen-presenting cells (54, 55). Last, C1q inhibits IFN-α 
production by DCs induced by SLE autoantibodies in the form 
of immune complexes (56–58). IFN-α is a SLE-pathogenic 
cytokine, which causes autoimmunity in patients following its 
therapeutic administration (59, 60). IFN-α is elevated in those 
SLE patients who register a chronically elevated signature of 
IFNα-stimulated gene transcription (61–63). Inhibition of IFN-α 
induction by C1q potentially contributes to protection against 
SLE pathogenesis.
Studies that evaluate the role of C1 proteases in these pro-
cesses are lacking. In fact, how C1r/C1s deficiency also causes 
SLE has not been investigated. There are two hypotheses that are 
relevant to explaining how C1 and C4 deficiencies may cause 
autoimmunity (64, 65). A clearance hypothesis emphasizes on 
the induction of autoantibodies and autoimmunity by apoptotic 
cellular debris, which may accumulate due to impaired clearance 
or excessive cell death (64). A tolerance hypothesis emphasizes 
on the contribution of complement to promoting self-antigen 
delivery to primary lymphoid organs for an effective negative 
selection (65). Considering that C1s cleaves intracellular antigens, 
it can be highly significant that the C1 complex both opsonizes 
apoptotic cells through C1q for effective clearance and degrades 
apoptotic cellular antigens through C1 proteases. Without rely-
ing on the rest of the complement system, both processes can 
reduce the autoantigenicity of apoptotic cell debris.
C1q was initially found to bind to apoptotic blebs, but the 
spectrum of C1q ligands in apoptotic cells and their contribu-
tions to C1q recognition need further delineation (9, 66). C1q 
appears to bind multiple regions of apoptotic cells (20). In early 
apoptotic cells, C1q binds to peripheral structures; however, in 
late apoptotic cells, it binds predominantly to the core nuclear 
bodies, i.e., the nucleoli (20). With purified nucleoli, C1q not only 
binds to these nuclear bodies but also causes C1s activation and 
cleavage of nucleolar proteins, e.g., nucleophosmin-1 (NPM1) 
and nucleolin (20). Nucleoli are highly immunogenic and contain 
many autoantigens (67).
This reminds an important aspect in cell apoptosis, i.e., the 
intrinsic proteolytic/enzymatic dismantling of intracellular 
structures (68). During cell apoptosis, autoantigens are cleaved 
and partially inactivated by endogenous proteases (69). It is pos-
sible that during late stage apoptosis, exogenous proteases and 
other enzymes also contribute to the antigen dismantling process. 
C1q recognizes multiple intracellular regions during apoptosis, 
including the highly immunogenic nucleoli (20). In cooperation 
with endogenous proteases, C1 could contribute significantly to 
the effective protease trimming of dead cells required to prevent 
their immunogenicity (Figure 4) (70).
C1r AND C1s SUBSTRATeOMe
In the complement network, proteases are highly specific and 
this is essential to the directional propagation of the comple-
ment activation (5, 6). Outside the complement network, what 
other proteins may be cleaved by these proteases are rarely 
studied. With regard to C1s, it has been known for some time 
that it cleaves cell surface MHC class I and the secreted IGFBP5 
(16–18). More recent addition to the list of non-complement 
17
FigURe 4 | Schematic proposal how C1 deficiency may cause systemic lupus erythematosus pathogenesis. In live cells, the nucleus and other 
intracellular structures are compartmentalized and excluded from complement recognition. When cells undergo apoptosis, the nucleus and other cellular structures 
disintegrate and, in late apoptotic cells, these fragments are recognized by C1q, which opsonize apoptotic cells for phagocytosis. This can also cause C1r/C1s 
activation and the activated C1s could cleave its classic substrate C4 and C2 and produce complement opsonins for phagocytosis. C1s may also cleave numerous 
exposed nuclear and other cellular proteins that are otherwise autoimmunogenic (autoantigens) and cause B cell production of autoantibodies. C1s may also cleave 
cellular proteins that are otherwise pro-inflammatory danger-associated molecular patterns (DAMPs) and activate DCs to cause B cell production of pathogenic IgG 
autoantibodies. C1s may not inactivate all autoantigens but effective inactivation of DAMPs can abrogate class switch of autoantibodies from IgM to pathogenic IgG.
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C1s substrates includes LRP6, NPM1, and nucleolin (19, 20). In 
fact, the substrates of C1s can potentially be numerous based on 
bioinformatics predictions. Using a library of phage-displayed 
peptides that were designed based on the classic C1s cleavage sites 
on C4 and C2, Kerr et al. identified a list of C1s-cleavable peptide 
variants (21). Based on the conserved peptide framework, a 
formula was constructed that predicted numerous intracellular 
proteins as potential C1s substrate (21). NPM1 and nucleolin, 
which were found to be cleaved by C1 proteases, indeed contained 
multiple predicted C1s cleavage sites (20). The conjunction of a 
broad C1s substrateome with a diversity of C1q ligands makes 
the C1 complex a potentially multifaceted module that can 
function in a range of biological processes. C1s cleavage of intra-
cellular proteins may be irrelevant to live cells, but this capacity 
could be important in the context of dead cell debris, reducing 
autoimmunogenicity by the inactivation of autoantigens and 
the destruction of danger-associated molecular patterns (DAMPs) 
(Figure 4). A recent example of this C1 protease function is the 
demonstrated C1s cleavage and inactivation of HMGB1, which is 
otherwise a nuclear DAMP (71).
C1q
The functional versatility of C1q draws support from the modu-
larity of its structures. C1q is a large, symmetrical, and delicate 
posttranslational assembly resulting from complex evolutionary 
innovations. At one stage, the complement system was defined 
by merely four identifiable components, C1–C4. In 1963, C1 
was first separated into three distinct subcomponents, C1q and 
the two proteases C1r and C1s (72, 73). For C1q, biochemical 
analysis revealed three types of subunit polypeptides each con-
taining a collagenous (Gly-Xaa-Yaa)n repeating sequence over 
18
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the N-terminal half (74, 75). Similar collagen-like domains were 
later found in the N-terminal halves of collectins, ficolins, and 
some C1q/TNF-related proteins (CTRPs) such as adiponectin 
and saccular collagen (76–79). The collagenous regions of all 
these proteins form triple-helices and the C-terminal halves form 
globular (gC1q) domains that are clustered in three. The triple 
helices further conjoin at the extreme N-terminal regions to align 
3–6 triple-helices in one final assembly (76, 77). In the overall 
“bundle of tulips” C1q assembly, the gC1q domains are periph-
erally extended as multivalent binding sites (74, 75). The six 
triple-helices in C1q form a scaffold for the tetrameric C1r2C1s2 
protease complex (80). Binding of C1q to various ligands via the 
gC1q domain activates the C1r/C1s proteases and C1s triggers 
effector reactions through cleavage of specific substrate, which, 
in the complement classical pathway, are C4 and C2.
THe STRUCTURe OF C1q AFFORDS  
A DeLiCATe SCAFFOLD AND  
LigAND-BiNDiNg DiveRSiTY
C1q is distinct from collectins, ficolins, and CTRPs in that it is 
assembled from more than one type of subunit polypeptide. The 
other proteins are considered largely homopolymers (76, 77). 
C1q is an 18-polypeptide macromolecule assembled equally 
from three similar but distinct subunit peptides, 6 × A, 6 × B, 
and 6 × C chains (74) (Figure 2). The C1q assembly is partially 
stabilized by disulfide bonds and, under denaturing conditions, 
the molecule crumbles into two basic structural identities, an 
A-B heterodimer and a C-C homodimer that are linked through 
N-terminal disulfide bonds (Figure 2). One C-C and two A-B 
dimers form two triple helices over the collagen-like regions 
(ABC-CBA) and C1q is assembled non-covalently from three 
such ABC-CBA structures (Figure  2). Therefore, despite the 
presence of three C1q genes, only one type of C1q is assembled. 
The collectins, ficolins, and CTRPs are, however, products of 
single genes (76, 77).
What prevented the formation of three different homopoly-
meric C1q molecules is not understood. The combination of 
divergent subunits, i.e., A, B, and C, and their extensive polym-
erization in C1q offers, besides a scaffold to embrace the C1r2 
C1s2 tetramer, diversity and multiplicity of binding sites for a 
broad ligand repertoire. The heterotrimeric congregation of 
the three globular head modules (ghA, ghB, and ghC) yielding 
gC1q domain at the C-termini is independent of the N-terminal 
triple-helix (81). The three different globular head modules in 
the cluster exhibit differential binding preferences toward known 
C1q ligands (82, 83).
THe BROAD TiSSUe ORigiNS OF C1q 
AND iTS ULTiMATe PLASMA DeSTiNY
A dominant source for plasma complement proteins, including 
C1r and C1s, are hepatocytes in the liver, but C1q is one exception 
for its extrahepatic origins (84). C1q was initially found produced 
by macrophages (85). It was later found to be produced by tissue 
and cultured DCs as well (86, 87). Studies on C1q gene promoters 
revealed active cis-acting elements for transcription factors PU.1 
and IRF8 (26). PU.1 and IRF8, especially PU.1, is a key tran-
scription factor that defines the macrophage and DC lineage of 
hematopoietic development (88). Tenner and colleagues recently 
clarified that, in the brain, C1q is also produced by local tissue 
macrophages, the microglia (89). Therefore, C1q could have 
evolved first as an effector molecule in macrophages or ancestral 
phagocytes and its association with the C1r/C1s proteases in 
the form of C1 complex represents a secondary evolutionary 
innovation.
Macrophages and DCs populate many tissues and are poorly 
represented in the blood circulation (90, 91). Monocytes are 
blood precursors of some tissue macrophages, but these cells 
only start to produce C1q upon differentiation into macrophages 
(92). How the broad and heterogeneous tissue origin of C1q 
and its steady plasma levels are regulated is not fully under-
stood. Tissue macrophages, which orchestrate inflammation 
and antigen presentation as well as scavenge tissue debris and 
microorganisms, are responsive to diverse stimuli (93, 94). The 
complement system is concentrated in the blood and is actively 
recruited to sites of tissue infections or injuries. The macrophage/
DC origin of C1q appears to ensure its steady state tissue distri-
bution. Macrophages also produce C1r/C1s proteases (84). DCs 
also broadly populate tissues, albeit at a lower density, and also 
produce C1q, C1r, and C1s (86, 87, 95). This mode of C1q and 
C1r/C1s production stresses an important C1q or C1 function in 
sterile tissue homeostasis and other molecular/cellular processes.
PLASTiCiTY iN C1q PRODUCTiON
Macrophages express a broad repertoire of scavenging and 
signaling receptors and exhibit a high degree of plasticity in dif-
ferentiation and activation. This is reflected in the heterogeneity 
of tissue macrophages in their morphology and effector molecule 
production (91). As previously summarized, C1q production 
by macrophages also vary in response to microbial structures, 
cytokines, hormones, and drugs (66, 96). Overall, microbial 
structures tend to inhibit C1q production and corticosteroid 
hormones tend to enhance it (66). With respect to cytokines, 
IFN-α appears to inhibit C1q production (87), whereas IFN-γ 
increases C1q production by DCs/macrophages (26, 97). Local 
and temporal tissue fluctuation in C1q production may not 
prominently alter plasma C1q levels, but it can impact on local 
tissue homeostasis, immunity, and tolerance. This can also be of 
great importance in the microenvironment of tumor, where C1q 
seems to have a tumor-promoting function (98).
DOeS C1r/C1s CLeAve OTHeR  
C1q-TARgeTeD PROTeiNS?
Besides IgG and IgM, many other protein ligands have been iden-
tified for C1q (66, 99). These C1q ligands, including soluble, cell 
surface, normal extracellular matrix, and pathogenic amyloid 
proteins, often activate C1r/C1s and the complement classical 
pathway. It has, however, not been addressed whether the acti-
vated C1r/C1s proteases also cleave these C1q ligands or proteins 
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near these ligands as they cleave LRP6, IGFBP5, MHC I, NPM1, 
and nucleolin (16–20). In some pathophysiological contexts, C1q 
functions were interpreted without specific consideration to its 
ligands. In the postnatal central nervous system, C1q is localized 
to synapses and contributes to synapse elimination resembling 
the disposal of dead cells, which is important for the maturation 
of neuronal connectivity and functions (100, 101). How C1q 
causes the selective dismantling of synapses is unclear, but it is 
tempting to suggest C1q binding to selective neuronal contexts 
and possible involvement of C1r/C1s-mediated molecular cleav-
age or cell signaling as observed with the Wnt receptor (19). 
In excess, the same C1q-mediated synapse elimination could 
accelerate neurodegeneration related to aging and neuropathol-
ogy (102, 103).
The scrapie pathogen, prion protein, is another C1q ligand 
(104, 105). C1q deficiency reduces scrapie pathogenesis (106, 107). 
To what extent the complement classical pathway may be involved 
in prion-mediated pathology is incompletely defined, but C4 is 
apparently activated on prion proteins and C3 depletion also 
reduced scrapie pathogenesis (104, 107). As C1q, C3, and C4 are 
all potent opsonins, a prevalent explanation is their involvement 
in prion transmission from the gut to the central nervous tissues. 
The role of activated C1r/C1s proteases in scrapie pathogenesis 
has not been considered.
C1q is also produced in the placenta (108, 109). At this 
feto–maternal interface, it was shown to mediate trophoblast 
invasion of the maternal decidua (108). Mechanistically, C1q was 
found to interact with decidual stroma, to activate trophoblast 
signaling, and to mediate trophoblast adhesion and migration 
(108). Whether C1r/C1s might play a role in this context is again 
unclear.
CONCLUDiNg ReMARKS
The complement system is an intimate proteolytic cascade 
responding to diverse triggering factors. In infections or injuries, 
the full impact of its activation is realized by three closely related 
effector reactions: inflammation, opsonization, and lysis (5, 6). 
The C3a and C5a anaphylatoxins recruit and activate phagocytes 
and other inflammatory leukocytes at sites of tissue infections 
or injuries. The membrane attack complexes cause cellular 
lysis. The C4b, C3b, and the further proteolytic fragments 
opsonize complement-reacted targets for effective phagocytic 
clearance (Figure  1). However, this article highlights that C1 
complex may function as a module, independent of the rest of 
the complement network, to participate in other molecular/
cellular processes.
Serine proteases are core components of the complement 
infrastructure and their sequential activation is at the heart of the 
formation of hierarchical proteolytic or lytic protein complexes. 
In the context of the complement network, these are highly 
specific proteases, e.g., C1r only cleaves C1s and C1s only cleaves 
C4, C2, and C1 inhibitor. The finding that the C1 proteases also 
cleave a growing list of non-complement proteins, including 
LRP6, MHC I, IGFBP5, NPM1, and nucleolin, supports a mul-
tifaceted, modular function for C1 complex. In this functional 
C1 module, C1q recognizes targets in various molecular/cellular 
processes and the C1r/C1s proteases bring about the effects by 
cleaving substrate in these molecular/cellular processes. Modular 
functions may also be found in other complement proteases such 
as factor B and MASPs.
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The immunopathological functions associated with human C1q are still growing in terms 
of novelty, diversity, and pathologic relevance. It is, therefore, not surprising that C1q is 
being recognized as an important molecular bridge between innate and adaptive immu-
nity. The secret of this functional diversity, in turn, resides in the elegant but complex 
structure of the C1q molecule, which is assembled from three distinct gene products: 
A, B, and C, each of which has evolved from a separate and unique ancestral gene 
template. The C1q molecule is made up of 6A, 6B, and 6C polypeptide chains, which 
are held together through strong covalent and non-covalent bonds to form the 18-chain, 
bouquet-of-flower-like protein that we know today. The assembled C1q protein displays 
at least two distinct structural and functional regions: the collagen-like region (cC1q) 
and the globular head region (gC1q), each being capable of driving a diverse range of 
ligand- or receptor-mediated biological functions. What is most intriguing, however, is 
the observation that most of the functions appear to be predominantly driven by the 
A-chain of the molecule, which begs the question: what are the evolutionary modifica-
tions or rearrangements that singularly shaped the primordial A-chain gene to become 
a pluripotent and versatile component of the intact C1q molecule? Here, we revisit and 
discuss some of the known unique structural and functional features of the A-chain, 
which may have contributed to its versatility.
Keywords: complement, classical pathway, c1q, A chain, charge pattern recognition, c1q receptor
tHe cOMPLeX strUctUre OF c1q
C1q is the first subcomponent of the complement classical pathway. In addition to its complement 
activation mediated immune functions, it has a broad range of developmental homeostatic functions 
that are not dependent on its ability to activate the classical pathway [reviewed in Ref. (1)]. The 
functional versatility of C1q depends on several unique structural and functional properties (1–3). 
It is made up of three chains, A, B, and C, which are the product of three distinct genes, found highly 
clustered and aligned 5′⇒3′, in the same orientation, in the order A–C–B on a 24 kb stretch of DNA 
on chromosome 1p at position 36.12 (4, 5). Each chain contains an N-terminal collagen-like region 
and a C-terminal globular head region. There are 18 chains in the intact C1q molecule: 6A, 6B, 
Abbreviations: ghA, ghB, and ghC, globular heads of the A, B, and C chains of C1q, respectively; gC1q, the globular heads 
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and 6C, which are arranged first as a single heterotrimeric strand 
comprising of A, B, and C, in which the A chain and B chain 
within the strand are covalently linked to each other, whereas the 
C-chain of one strand which is non-covalently associated with 
the AB dimer, nonetheless forms a covalent link with the C chain 
of a neighboring ABC strand to form an ABC-CBA doublet. 
Three such doublets are then held together with non-covalent 
bonds to give rise to the well-recognized hexameric structure of 
C1q. The globular “heads” of each ABC strand are linked via six 
collagen-like “stalks” to a fibril-like central region resulting in 
two unique structural and functional domains: the collagen-like 
region (cC1q) and the globular “heads” or domains (gC1q) (6, 7). 
Each of the gC1q domains is a heterotrimeric structure made up 
of each of the individual chains (ghA, ghB, and ghC). What has 
become apparently clear is the fact that each of the gh domains 
is capable of recognizing a gh-specific ligand independent of the 
other gh domains (3, 8, 9). Therefore, assuming that each of the 
gh domains recognizes a single target or ligand, the C1q molecule 
can recognize and bind simultaneously six individual molecular 
patterns, making it one of the most efficient, and versatile pattern 
recognition molecules.
The crystal structure of the heterotrimeric gC1q domain 
revealed a compact jellyroll β-sandwich fold similar to that 
of the multifunctional tumor necrosis factor (TNF) family of 
proteins (10, 11). This suggested that C1q not only diverged 
from a primordial ancestral gene template of the innate immune 
system that gave birth to the TNF-α and other C1q-like proteins, 
but also retained some of its ancestral “cytokine-like” functions 
(2, 10). Therefore, C1q could be considered as a prototype “com-
plekine,” i.e., complement protein with cytokine-like activity, 
which is capable of mimicking some, if not all, functions of the 
TNF family of proteins, including the induction of cytokines (IL-6 
and IL-8) and chemokines (e.g., MCP-1) that orchestrate a myriad 
of a rapidly expanding list of pathophysiological processes (12, 13).
There is also an abundance of clinical evidence, which shows 
that genetic deficiency in C1q is associated with a wide range of 
clinical syndromes closely related to SLE, with rashes, glomerulo-
nephritis, and CNS disease as well as other autoimmune diseases 
(14). In addition, C1q also can have a major role in tumor growth 
and progression (15–19). The role of C1q, being a part of tumor 
microenvironment, has appeared to be complex so far. In some 
reports, it has been shown to be protumorigenic (15–17), whereas 
there are recent reports of antitumor activities of C1q in the case 
of prostrate (18) and ovarian cancers (19).
Although individuals with congenital C1q deficiency constitute 
only a small cohort of patients, this strong association nonethe-
less implicates an important role for complement in general, and 
C1q in particular, in the development of SLE and other autoim-
mune diseases (20–24). What is perplexing, however, is the fact 
that among the C1q deficiencies, the A-chain of C1q should take 
center stage in significance as homozygous deficiency or muta-
tion in the A-chain is almost invariably associated with various 
diseases (20–24). The mutation in the A-chain is due to a homo-
geneous mutation in which the C to T transition in codon 186 of 
exon 2 results in Gln-to Stop (Q186X) substitution. The question 
is: what are the structural signatures that make the C1q-A chain 
such a powerful susceptibility biomarker of these diseases? It is 
worth noting that although the most prevalent mutation is the 
C1qA, Gln208X mutation, there are other mutations in B and C 
chains too (25).
strUctUrAL AND FUNctiONAL 
cHArActeristics OF tHe c1q A-cHAiN
The genes encoding the three chains of C1q are highly conserved 
from zebrafish to human. Phylogenetic analysis also intimates 
that the C1qA, C1qB, and C1qC may have originally been gen-
erated by gene duplications from a single copy of an ancestral 
C1qB gene, since the latter is found in the same branch as amphi-
oxus C1q, which is an earlier lower vertebrate than zebrafish (26). 
Furthermore, the IgG binding properties between fish and mam-
malian C1q show no difference since substitution of human C1q 
by fish C1q has the same activity, suggesting that the IgG or IgM 
recognizing properties have remained conserved throughout the 
evolutionary history (26, 27). However, more recent studies have 
shown that there is a preferential binding of the gC1q modules 
when it comes to IgG binding. Whereas the gC1qA (or ghA) 
module binds aggregated IgG and IgM in a similar manner, 
gC1qB (ghB) binds aggregated IgG in preference to IgM (28). 
The functional preferences of the gC1q domains, therefore, may 
reflect an evolutionary structural adaptation that resulted in 
recent history.
In an elegant and in depth review, Trinder et al. (29) analyzed 
the structural and functional correlates that distinguish the 
A-chain from the B- and C-chains. First, while the B and C chains 
are highly conserved, the A-chain is not. This fact alone should 
support the notion that the A-chain developed to be functionally 
adaptable throughout evolution. Second, various types of cells 
including macrophages and dendritic cells among a long list of 
others, synthesize the C1q molecule. The cell-associated molecule 
in turn, is anchored in the membrane via a 22 amino acid long 
leader peptide, which is found only in the A-chain (29). Third, 
the A-chain contains several antigen recognition sites (Figure 1), 
but in particular, possesses one major (aa 14–26) and one minor 
(aa 76–92) promiscuous region (29), which serve as a binding 
site for a wide range of non-immunoglobulin antigens including 
lipopolysaccharide, C-reactive protein (CRP), DNA, heparin, 
fibronectin, monosodium, urate crystals, amyloid P component, 
von Willebrand factor (30) as well as bacterial and mitochondrial 
membranes (29–42). Importantly, this A chain region has also 
been shown to bind specifically by SLE patients’ sera compared to 
serum derived from healthy control (43). Although recent studies 
have suggested that the interaction site for CRP is located in the 
gC1q rather than the cC1q (44–46), it is plausible to assume that 
certain molecules could actually bind to multiple regions of the 
A-chain. Regardless, these non-immunoglobulin antigens have 
been shown to activate the classical pathway by binding to the 
cC1q region of the A-chain rather than to the globular heads 
(29–42). In addition, the A-chain contains a collagen-type II-like 
sequence comprising of residues 26–34, which has been shown to 
suppress collagen type-II-induced arthritis in a mouse model (47). 
Interestingly, this same region is also predicted to be a potential 
MHC class II binding site (48). However, little is known about the 
significance of this finding but may have potential implications 
5
FigUre 1 | The structural and functional correlates of the C1q A-chain. The intact C1q molecule is anchored to the cell membrane by a leader peptide in the A 
chain. The major and minor ligand bind sites as well as the putative MHC class II binding domain are highlighted. Although the major gC1qR-binding domain spans 
residues 155–164, unexpected sites in the promiscuous collagen domain spanning residues 14–26 and another at 76–92 have also been shown very recently [the 
figure is adapted from Ref. (29)].
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in autoimmunity and tolerance (48), especially since C1q has 
been shown to keep monocytes in a predendritic or immature 
phenotype, thus ensuring that unwarranted DC-driven immune 
response does not occur, a fact that is relevant to the development 
of SLE (49). Finally, although it is found only in the mouse, and 
not in the human C1q A-chain, the presence of an RGD sequence 
may also explain why human C1q still retains its ability to support 
adhesion of normal endothelial cells and fibroblasts (50–53) in a 
manner that is inhibited by an RGD peptide but not an RGE (51). 
Very recently, Agostinis et al. have shown that C1q can act as a 
bridge between hyaluronic acid (HA), an abundant matrix com-
ponent of the tumor microenvironment, and the HA receptor on 
tumor cells, i.e., CD44, thus inducing considerable proliferation 
of primary tumor cells derived from malignant pleural mesothe-
lioma (MPM) (17). Curiously, the A-chain of the globular region 
of C1q bound specifically and differentially to a range of LPS-free 
HA, leaving C-chain to liaise with MPM cells.
Thus, although it may be overly simplistic to suggest that the 
A-chain is the functional anchor of the C1q molecule, it appears to 
be clear that of the three chains, the A-chain has singularly under-
gone systematic and adaptable molecular evolution. Whether the 
selection of the A-chain to evolve as a master orchestrator of C1q 
functions was by design or serendipity, or whether the B- and 
C-chains are also undergoing similar evolution albeit at a much 
slower rate, are questions still for the future.
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Binding of the complement component C1q to the CH2 domain of antigen-bound 
immunoglobulin gamma (IgG) activates the classical complement pathway and depends 
on its close proximity to Fc fragments of neighboring antibodies. IgG subclasses con-
tain a highly conserved asparagine 297 (N)-linked biantennary glycan within their CH2 
domains, the core structure of which can be extended with terminal galactose and sialic 
acid residues. To investigate whether Fc-glycosylation regulates effector functions of 
human IgG subclasses, we cloned the antigen-binding region of the CD20-specific 
monoclonal antibody rituximab into IgG isotype expression vectors. We found that 
Fc-galactosylation enhances the efficacy of CD20-targeting complement-fixing anti-
bodies for C1q binding and complement-mediated tumor cell lysis. Increased efficacies 
were restricted to IgG1 and IgG3 subclasses indicating that Fc-galactosylation alone 
is not sufficient for IgG2 and IgG4 to acquire complement-fixing properties. Addition of 
terminal galactose to the N-glycan specifically improved binding of C1q without chang-
ing antigen- and FcγRIIIa-binding affinities of IgG isotypes. These data indicate that Fc 
galactosylation can be harnessed to enhance the complement-activating properties of 
IgG1 and IgG3 antibodies.
Keywords: c1q, complement system proteins, antibodies, monoclonal, glycan, igg subclasses
inTrODUcTiOn
Immunoglobulin gamma (IgG) antibodies are preeminent effector proteins of the immune system. 
The bimodal architecture of IgG allows for simultaneous recognition of antigen (by the antigen-
binding fragment, Fab) and the initiation of IgG effector functions such as recruitment and activa-
tion of leukocytes and antibody-dependent cell-mediated cytotoxicity (ADCC) through interaction 
with FcγRs as well as complement activation through binding of the constant, crystallizable fragment 
(Fc) binding of C1q. Human IgG is subdivided in the four isotypes IgG1 to IgG4, numbered based on 
their abundance in serum (1). Despite being more than 90% identical in amino acid sequence, IgG 
isotypes differ in key functional regions responsible for flexibility, FcγR binding, and complement 
fixation (2).
All IgG subclasses contain a highly conserved asparagine-linked (N-)oligosaccharide located in 
the CH2 domain of the Fc region. Presence of this glycan serves important functions in protein 
29
FigUre 1 | Generation of degalactosylated and galactosylated immunoglobulin gamma (IgG) isotypes derived from rituximab. (a) Schematic depiction of an IgG 
antibody with its two Fc N-glycans (up) and detailed glycan composition of a fully galactosylated IgG-Fc N-glycan. (B) Gel electrophoresis and coomassie staining to 
detect total protein showing heavy and light chains of antibodies (up) and immunoblots using galactose- (Erythrina Cristagalli lectin) or mannose- (Lens Culinaris 
agglutinin) specific lectins.
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folding and post-translational quality control mechanisms and 
is essential for antibody-mediated effector functions (3, 4). The 
biantennary core glycan structure, which is composed of two 
N-acetylglucosamines (GlcNAc) and three mannose residues, 
can be further decorated with fucose, bisecting GlcNAc and 
terminal GlcNAc, galactose, and sialic acid. The highest degree 
of variability among IgG antibodies stems from the presence or 
absence of galactose with around 40% containing one galactose, 
20–40% two galactoses, and the remainder none (5–7).
Presence or absence of distinct N-glycan residues such as 
fucose and sialic acid can dramatically alter pro- and anti-
inflammatory IgG activities. Removal of the fucose residue 
from human IgG1 increases antibody-dependent cell-mediated 
cytotoxicity (ADCC) through improved affinity for Fcγ recep-
tor IIIa (FcγRIIIa) (8, 9). We have previously shown that IgG 
Fc sialylation of human monoclonal IgG1 molecules impairs 
their efficacy to induce complement-dependent cytotoxicity 
(CDC) (10). Here, we determined whether Fc galactosylation 
of human IgG isotypes (IgG1–4) regulates antibody effector 
functions.
resUlTs
generation of Degalactosylated and 
galactosylated igg isotypes  
Targeting cD20
To test the impact of Fc galactosylation of human IgG isotypes on 
target cell depletion, we first cloned the sequence encoding the 
heavy chain (HC) and light chain (LC) antigen-binding regions 
of the monoclonal CD20-targeting antibody rituximab into 
human IgG1–4 HC and kappa LC expression vectors. Plasmids 
were cotransfected in HKB11 cells and antibodies were purified 
from the supernatant using protein G columns. Next, we either 
treated the antibodies with recombinant galactosidase to com-
pletely remove galactose or with β-1,4-galactosyltransferase in 
the presence of uridine diphosphate (UDP-) galactose to obtain 
galactosylated antibodies. After repurification, antibodies were 
analyzed for purity and integrity by gel electrophoresis and 
immunoblotting with the galactose-specific Erythrina Cristagalli 
lectin to confirm the successful generation of glycovariants 
(Figure 1).
30
FigUre 2 | Fc-galactosylation does not increase CD20 binding of rituximab-derived IgG isotypes. Target antigen recognition by galactosylated and 
degalactosylated human IgG1–4 isotypes specific for CD20 analyzed by flow cytometry via titration on CD20+ Raji cells. MFI, median fluorescence intensity;  
IgG, immunoglobulin gamma.
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addition or removal of igg-Fc galactose 
Does not affect antigen Binding
Modifications in the Fc domain may change the structural 
properties of the antibody, potentially leading to changes in its 
antigen-binding region. To determine antigen-binding affinities 
of IgG isotype glycovariants, we titrated the antibodies on CD20 
expressing human Raji-Burkitt’s lymphoma cells and analyzed 
binding by flow cytometry (Figure 2). For each isotype, galacto-
sylated and degalactosylated glycovariants did not differ in their 
antigen-binding characteristics.
igg-Fc galactosylation of igg1 and igg3 
isotypes increases c1q Binding and 
complement-Dependent cytotoxicity
The efficacy of IgG isotype-derived glycovariants to induce 
complement-dependent cytotoxicity (CDC) was determined 
in Burkitt’s lymphoma-derived Raji cells in the presence of 
active complement (human serum). Rituximab-derived IgG3 
glycovariants showed the highest efficacy for CDC, followed by 
IgG1 (Figure  3). Glycovariants of IgG2 and IgG4 isotypes did 
not induce CDC. Galactosylation increased CDC mediated by 
both IgG1 (26% reduction of EC50) and IgG3 (13% reduction 
of EC50) but did not provide IgG2 and IgG4 with de novo ability 
to lyse target cells (Figure 3). To investigate the mechanism by 
which Fc-galactosylation impacts CDC, we determined the C1q 
binding affinities and kinetics of galactosylated and degalacto-
sylated antibody variants (10). Incubation of CD20-expressing 
Raji cells in the presence of human serum depleted for C5, an 
essential component of the complement cascade, which allows 
to analyze the binding of members of the complement cascade to 
target cells while preventing cell lysis (10), led to rapid binding 
of C1q (Figure  4). Fc-galactosylation substantially enhanced 
the antibodies’ capacity to bind C1q for IgG1 and IgG3 isotypes 
(Figure  4). These data indicate that the addition of terminal 
galactose to the Fc-glycan enhances cell-depleting efficacies of 
human IgG1 and IgG3 isotypes through increased C1q binding.
Fc-galactosylation Does not increase 
igg:Fcγriiia-Binding affinities
Rituximab depletes B  cells through a combination of CDC and 
antibody-dependent cell-mediated cytotoxicity (ADCC), which 
requires antibody binding to the human-activating FcγRIIIa 
(CD16) (10, 11). Absence of the IgG-Fc core fucose increases 
binding to FcγRIIIa (8, 12), a finding increasingly being used 
to improve the efficacy of therapeutic antibodies (13–15). Two 
studies reported that Fc-galactosylation results in a slight, albeit 
not statistically significant increase in FcγRIIIa-binding affinity 
and ADCC activity (16, 17). A more recent study confirmed 
that afucosylated glycoforms show higher binding affinities for 
FcγRIIIa, while Fc-galactosylation did not significantly impact 
FcγRIIIa binding (18). To investigate whether Fc-galactosylation 
of IgG isotype glycovariants increases binding affinities of IgG 
isotypes for FcγRIIIa, thereby potentially enhancing the anti-
bodies’ ability to induce ADCC, we titrated IgG glycovariants 
onto CHO-derived cell lines recombinantly expressing FcγRIIIa. 
FcγRIIIa binding was strongest for IgG1 and IgG3 isotypes 
1
FigUre 3 | Increased CDC of rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3 but not IgG2 and IgG4 upon Fc-galactosylation. Complement-
dependent lysis of CD20+ target cells in the presence of galactosylated or degalactosylated human anti-CD20 IgG isotypes. Exemplary lysis curves and EC50 values 
of three independent experiments are shown. Statistical analysis: paired two-tailed Student’s t-test *p < 0.05, **p < 0.01.
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(Figure  5). IgG-Fc galactosylation showed, however, no effect 
on FcγRIIIa-binding affinities for any of the IgG isotypes tested 
(Figure 5). Thus, while increasing the antibodies’ affinity for C1q 
binding and their efficacy to induce CDC, Fc-galactosylation did 
not change the affinity of human IgG isotypes for FcγRIIIa which, 
upon ligation, mediates ADCC.
DiscUssiOn
Initiation of the classical complement cascade trough binding 
of C1q is a potent proinflammatory mechanism by which IgG 
antibodies trigger immune responses during infection and its 
deregulation causes tissue damage in a wide array of human 
inflammatory, degenerative, and autoimmune diseases (19). Our 
study shows that Fc-galactosylation enhances the efficacy of com-
plement-fixing IgG isotypes to induce CDC through improved 
binding of C1q.
The antibody-dependent classical complement pathway is 
initiated if the C1 complex, formed by the multimeric pattern 
recognition molecule C1q and the modular proteases C1r and 
C1s, docks on antigen-bound IgG (20). C1q binds to monomeric 
IgG with very low affinity but antigen-driven antibody clustering 
allows for the formation of IgG hexamers that bind C1q with high 
avidity and promote efficient complement activation (21). The 
N-glycan resides in the CH2 domain, which is required for C1q 
binding (22). Sites on the surface of human IgG1 that constitute 
the C1q-binding epicenter are conserved in human IgG isotypes 
that are deficient in C1q binding and it has therefore been sug-
gested that the composition of the N-glycan might be critical for 
the antibodies’ conformation and its ability to bind C1q (23). 
Each biantennary oligosaccharide chain extends one arm toward 
the CH2–CH3 interface region and the other arm into the space 
between the CH2 domains, resulting in multiple interactions with 
the surface of the CH2 domain and the glycan of the opposing 
CH2 domain, respectively (4). Indeed, optimal C1 activation 
requires the presence of the Fc-glycan since C1q-mediated effec-
tor functions are compromised or lost in aglycosylated or degly-
cosylated IgGs (24–26). The effect of deglycosylation on reducing 
C1q binding has recently been attributed to its inhibition of IgG 
hexamerization via modulation of IgG Fc:Fc interactions rather 
than reduction of direct C1q-Fc-binding affinities (27). Based 
on these data and our results, we suggest that Fc-galactosylation 
modulates Fc:Fc interactions for antigen-bound IgG, thereby 
improving binding of C1q and increasing the antibodies’ ability 
to induce classical complement activation and CDC.
We systematically investigated whether Fc-galactosylation 
facilitates C1q binding and CDC effector functions across all 
human IgG isotypes. For murine IgG2b and IgG1, it has been 
demonstrated that addition of terminal galactose increases bind-
ing of C1q (28). While presence of terminal galactose enhanced 
complement activation by CD20 targeting, C1q-fixing human 
IgG1 and IgG3 isotypes, IgG2 and IgG4 remained deficient in 
initiating the classical complement cascade indicating that 
Fc-galactosylation alone is not sufficient for IgG2 and IgG4 to 
acquire complement-fixing properties.
Rituximab and therapeutic monoclonal antibodies (mAbs) 
that target tumor cells via ADCC or CDC are approved for the 
treatment of various cancers (29). B-cell depletion by CD20-
targeting antibodies is also widely used for the treatment of auto-
immune diseases (30). However, some patients do not sufficiently 
32
FigUre 4 | Increased C1q binding of Fc-galactosylated rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3. Kinetic of C1q binding to CD20+ Raji cells in 
the presence of galactosylated or degalactosylated glycovariants of human IgG1–4. Exemplary C1q-binding curves (left), flow cytometry histograms of C1q binding 
after 60 min (center) and statistics at time point 60 min of at least three independent experiments. Statistical analysis: unpaired two-tailed Student’s t-test, 
mean ± SEM, ns, not significant, *p < 0.05, **p < 0.01, and ***p < 0.001. MFI, median fluorescence intensity.
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FigUre 5 | Immunoglobulin gamma (IgG) binding to FcγRIIIa does not require Fc-galactosylation. Binding of galactosylated and degalactosylated IgG isotypes to 
CHO cells transfected with FcγRIIIa was analyzed by flow cytometry. Binding curves and flow cytometry histograms at 10 µg/ml are shown.
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respond to rituximab therapy (31, 32) and improved versions 
of B  cell depleting antibodies have been developed to increase 
ADCC activity and improve clinical efficacy (33, 34). Our data 
indicate that Fc-galactosylation, in addition to the established 
effect of defucosylation on ADCC, increases target cell cytotox-
icity through enhancing CDC. Fc-galactosylation specifically 
improved binding of C1q to human IgG1 and IgG3 without 
changing antigen-binding affinities. Our data therefore indicate 
that Fc-galactosylation should be harnessed in glycoengineering 
therapeutic antibodies for effective antibody-dependent comple-
ment activation and target cell killing.
MaTerials anD MeThODs
Buffers and reagents
Human serum complement (Cat. No.: A100; Lot No.: 035997) 
and C5-depleted human serum (Cat. No.: A501; Lot No.: 
031795) were purchased from Quidel® Corporation. Accutase 
was purchased from StemCell Technologies Inc. (Cat. No.: 
07920), Gibco™ RPMI-1640, HEPES (Cat. No.: 52400025), 
penicillin–streptomycin (P/S; 5,000 U/ml; Cat. No.: 15070063), 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Cat. No.: 
L34957), LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit 
(Cat. No.: L10119), and TO-PRO-3 Stain (Cat. No.: T3605) 
were purchased from Invitrogen. Fetal calf serum (FCS) was 
purchased from Sigma-Aldrich (Cat. No.: F7524-500M; Lot 
No.: 051M3395) and from Bioswisstech (Cat. No.: S0615; Lot 
No.: 1047D). β1-4 galactosidase (Cat. No.: 345806-50MIU) 
and UDP-galactose (Cat. No.: 670111-50MG) were pur-
chased from Merck Millipore Corporation, Calbiochem®. 
Protein-G sepharose was purchased from GE healthcare 
(Cat. No.: 17-0618-01). Biotinylated Erythrina Cristagalli lectin 
(Cat. No.: B-1145) and Lens Culinaris Agglutinin (Cat. No.: 
B-1045) were purchased from Reactolab. Phosphate-buffered 
saline (PBS; 2.68 mM KCl, 8 mM Na2HPO4, 1.8 mM KH2PO4, 
137 mM NaCl, pH adjusted to 7.3) was produced in-house.
antibodies and streptavidin
Monoclonal mouse anti-human C1q (Cat. No.: A201) and 
biotinylated anti-human C1q (Cat. No.: A700) were purchased 
from Quidel® Corporation. Polyclonal rabbit anti-mouse IgG 
(H  +  L)-Alexa Fluor 488 (Cat. No.: A-11059) was purchased 
from Invitrogen. PE-conjugated streptavidin (Cat. No.: 405203) 
was purchased from Biolegend.
cDc assay
Raji cells were used as CD20+ target cells to assess CDC. 
Accordingly, 7 × 104 Raji cells were cultivated in RPMI-1640 con-
taining P/S (50 U/ml) in a humidified incubator (37°C, 5% CO2) 
in 96-well V-bottom plates. Cells were incubated with titrated con-
centrations of the respective galactosylated and degalactosylated 
anti-CD20 antibody isotypes. After 30 min, human serum comple-
ment was added to a final concentration of 5% and incubation was 
continued for another 12 h. Thereafter, cells were washed twice by 
adding 200 µl cold PBS and centrifugation at 400 × g and 4°C for 
5 min. Cells were resuspended in cold PBS and TO-PRO3 stain 
(final concentration of 200 nM) was added to detect dead cells. All 
samples were analyzed on a BD FACSCanto-II using FACSDiva 
v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.). Specific 
lysis was calculated as percent increase in dead cells compared to 
spontaneous lysis in the absence of an anti-CD20 antibody. EC50 
values were calculated via a non-linear regression in GraphPad 
Prism 5.
c1q-Binding assay
A total of 2 × 105 Raji cells were incubated with 10 µg/ml with 
galactosylated and degalactosylated anti-CD20 antibody isotypes 
in RPMI-1640 containing 1% P/S (50 U/ml) and 1% C5-depleted 
human serum for 5, 15, 30, or 60 min in a humidified incubator 
(37°C, 5% CO2). After incubation with the different anti-CD20 
antibody isotypes, cells were washed twice with 200 µl cold PBS, 
and C1q binding was determined by adding biotinylated anti-C1q 
antibody (25 µg/ml in PBS) for 1 h on ice followed by washing 
34
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twice with 200 µl cold PBS and incubation with PE-conjugated 
streptavidin (1:400 in PBS) and dead cell stain (LIVE/DEAD 
Fixable Aqua Dead Cell Stain Kit; 1:250 in PBS) for 20  min. 
After washing twice with 200 µl PBS, samples were analyzed on 
a BD FACSCanto-II using FACSDiva v6.1.3 software and FlowJo 
software v9.3.1 (Tree Star Inc.).
cD20-Target-Binding assay
Raji cells were maintained in RPMI-1640 containing P/S 
(50  U/ml) and 10% FCS in a humidified incubator (37°C, 5% 
CO2). 1.2 × 105 Raji cells and anti-CD20 antibody isotypes and 
glycovariants were incubated for 25 min on ice. Dead cells were 
excluded using LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit. 
Cells were washed twice with 200  µl PBS and anti–mouse IgG 
(H + L)-Alexa Fluor 488 was added and incubated for 20 min 
on ice followed by two washing steps with 200 µl cold PBS. All 
samples were analyzed on a BD FACSCanto-II using FACSDiva 
v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.).
Fcγr-Binding assay
Human FcγRIIIa-expressing CHO cells (35) were kindly provided 
by Falk Nimmerjahn (Department of Biology, University of 
Erlangen-Nürnberg, Germany). Cells were maintained in RPMI-
1640 containing P/S (50  U/ml) and 10% FCS in a humidified 
incubator (37°C, 5% CO2). To detect binding of anti-CD20 anti-
bodies, cells were detached using accutase, washed with cold PBS, 
and 2 × 105 cells were incubated on ice for 30 min with anti-CD20 
antibodies. After incubation, cells were washed twice with 200 µl 
cold PBS and anti-mouse IgG (H + L)-Alexa Fluor 488 was added 
for 20 min on ice. All samples were washed twice with 200 µl cold 
PBS and analyzed on a BD FACSCanto-II using FACSDiva v6.1.3 
software and FlowJo software v9.3.1 (Tree Star Inc.).
generation of recombinant Monoclonal 
anti-cD20 igg isotypes
The DNA encoding for the N terminal region of the light chain 
(amino acids QIVLS until KLEIK) and heavy chain (amino acids 
QVQLQ until TVSAA) of rituximab (www.drugbank.ca; accession 
number DB00073) was synthesized by Invitrogen GeneArt gene 
synthesis. The N terminal region of the light chain was cloned into 
the multiple cloning site (MCS) of Igκ-AbVec (NCBI GenBank 
accession number FJ475056.1) using AgeI and BsiWI as previ-
ously described (36). To obtain human IgG-1, -2, -3 and -4 heavy 
chain expression vectors IgG-AbVec (NCBI GenBank accession 
number FJ475055.1) (36) was modified to encode for human IgG1 
(allotype G1m17,1), IgG2 (allotype G2m), IgG3 (allotype G3m), 
and IgG4 (kindly provided by Lars Hangartner, the Scripps 
Research Institute, Department of Immunology and Microbial 
Science, La Jolla, CA, USA) (2, 37, 38). The N terminal region of 
the rituximab heavy chain was cloned into the MCS using AgeI 
and SalI as previously described (36). Recombinant monoclonal 
antibodies were expressed and purified as previously described 
(10, 32, 39). Briefly, heavy and light chain expression plasmids 
were cotransfected into a human B cell–epithelial cell fusion cell 
line (HKB11) supporting high-level recombinant protein expres-
sion (40) using calcium phosphate-mediated transfection. After 
6 days, antibodies were purified from cell culture supernatants 
by binding to a protein G column and elution with 0.1 M glycine 
(pH 2) followed by neutralization with 1  M Tris pH 8.8 and 
dialysis to PBS. Antibody purity and integrity were confirmed 
by polyacrylamide gel electrophoresis, coomassie brilliant blue 
staining and Western blotting with isotype-specific monoclonal 
antibodies.
generation of galactosylated and 
Degalactosylated antibody glycovariants
Antibody glycovariants were generated as previously described 
(10, 39). For removal of galactose, antibodies were dialyzed to 
50 mM sodium phosphate buffer pH 6.0, 60 mU β1–4 galactosi-
dase was added per mg of antibody and the reaction was incu-
bated for 6 h at room temperature followed by 1 h at 37°C. To add 
galactose, antibodies were dialyzed to 0.2 M MES pH 6.5 followed 
by the addition of 10 mM MnCl2, UDP-galactose, 0.02% NaN3, 
and 5 µg recombinant β1–4 galactosyltransferase [produced in-
house (39)]. The reaction was incubated at 37°C for 48 h. Finally, 
all antibodies were centrifuged for 2 h at 4°C and >20,000 × g to 
remove aggregates, repurified by gravity-flow protein-G sepha-
rose columns, and dialyzed to PBS. Successful degalactosylation 
and galactosylation were monitored by lectin-blotting using the 
galactose-specific lectin from Erythrina Cristagalli.
statistics
A p-value of 0.05 or less was defined as statistically significant. For 
all analyses, Prism software, version 5 (GraphPad Software, Inc.) 
was used. Specific statistical tests are indicated in the respective 
figure legends.
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IgG antibodies (Abs) mediate their effector functions through the interaction with Fcγ 
receptors (FcγRs) and the complement factors. The main IgG-mediated complement 
activation pathway is induced through the binding of complement C1q to IgG Abs. This 
interaction is dependent on antigen-dependent hexamer formation of human IgG1 and 
IgG3 to increase the affinity for the six-headed C1q molecule. By contrast, human IgG4 
fails to bind to C1q. Instead, it has been suggested that human IgG4 can block IgG1 and 
IgG3 hexamerization required for their binding to C1q and activating the complement. 
Here, we show that murine IgG1, which functionally resembles human IgG4 by not 
interacting with C1q, inhibits the binding of IgG2a, IgG2b, and IgG3 to C1q in vitro, and 
suppresses IgG2a-mediated complement activation in a hemolytic assay in an antigen- 
dependent and IgG subclass-specific manner. From this perspective, we discuss the 
potential of murine IgG1 and human IgG4 to block the complement activation as well 
as suppressive effects of sialylated IgG subclass Abs on FcγR-mediated immune cell 
activation. Accumulating evidence suggests that both mechanisms seem to be respon-
sible for preventing uncontrolled IgG (auto)Ab-induced inflammation in mice and humans. 
Distinct IgG subclass distributions and functionally opposite IgG Fc glycosylation patterns 
might explain different outcomes of IgG-mediated immune responses and provide new 
therapeutic options through the induction, enrichment, or application of antigen-specific 
sialylated human IgG4 to prevent complement and FcγR activation as well.
Keywords: complement, c1q, igG4, igG, igG hexamer, igG glycosylation, immunosuppression, murine igG1
iNtrODUctiON
IgG antibodies (Abs) mediate their effector functions through the interaction with Fcγ receptors 
(FcγRs) and the complement system. The different IgG subclasses thereby differ by their specifici-
ties and affinities to the classical activating and inhibitory FcγRs (1–5). Furthermore, the effector 
function of IgG Abs depends on the type of IgG Fc glycosylation pattern. Non-(a)galactosylated IgG 
Abbreviations: Ab, antibody; BCR, B cell receptor; BDCA-2, blood dendritic cell antigen 2; DC-SIGN, dendritic cell-specific 
ICAM-3-grabbing non-integrin; DCIR, dendritic cell inhibitory receptor; IC, immune complex; FcγR, Fcγ receptor; OVA, 
ovalbumin; RBC, red blood cell; sv, swich variant; SIGN-R1, specific ICAM-3-grabbing non-integrin-related 1; TNBS, 
2,4,6-trinitrobenzenesulfonic acid or picrylsulfonic acid; TNP, 2,4,6-trinitrophenyl.
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Abs are associated with pro-inflammatory functions, such as IgG 
autoAbs in rheumatoid arthritis patients, whereas galactosylated 
and sialylated IgG Abs have reduced inflammatory and even 
immunosuppressive potential (6–19). IgG Fc sialylation reduces 
the affinity to the classical FcγRs and, instead, promotes interac-
tion with members of the sugar-binding C-type lectin receptor 
family (6–8, 13, 14, 19).
In the context of the complement activation, IgG Abs of dif-
ferent subclasses show highly diverse affinities to the complement 
C1q molecule, which initiates the classical complement pathway 
(3, 20–23).
Antigen-dependent hexamer formation of six monomeric 
human IgG1 or IgG3 Abs through non-covalent Fc:Fc interac-
tions, such as polymeric IgM, favors the interaction with one six-
headed C1q molecule leading to complement activation (22–27). 
Upon hexamerization, only one Fab arm of each IgG Ab interacts 
with the antigen. The other Fab arm is positioned in the plane of 
the Fc hexamer (22, 23).
By contrast, human IgG4 fails to activate the complement 
through C1q binding (22, 25). It has been suggested that human 
IgG4 might still be able to form hexamers, but subclass-specific 
sequence differences affect orientation of the loops in the CH2 
domain, which in turn alters the position of the C1q-binding site 
and therewith prevents the interaction with C1q (3, 28).
On the other hand, human IgG4 as well as IgA might prevent 
the hexamer formation of human IgG1 and IgG3 and ultimately 
C1q binding by steric interference (25, 28–32).
To explore the extent of this suggested inhibition, we studied 
whether murine IgG1, which functionally resembles human IgG4 
by not interacting with C1q, can prevent the interaction of the 
murine C1q-binding IgG2a, IgG2b, and IgG3 subclasses with C1q 
and therefore block the complement activation.
We further discuss the potential of murine IgG1 and human IgG4 
to inhibit the complement activation as well as how different IgG 
Fc glycosylation patterns and IgG subclasses affect IgG Fc receptor 
interactions during IgG-mediated immune responses, which may 
be exploited for development of novel therapeutic strategies.
MAteriALs AND MetHODs
reagents
For the experiments described below, 2,4,6-trinitrophenyl (TNP)-
coupled Ficoll (TNP-Ficoll) was purchased from Biosearch 
Technologies (Petaluma, CA, USA). 2,4,6-trinitrobenzenesulfonic 
acid or picrylsulfonic acid (TNBS)-solution was purchased from 
Sigma-Aldrich (St. Louis, MO, USA).
Production of Monoclonal igG Abs
The TNP-specific monoclonal hybridoma IgG1 (clone H5) (10, 11, 
19, 33, 34) and IgG1, IgG2a, and IgG2b class-switch variant (sv; 
with identical VDJ sequences) (19) Abs as well as the ovalbumin 
(OVA)-specific IgG1 (clone 4C9) (10) Abs were produced, puri-
fied and verified as described (19).
c1q eLisA
96-well ELISA plates were coated with 10 µg of TNP-Ficoll per 
milliliter overnight and subsequently incubated with the indicated 
combinations of monoclonal anti-TNP IgG subclass Abs in PBS 
containing 0.1% TWEEN 20 (Sigma-Aldrich). Unbound Abs 
were removed with PBS containing 0.05% TWEEN 20, and 
wells were incubated with human serum from healthy voluntary 
donors diluted 1:20 in HBSS with Ca2+ and Mg2+ (Gibco® by 
LifeTechnologies, Paisley, UK) containing 0.1% TWEEN 20 for 
1 h at room temperature. Unbound serum C1q was removed with 
PBS containing 0.05% TWEEN 20, and bound C1q was detected 
with HRP-labeled polyclonal sheep anti-human C1q IgG Abs 
(AbD Serotec, Bio-Rad, UK) and TMB substrate (BD Bioscience 
San Diego, CA, USA) at OD 450 nm. As a negative control, unspe-
cific serum C1q binding was detected in TNP-Ficoll-coated wells 
without anti-TNP IgG Abs (OD at 450 nm was below 0.09).
Preparation of tNP-Labeled red Blood 
cells (rBcs)
2,4,6-Trinitrophenyl labeling of human RBCs from healthy 
voluntary donors was performed in cacodylate buffer (pH 6.9) 
containing 0.4% TNBS-solution (both from Sigma-Aldrich) for 
1  h at room temperature. Subsequently, the cells were centri-
fuged, resuspended in PBS containing 1 mg/ml of glycylglycine 
(Sigma-Aldrich) and washed with PBS. TNP-coupled RBCs were 
stabilized in citrate-phosphate-dextrose solution containing 
adenine (Sigma-Aldrich) and stored up to 4 weeks at 4°C. TNP-
coupling to RBCs was verified by flow cytometry with murine 
anti-TNP IgG2a (sv) and FITC-labeled anti-murine IgG2a 
(Bethyl Laboratories, Montgomery, TE, USA) Abs (Figure S1E in 
Supplementary Material).
Hemolysis Assay
2,4,6-Trinitrophenyl-coupled RBC suspensions (109 cells/ml) 
were prepared as described (35). 50  µl of cells was sensitized 
with the indicated concentrations and combinations of one or 
two monoclonal anti-TNP IgG subclass Abs for 30 min at 37°C. 
To avoid unwanted agglutination, the highest non-agglutinating 
concentration was determined (22.5 µg/ml for IgG2a) (data not 
shown). Unbound Abs were removed by washing the samples 
first with GVB° and then GVB++ (with Ca2+ and Mg2+) buffer 
(ComplementTechnology, Tyler, TX, USA). Anti-TNP IgG 
subclass Ab-sensitized TNP-labeled RBCs were incubated with 
human serum from healthy volunteers diluted 1:3 in GVB++ 
buffer to induce complement-mediated RBC lysis. Complement 
activation and RBC lysis were stopped after 30 min at 37°C by 
adding 1 ml of ice cold 0.9% NaCl. Samples were centrifuged at 
2,000 g for 5 min at 4°C and free hemoglobin in the supernatant 
was measured at 414 nm. The degree of RBC lysis (in %) was set in 
relation to a positive control lysis with H2O (100%). As a negative 
control, non-IgG sensitized TNP-coupled RBCs were incubated 
with the same serum-GVB++ preparation resulting in less than 
4% lysis compared with the H2O-induced lysis. The induction of 
the classical complement pathway in this lysis assay was verified 
by blocking Ca2+ with EGTA (data not shown).
statistical Analysis
Statistical analyses were performed using GraphPad Prism 
software. Student’s t-test was used for comparing two groups or 
one-way ANOVA for comparing more than two groups: P-values 
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A
D E F G
B C
FiGUre 1 | Murine IgG1 prevents C1q binding and complement activation by IgG2a, IgG2b, or IgG3 antibodies (Abs) in an antigen-specific manner.  
(A) Schematic description of the C1q ELISA applied in panels (B,c) and Figure S1 in Supplementary Material. 2,4,6-Trinitrophenyl (TNP)-Ficoll-coupled 96-well 
plates were incubated with different concentrations of one or two anti-TNP monoclonal IgG subclass Abs [anti-TNP IgG1 (clone H5; red), IgG3 (clone 9A6; gray)  
as well as IgG1 (orange), IgG2a (blue), and IgG2b (green) class-switch variants (sv; with identical VDJ sequences)] and subsequently with C1q-containing serum; 
C1q was detected with an anti-C1q-HRP-coupled secondary Ab system. (B,c) Mean of the resulting C1q ELISA values measured at 450 nm (OD450) with the 
indicated (μg/ml) single or paired anti-TNP IgG subclass Abs (n = 2). IgG subclass-specific half-maximal effective concentrations (EC50; ×) were calculated by the 
interpolated subclass-specific C1q-binding curves in panel (c) (R2 > 0.99). (D) Schematic description of the applied red blood cell (RBC)-lysis assay. TNP-coupled 
RBCs (Figure S1E in Supplementary Material) were incubated with one or two anti-TNP monoclonal IgG subclass Abs or an anti-ovalbumin IgG1 (clone 4C9) Ab  
and subsequently treated with serum containing C1q and further complement components. (e) Exemplary hemolysis approach with centrifuged TNP-coupled  
RBCs after reaction with serum, serum plus anti-TNP IgG2a or H2O as a positive control (100% lysis). (F,G) Mean of the resulting RBC lysis [measured hemoglobin 
(OD 414 nm) in the supernatant of centrifuged RBCs], which was calculated as the percentage of H2O-induced positive control RBC lysis (100%; maximum of the 
y-axes) with the indicated (μg/ml) single or paired IgG subclass Abs (n = 2). The results from one of at least two independent experiments are presented.
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below 0.05 were considered statistically significant (*P  <  0.05, 
**P < 0.01, and ***P < 0.001). EC50 values were calculated using 
a non-linear regression with the variable slope model.
resULts
Murine igG1 Prevents complex Formation 
of igG2a, igG2b, and igG3 With c1q
To investigate antigen-dependent interference between non- 
C1q-binding murine IgG1 and C1q-binding IgG2a, IgG2b, and 
IgG3 subclasses for C1q binding, we used TNP-specific murine 
monoclonal IgG1 (clone H5), IgG3 (clone 9A6), and IgG1, IgG2a, 
and IgG2b class-switch variant (sv; with identical VDJ sequences) 
Abs (10, 19, 33, 34, 36, 37). Incubation of plate-bound TNP-
Ficoll with different concentrations of single TNP-specific IgG 
subclasses and serum as a source of C1q showed preferential bind-
ing of C1q to IgG2a (sv), but also to IgG2b (sv) and IgG3 (9A6). 
The calculated half-maximal effective concentrations (EC50) of 
the interpolated IgG subclass-specific C1q-binding curves in this 
approach were 1.1 µg/ml for IgG2a (sv), 4.3 µg/ml for IgG2b (sv), 
and 12.5–12.9  µg/ml for IgG3 (9A6), although the EC50 value 
for IgG3 could not directly be compared with the values for the 
switch variants IgG2a and IgG2b due to differences in their VDJ 
sequences (Figures 1A–C; Figure S1 in Supplementary Material). 
The two monoclonal IgG1 clones (sv and H5) failed to interact 
with C1q in this approach (Figures 1A–C).
However, the combination of two different IgG subclasses 
showed that both IgG1 clones inhibited the binding of C1q to 
IgG2a, IgG2b, and IgG3 in a concentration-dependent manner 
(Figures 1A–C; Figure S1 in Supplementary Material). The IgG1 
clone H5 showed a stronger inhibition than the IgG1 sv clone 
9
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because of a higher affinity to TNP (measured by affinity ELISA; 
data not shown).
At an almost saturated C1q-binding dosage of IgG2a (5 µg/ml), 
C1q binding was inhibited about 2- or 10-fold by a 2-fold amount 
of the IgG1 sv or using IgG1 clone H5 of higher affinity, respec-
tively (Figure 1B; Figure S1A in Supplementary Material). At an 
IgG2a concentration (1.5 µg/ml) near its EC50, C1q binding to 
IgG2a was inhibited about 1.4-fold by a 2-fold amount of the IgG1 
clone H5 (Figure  1C; Figure S1B in Supplementary Material). 
At an almost saturated C1q-binding dosage of IgG2b (10 µg/ml), 
C1q binding was downregulated about 4- or 9-fold by only 1.5-fold 
amount of the IgG1 sv or the IgG1 clone H5, respectively (Figure 
S1C in Supplementary Material). At IgG3 concentrations (12 or 
16 µg/ml) near its EC50 value, C1q binding was even inhibited 
threefold to fourfold by adding only half the dose of the IgG1 
clone H5 (Figure S1D in Supplementary Material).
In summary, the weaker was the C1q-binding potential of an 
IgG subclass, the more efficient was the inhibition by the IgG1 
Abs and the higher was the concentration of IgG2a, IgG2b, or 
IgG3, the stronger was the dose-dependent C1q-binding inhibi-
tion by IgG1.
By contrast, a combination of IgG2a with IgG2b further 
enhanced C1q binding compared with IgG2a alone and a 
combi nation of IgG2a with IgG3 (at a concentration at which 
IgG3 showed almost no C1q binding) or IgG2b with IgG3 did 
not reduce C1q binding compared with IgG2a or IgG2b alone 
(Figure  1C; Figure S1A–D in Supplementary Material). Thus, 
the murine IgG1 subclass exclusively inhibited binding of C1q to 
murine IgG2a, IgG2b, and IgG3.
Murine igG1 Prevents c1q-Mediated 
complement Activation by igG2a
Next, we investigated in  vitro whether murine IgG1 can also 
inhibit complement-mediated lysis of RBCs induced by the 
other murine IgG subclasses. TNP was conjugated to purified 
RBCs (Figure S1E in Supplementary Material), and these cells 
were incubated with one murine IgG subclass or a combination 
of two different IgG subclasses. Serum was used as a source of 
C1q and further complement components to induce RBC lysis 
and hemoglobin release (Figures 1D–G). Complement-mediated 
RBC lysis was calculated as the percentage of complete lysis of the 
same amount of cells with H2O (set 100%; the positive control) 
(Figures 1E–G).
IgG2a alone induced a dose-dependent C1q-mediated RBC lysis 
when applied in the concentration range between 2.5 and 22.5 µg/ml 
(the highest used non-agglutinating concentration) and reached up 
to 70% of positive control H2O lysis (Figures 1E–G and data not 
shown). IgG2b alone poorly induced RBC lysis in the concentration 
range between 7.5 and 22.5 µg/ml and reached no more than 8% of 
positive control H2O lysis (data not shown). Murine IgG1 and also 
IgG3 alone barely induced any RBC lysis in this setting (1–4% of 
positive control H2O lysis), which was in the range of the negative 
control, when no IgG applied (Figures 1F,G and data not shown). 
Because IgG2b and IgG3 failed to induce significant RBC lysis, we 
further tested how IgG1 affects IgG2a-mediated RBC lysis only.
Both IgG1 clones inhibited IgG2a-induced RBC lysis. The 
IgG1:IgG2a ratio of 2:1 led to a 2.4- or 3-fold inhibition of the 
IgG2a-mediated lysis with the IgG1 sv or the IgG1 clone H5, 
respectively. By contrast, IgG2b enhanced IgG2a-induced RBC 
lysis, whereas IgG3 had no effect (Figures  1F,G and data not 
shown). Furthermore, the IgG1-mediated complement inhibition 
was antigen-specific, because antigen-unspecific, OVA-specific 
murine IgG1 failed to inhibit the IgG2a-mediated RBC lysis 
(Figure 1F).
Thus, the murine IgG1 subclass exclusively inhibited IgG2a- 
and C1q-dependent complement activation in the hemolysis 
assay, in an antigen-specific manner.
DiscUssiON
Murine igG1 and Human igG4 May inhibit 
Hexamer Formation of the Other igG 
subclasses and consequently their  
c1q Binding by steric interference
Human IgG1 and IgG3 Abs form hexamers via non-covalent 
Fc:Fc interactions in an antigen-specific manner to bind C1q. 
Although it has not been determined whether the murine IgG2a, 
IgG2b, and IgG3 Ab subclasses can also form hexamers to bind 
C1q and activate the classical complement pathway, we showed 
that murine IgG1 can prevent the interaction of C1q-binding 
murine IgG subclasses with C1q, as suggested for human IgG4 
(25). Dampening of C1q binding by murine IgG1 or human 
IgG4 might result from competition for antigen binding and/or 
from steric interference between antigen-bound murine IgG1 or 
human IgG4 and the other IgG subclasses to inhibit hexamer for-
mation of the latter Abs (25) (Figure 2A). The potential binding 
of murine IgG1 or human IgG4 to an antigen in close vicinity to 
the C1q-binding IgG subclasses might interfere with Fc:Fc con-
tact formation, potentially leading to reduced hexamerization, 
C1q binding, and complement activation (23, 25). Efficient steric 
interference may be dependent on antigen density and epitope 
specificity, as well as on affinity of murine IgG1 and human IgG4.
Human IgG4 exploits additional properties to modify 
immune responses, such as dynamic Fab-arm exchange, which 
results in formation of bispecific IgG4 Abs (38, 39), and the 
interaction with the Fc part of other IgG subclass Abs (40–45). 
Both mechanisms might also contribute to the human IgG4-
mediated suppression of the hexamer formation by other IgG 
subclasses; but it has not been yet demonstrated for murine IgG1.
The possibility that antigen-dependent steric interference by 
murine IgG1 or human IgG4 prevents the hexamer formation by 
other IgG subclasses might suggest a scenario, in which a single 
murine IgG1 or human IgG4 molecule is sufficient to reduce the 
hexamer formation of the other IgG subclass molecules, confer-
ring anti-inflammatory properties to murine IgG1 or human 
IgG4 via blocking the complement activation.
Anti-inflammatory Functions of Murine 
igG1 and Human igG4 in the context  
of Fcγr interactions
Fcγ receptor-mediated effector functions vary between IgG 
subclasses and depend on FcγR distribution on the surface 





FiGUre 2 | Inhibitory potential of (sialylated) murine IgG1 and human IgG4. (A–c) Summary of our perspective about the inhibitory and therapeutic potential of 
(sialylated) murine IgG1 and human IgG4 (see text for details). IgG antibodies have one conserved N-glycosylation site at Asn 297 in each of their constant heavy 
chain regions. The biantennary core glycan structure that consists of four N-acetylglucosamine (GlcNAc) and three mannose residues can be further decorated with 
fucose, a bisecting GlcNAc and terminal galactose or galactose and sialic acid. (D) Average distribution of total human and mouse serum IgG Fc glycosylation 
patterns coupled to Asn 297 of total human serum IgG (IVIg; pooled intravenous immunoglobulin from healthy donors) and total murine serum IgG from 8- to 
10-week-old untreated female C57BL/6 wild-type mice were analyzed by high-pressure liquid chromatography [data from Epp et al. (19)].
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as human IgG4, show limited specificities and affinities to 
the classical activating FcγRs and preferably interact with the 
classical IgG inhibitory receptor FcγRIIb, as compared with 
murine IgG2a and IgG2b as well as human IgG1 and IgG3 
(Figure 2B; Figure S2 in Supplementary Material) (1–5, 46, 47). 
Thus, both the IgG subclass distribution and the expression 
levels of classical activating and inhibitory FcγRs determine 
the balance between activating and inhibitory signals in the 
target cells.
Mechanistically, crosslinking of IgG Abs with classical 
activating FcγRs induces phosphorylation of their own or their 
associated Fc receptor gamma (FcRγ)-chain intracellular immu-
noreceptor tyrosine-based activation motif (ITAM) (Figure S2 
in Supplementary Material) and activation of the target cell 
(Figure S2 in Supplementary Material) (2). However, additional 
IgG-mediated crosslinking of the inhibitory FcγRIIb can lead 
to the phosphorylation of its intracellular immunoreceptor 
tyrosine-based inhibition motif (ITIM) and thereby inhibition 
41
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of cell activation (Figure S2 in Supplementary Material) (2). 
In general, the phosphorylation of an ITIM motif always depends 
on upstream ITAM phosphorylation, for example, here, of acti-
vating FcγR (Figure S2 in Supplementary Material) (2).
Moreover, FcγR-mediated pro- or anti-inflammatory effector 
functions of murine and human IgG Abs are effected by the IgG Fc 
N-glycosylation pattern at Asn 297 in the CH2 region. Enriched 
amounts of non-(a)galactosylated IgG (auto)Abs are associated 
with pro-inflammatory effector functions of the IgG Abs and 
(auto)immune disease severity, such as IgG autoAbs in patients 
with rheumatoid arthritis, whereas galactosylated and sialylated 
IgG Abs possess reduced inflammatory and even immunosup-
pressive potential (Figure 2D) (6–12, 14, 17–19, 34, 48). IgG Fc 
galactosylation and sialylation seems to alter the conformation of 
the Fc portion and ultimately shifts its affinity from the classical 
FcγRs toward the so-called type II FcRs that mediate inhibitory 
signaling. Several sugar-binding C-type lectin receptors belong 
to the type II FcRs, including murine specific ICAM-3-grabbing 
non-integrin-related 1 (SIGN-R1) and its human homolog den-
dritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN); 
CD209, murine dendritic cell inhibitory receptor (DCIR), and 
CD23 (Figure 2B; Figure S2 in Supplementary Material) (4, 7, 8, 
12–15, 18, 19, 49–53).
SIGN-R1 and DC-SIGN have originally been identified as 
receptors that recognize carbohydrates of some bacteria, e.g., S. 
pneumonia (4, 7, 14, 51). SIGN-R1 and DC-SIGN contain neither 
an ITAM nor an ITIM motif and the induction of inhibitory 
signals by sialylated IgG Abs via these receptors is yet unclear 
(Figure S2 in Supplementary Material).
Dendritic cell inhibitory receptor interacts with glycans of 
both pathogenic and endogenous origins and has, in contrast 
to SIGN-R1/DC-SIGN, an intracellular ITIM motif (4, 13, 
49, 50, 54). However, it is still unknown whether sialylated 
IgG immune complexes (ICs) crosslink DCIR with ITAM-
containing classical FcγRs or other ITAM-containing recep-
tors to deliver inhibitory signals (Figure S2 in Supplementary 
Material).
CD23 is known as the low-affinity IgE receptor present on 
some immune cells, including B lymphocytes. However, also sia-
lylated IgG Abs can crosslink CD23, which leads to up-regulation 
of FcγRIIB expression (Figure S2 in Supplementary Material) 
(4, 14, 15, 55). The induced inhibitory signals by CD23 might be 
mediated by crosslinking of CD23 with the B cell receptor (BCR) 
and thereby modulating the BCR signal.
The structure of the IgG Fc glycan has different impact on 
the effector functions of the different IgG subclasses: it strongly 
influences functional properties of murine IgG1, less of IgG2b, 
but barely of IgG2a (10, 11, 19, 34, 48).
Recent studies have shown that sialylated antigen-specific 
murine IgG1 Abs can be used to induce antigen-specific immune 
tolerance, making such Abs a potential therapeutic tool to treat 
inflammatory immune diseases in an antigen-specific manner 
(10–12, 16).
In addition to the anti-inflammatory potential of sialylated 
murine IgG1, only galactosylation of murine IgG1 has also 
induced inhibitory signals in a mouse model of autoimmune 
hemolytic anemia and via crosslinking the C-type lectin receptor 
Dectin-1 (Clec7a) with the inhibitory receptor FcγRIIb (Figure 
S2 in Supplementary Material) (12, 34, 56). Dectin-1 recognizes 
bacterial carbohydrates and activates effector cells via an intra-
cellular ITAM-like (hemITAM) motif (34, 51, 57). However, in 
proximity to FcγRIIb, the ITAM-like motif of Dectin-1 induces 
phosphorylation of the ITIM motif of FcγRIIb and promotes 
inhibitory signaling (34). Recently, it has further been suggested 
that the galactose-binding receptor galectin-3 is additionally 
involved in this complex and directly interacts with galactosylated 
murine IgG1 and induces complex formation between Dectin-1 
and FcγRIIb (58). In humans, inhibitory effects of galactosylated 
IgG Abs have been described for the plasmacytoid dendritic 
cell-specific type II C-type lectin receptor blood dendritic cell 
antigen 2, which signals via the ITAM-containing FcRγ-chain as 
signaling molecule (59, 60).
It has still to be determined to which extent Fc glycosylation 
affects effector properties of human IgG molecules in a subclass-
dependent manner, but the current suggestion is that the effector 
function of all human IgG subclasses depends on the Fc glyco-
sylation pattern.
Interestingly, the hexamer formation of human IgG1 is 
dependent on the conserved IgG Fc glycosylation site (23) and 
human IgG1 Fc galactosylation favors C1q binding, as compared 
with agalactosylated as well as sialylated human IgG1 (61, 62).
Together, the observations mentioned before show that 
sialylated murine IgG1 and seemingly human IgG4 have an 
anti-inflammatory potential in the context of FcγR-mediated 
activation of the immune system.
igG subclass Distribution and Fc 
Glycosylation Pattern Determine the 
effector Function of igG Abs, Making 
sialylated Murine igG1 and Human igG4 
Attractive inhibitory (therapeutic) tools
In line with the above mentioned findings, it has recently been 
demonstrated that IgG1-deficient mice develop severe autoim-
mune conditions in different inflammatory autoimmune disease 
models (63, 64) as well as enhanced antigen-dependent IgG3 IC 
depositions in the kidneys (37). The autoimmune models used in 
these studies (63, 64), similar to other inflammatory autoimmune 
models, are apparently dependent on C1q and the complement 
activation as well as on classical FcγR-mediated immune cell 
activation (21, 61, 63–69). In future studies, it would be impor-
tant to explore the inhibitory potential of murine IgG1 and its Fc 
glycosylation status in terms of the complement activation and 
FcγR-mediated regulation of effector cells using various models 
of autoimmunity and inflammation.
In summary, the mentioned results show that the analysis of 
the IgG subclass distribution and Fc glycosylation pattern during 
an immune response provides important information about the 
inflammatory state of the immune reaction. It is still a common 
practice that inflammatory and autoimmune diseases are diag-
nosed only by analysis of total (auto)antigen-specific IgG Abs. 
We believe that the additional analysis of IgG subclass distribution 
and their Fc glycosylation patterns will be essential for under-
standing the current inflammatory status of antigen-specific 
42
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IgG-mediated immune response and associated pathologies. 
These data also suggest that murine IgG1 and human IgG4 Abs 
in particular might have the strongest inhibitory potential toward 
all other IgG forms, due to their possible inhibitory effect on both, 
complement and classical FcγR activation (Figure 2C).
Total IgG fraction in human serum mainly consists of human 
IgG1 and less of human IgG4 (IgG1  >  IgG2  >  IgG3  >  IgG4). 
Changes in this distribution of IgG subclasses as well as in their 
Fc glycosylation patterns will presumably have a strong impact on 
IgG-mediated immune responses.
For many years, the induction of human IgG4 (for instance, 
induced by allergen-specific immunotherapies) has been 
associated with the inhibition of IgE-mediated allergic immune 
responses (19, 70). However, in the presence of high doses of 
allergen IgG Abs can also induce allergic reactions (19). In this 
context, an inhibitory role of human IgG4 has been discussed 
(19, 29). Furthermore, the MHC-specific human IgG1/3 to 
IgG4 ratio might be a critical parameter that determines the 
risk of complement-mediated transplant rejection in patients 
after organ transplantation and blood transfusion (71). More 
in-depth analysis of the IgG subclass distribution and Fc gly-
cosylation might clarify inhibitory effects of human IgG4 in 
these studies.
Blockade of C1q with designer molecules has been proposed 
as a potent approach to treat inflammatory diseases. However, 
the shift of antigen-specific T and B  cell responses to produce 
primarily sialylated human IgG4 or the application of enriched or 
in vitro-produced antigen-specific sialylated IgG4 Abs might be a 
promising alternative therapeutic approach to treat complement-
mediated inflammatory diseases and to inhibit FcγR-mediated 
inflammatory responses at the same time. Recent studies have 
indeed shown for the first time that enrichment of type XVII 
collagen (Col17)-specific human IgG4 autoAbs from autoim-
mune patients with bullous pemphigoid skin disease and their 
administration to humanized Col17 mice inhibited the comple-
ment activation and disease development by interfering with the 
other IgG subclasses (72).
cONcLUsiON AND PersPective
We showed that murine IgG1 inhibits C1q binding of IgG2a, 
IgG2b, and IgG3 and complement activation by murine IgG2a in 
an antigen-dependent manner, and suggested potential applica-
tion of these findings for human IgG4. We further outline other 
inhibitory functions of murine IgG1 and human IgG4 and stressed 
the importance of future analysis of IgG subclass distribution 
and Fc glycosylation patterns in developing novel therapeutic 
approaches. We conclude that antigen-specific sialylated murine 
IgG1 and human IgG4 Abs might be a promising therapeutic tool 
to inhibit complement activation and abolish FcγR-mediated 
inflammatory responses in inflammatory (autoimmune) 
diseases.
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FiGUre s1 | Inhibition of C1q binding to IgG2a, IgG2b, and IgG3 by IgG1. (A–D) C1q 
ELISA experiments as described and partially shown in Figures 1A–c with 
2,4,6-trinitrophenyl (TNP)-Ficoll-coated 96-well plates, which were incubated with 
different concentrations of one or two anti-TNP monoclonal IgG subclass Abs 
[anti-TNP IgG1 (clone H5; red), IgG3 (clone 9A6; gray) as well as IgG1 (orange), 
IgG2a (blue), and IgG2b (green) class-switch variants (sv; with identical VDJ 
sequences)] and subsequently with serum containing C1q that was detected with 
an anti-C1q-HRP-coupled secondary Ab system. The left figure parts in panels 
(A–D) show the single IgG2a (blue), IgG2b (green), or IgG3 (gray) OD 450 nm (OD 
450; left y-axes; each point: mean of n = 2) value binding curves and their 
interpolated binding curves with the percentage (right y-axes) of their maximal 
C1q binding [black; R2 of interpolation was >0.99; the top of the (interpolated) 
IgG subclass-specific curves was set to 100%, and the bottom of the curves was 
set to 0%]. The IgG subclass-specific half-maximal effective concentration (EC50) 
was calculated from the interpolated C1q-binding curves. To the indicated 
(dashed line) amounts of single IgG subclasses [(A) 5 µg/ml IgG2a; (B) 1.5 µg/ml 
IgG2a; (c) 10 µg/ml IgG2b; (D) 12 or 16 µg/ml IgG3], the indicated x-fold 
amounts of a second indicated anti-TNP IgG subclass were added. Their 
resulting OD 450 values and calculated percentages are presented in the right 
figure parts. (e) Verification of the TNP-coupling to red blood cell (RBC) as 
described in Figure 1D. TNP coupling to RBCs was verified by flow cytometry 
with murine anti-TNP IgG2a (sv) and FITC-labeled anti-murine IgG2a Abs. The 
results from one of at least two independent experiments are presented.
FiGUre s2 | Expression of IgG Fc interacting receptors by human and murine 
immune effector cells and their immunoreceptor tyrosine-based activation motif 
(ITAM)/immunoreceptor tyrosine-based inhibition motif (ITIM) signaling motifs. List of 
type I and type II IgG Fc receptors as mentioned in the text. The expression pattern 
of the individual receptors on different immune cell types has been described 
before (1–5, 7, 8, 12–15, 18, 19, 34, 46, 47, 49–54, 57–60). Abbreviations: BC, 
B cells; TC, T cells; NK, natural killer cells; Mo, monocytes; MΦ, macrophages.
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Complement C1q, the initiation molecule of the classical pathway, exerts various
immunomodulatory functions independent of complement activation. Non-classical
functions of C1q include the clearance of apoptotic cells and cholesterol crystals (CC),
as well as the modulation of cytokine secretion by immune cells such as macrophages.
Moreover, C1q has been shown to act as a binding partner for von Willebrand
factor (vWF), initiation molecule of primary hemostasis. However, the consequences of
this C1q-vWF interaction on the phagocytosis of CC by macrophages has remained
elusive until now. Here, we used CC-C1q-vWF complexes to study immunological
effects on human monocyte-derived macrophages (HMDMs). HMDMs were investigated
by analyzing surface receptor expression, phagocytosis of CC complexes, cytokine
secretion, and caspase-1 activity. We found that vWF only bound to CC in a
C1q-dependent manner. Exposure of macrophages to CC-C1q-vWF complexes resulted
in an upregulated expression of phagocytosis-mediating receptors MerTK, LRP-1, and
SR-A1 as well as CD14, LAIR1, and PD-L1 when compared to CC-C1q without vWF,
whereas phagocytosis of CC-C1q complexes was hampered in the presence of vWF.
In addition, we observed a diminished caspase-1 activation and subsequent reduction
in pro-inflammatory IL-1β cytokine secretion, IL-1β/IL-1RA ratio and IL-1α/IL-1RA ratio.
In conclusion, our results demonstrate that vWF binding to C1q substantially modulates
the effects of C1q on HMDMs. In this way, the C1q-vWF interaction might be beneficial
in dampening inflammation, e.g., in the context of atherosclerosis.
Keywords: macrophages, complement C1q, von Willebrand factor, cholesterol, atherosclerosis, innate immunity
INTRODUCTION
The complement system is a highly effective part of the innate immune system. The multiple
functions of complement include defense against bacterial infections, bridging innate and adaptive
immunity and the clearance of immune complexes, and components of inflammation (1).
The complement system can be activated through three distinct pathways: the classical, the
lectin and the alternative pathway. All three pathways converge in a shared terminal response
resulting in the formation of C5a and C3a as potent inflammatory effector molecules and C5b-9
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as membrane attack complex. However, each pathway is initiated
through different characteristic recognition molecules (2). The
initiation of the classical pathway is triggered by C1q through
sensing of bound antibodies as well as pathogen- and damage-
associated molecular patterns (PAMPs/DAMPs). In addition,
more recent research has shown a number of functions for
C1q that are independent of downstream complement activation
(3). On the one hand, opsonization with C1q enhances the
clearance of diverse structures, namely immune complexes (4)
and apoptotic cells (5) as well as atherogenic lipoproteins (6)
and cholesterol crystals (CC) (7) by phagocytes. On the other
hand, anti-inflammatory properties for C1q have been well-
described. For example, bound C1q decreases the release of
pro-inflammatory cytokines and increases the production of
anti-inflammatory mediators by phagocytes (8, 9). Additionally,
the presence of C1q on apoptotic cells skews macrophage
polarization toward an anti-inflammatory phenotype (10).
Apart from C1q’s extensively studied involvement in
immunity, a complex cross-talk between complement
and coagulation is becoming more and more evident (11).
Complement components have been found to induce hemostasis
and vice versa coagulation factors can trigger complement
activation, thereby combining two powerful plasma cascades.
Within the hemostatic cascade, von Willebrand factor (vWF)
acts as an important starter molecule by mediating platelet
adhesion and aggregation. Immune cells, such as macrophages,
are competent to take up and clear vWF through scavenger
receptors (12, 13). Moreover, vWF has been shown to interact
with complement factor H (14, 15) and therefore can modulate
the activation of complement via the alternative pathway (16).
Furthermore, a direct interaction between vWF and C1q was
found by our group, demonstrating that C1q, bound to surfaces
such as apoptotic cells, acts as a binding partner for vWF (17).
The C1q-vWF interaction also seems to occur on the surface
of CC.
CC can be found as a characteristic feature in the intima
of atherosclerotic arteries from early lesions to late plaque (18)
and are widely used in in vitro models of atherosclerosis (19–
21). Formation of CC occurs upon fatty streak development
by an increased uptake and exhausted efflux of cholesterol by
lipid-laden macrophages known as foam cells. In in vitro and
in vivo models of atherosclerosis, CC have been implicated
in the activation of the NOD [nucleotide oligomerization
domain]-, LRR [leucine-rich repeat]-, and PYD [pyrin domain]-
containing protein 3 (NLRP3) inflammasome and downstream
cytokine secretion, consequently triggering local and systemic
inflammation (22–24). While the role of CC and macrophages
in atherosclerosis appears unambiguous, C1q can play a dual
role. On the one hand, C1q bound to oxidized low-density
lipoproteins (LDL) or CC has been shown to activate the
classical pathway, and in this context to drive the progression
of atherosclerosis in animal models (25, 26). On the other
hand, C1q has also been described to be protective in early
atherosclerosis in vivo (27, 28) and to increase cholesterol efflux
transporter expression in vitro (6), suggesting atheroprotective
properties. Similarly, the role of vWF in atherosclerosis is still
a matter of debate. Although various studies suggest that vWF
deficiency provides protection from atherosclerosis in animals,
in humans, an unequivocal protective effect of vWF deficiency
on atherosclerosis has not been demonstrated so far (29).
In summary, CC, macrophages, C1q and vWF have all been
implicated in atherosclerosis. Nevertheless, the consequences
of the interaction between C1q and vWF, especially on
phagocytes, remain to be determined. In order to better
understand this interaction, the aim of our study was to
investigate the immunological effect of complexes consisting of
cholesterol crystals, C1q and von Willebrand factor (CC-C1q-
vWF complexes) by studying receptor expression, phagocytosis
and cytokine secretion of macrophages.
MATERIALS AND METHODS
Preparation of CC
Cholesterol (suitable for cell culture, Sigma Aldrich, St. Louis,
MO, USA) was dissolved in 95% ethanol at 60◦C (12.5 g/l), sterile
filtered and allowed to crystallize at room temperature (RT) for
7 days (d). Excess liquid was removed from the suspension,
followed by drying for 5 d. Finally, CC were ground and stored as
stock CC at−20◦C until use.
Preparation of CC, CC-C1q, and
CC-C1q-vWF Complexes for
Characterization of C1q and vWF Binding
Dry stock CC were weighed and suspended in PBS (Life
Technology, Carlsbad, CA, USA) at a concentration of 1.6mg/ml,
vortexed, and sonicated until a visually homogenous suspension
was achieved. This CC suspension was split in three fractions
for generation of CC, CC-C1q complexes, and CC-C1q-vWF
complexes. Fractions were washed with PBS by centrifugation
(1,000 x g, 5min, RT) and resuspended at the same concentration.
For generation of CC-C1q complexes, 50µg/ml purified C1q
(Complement Technology, Tyler, Tx, USA), diluted in PBS,
was added and incubated for 1 h at RT on a shaker (700
rpm). Afterwards, CC and CC-C1q complexes were washed (as
described above). For generation of CC-C1q-vWF complexes,
10µg/ml recombinant vWF {provided by Baxalta, Lexington,
MA, USA [former Baxter; characterization by Turecek et al.
(30)]}, diluted in PBS, was added to washed CC-C1q complexes,
vortexed rigorously, and further incubated for 1 h at RT on a
shaker (700 rpm). After another washing step, CC complexes
were further incubated with monoclonal mouse anti-C1q [clone
32A6 cell supernatant (31)], diluted 1:20 in PBS, or polyclonal
rabbit anti-vWF (Abcam, Cambridge, UK), diluted 1:1,000
in PBS, for 1 h at RT on a shaker (700 rpm). Secondary
antibody staining was performed with donkey anti-mouse IgG-
AlexaFluor (AF)555 (Life Technology) and goat anti-rabbit IgG-
AF647 (Abcam), both diluted 1:200 in PBS/1%BSA (Sigma
Aldrich)/0.5M NaCl for 30min at 4◦C in the dark, followed by
a final wash step and resuspension in PBS/1%BSA/0.5M NaCl.
All fractions were washed and treated with either active substance
(protein or antibodies) or solution only in the same manner. For
flow cytometry, data were acquired using a BD Accuri 6 (BD
Biosciences, San Jose, CA, USA) and analyzed with FlowJo10.
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For confocal microcopy, CCwere spun onto cytoslides (Shandon,
Pittsburg, PA, USA) by a Cytospin centrifuge (Thermo Fisher
Scientific, Waltham, MA, USA) and analyzed using Nikon A1R
Nala and NIS software (both Nikon, Tokyo, Japan). For imaging
flow cytometry, analyses were carried out using ImageStreamX
Mark II and IDEAS software (both EMD Millipore, Billerica,
MA, USA).
Cell Culture
Peripheral blood mononuclear cells were isolated from fresh
buffy coats (Blood Transfusion Center of the University Hospital
Basel, Basel, Switzerland) by density gradient centrifugation
using Lymphoprep (Stemcell Technologies, Vancouver, Canada).
Monocytes were obtained by CD14+ magnetic-activated cell
separation beads (Miltenyi, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions (yielding an
average purity of 95–98% CD14+ monocytes determined by
flow cytometry). Monocytes were differentiated into human
monocyte-derived macrophages (HMDMs), cultured in
DMEM supplemented with 100 U/ml penicillin and 100µg/ml
streptomycin (DMEM+), 10% fetal calf serum (FCS) (all
from Life Technology), and 50 ng/ml GM-CSF (Immunotools,
Frisoythe, Germany) at a cell concentration of 5 × 105 cells/ml
in 6-well plates (BD Biosciences, Franklin Lakes, NJ, USA) and
maintained in 5% CO2 at 37
◦C for 7 days.
Treatment With CC Complexes
After 7 days, HMDMs were washed with prewarmed DMEM+,
optionally stimulated with 100 ng/ml lipopolysaccharide (LPS)
(E. coli O127:B8, Sigma Aldrich), diluted in prewarmed
DMEM+, and treated with CC, CC-C1q, or CC-C1q-vWF
complexes for indicated time points. CC and CC-complexes
were prepared as described above, washed once with PBS by
centrifugation (1,000 × g, 5min, RT) and resuspended in
prewarmedDMEM+ at a final concentration of 0.5 mg/ml before
adding to cells.
Surface Receptor Expression
HMDMs were stimulated with LPS and treated with CC, CC-
C1q, or CC-C1q-vWF complexes as described above. After 18 h,
HMDMs were washed with PBS and incubated with PBS/10mM
EDTA (AppliChem, Darmstadt, Germany) for 30min at 4◦C.
Cells were collected in FACS buffer (PBS/0.1% FCS/1mMEDTA)
and resuspended at a cell concentration of 5 × 105 cells/100 µl
and incubated with 2µg/ml of human IgG for 45min at 4◦C to
block unspecific binding of antibodies to Fcγ receptors. Staining
was performed for 30min at 4◦C in the dark in PBS using
the following antibodies: anti-MHC II-FITC (Immunotools),
anti-tyrosine-protein-kinase Mer (MerTK)-PE (R&D Systems,
Minneapolis, MN, USA), anti-programmed death ligand 1 (PD-
L1/CD274)-APC and anti-CD14-PeCy7 (both from Biolegend,
San Diego, CA, USA) (antibody panel 1), or anti-CD86-
FITC (Biolegend), anti-lipoprotein receptor-related protein 1
(LRP-1/CD91)-PE (Thermo Fisher Scientific, Waltham, MA,
USA), anti-leukocyte-associated immunoglobulin-like receptor
1 (LAIR1/CD305)-AF647 and anti-scavenger receptor A 1 (SR-
A1/CD204)-PeCy7 (both from Biolegend) (antibody panel 2).
HMDMs were washed and resuspended in FACS buffer. Data
were aquired using a BD LSRFortessa (BD Biosciences) and
analyzed with FlowJo10. Gating was performed on SSC/CD14+
cells (antibody panel 1) or SSC/CD91+ cells (antibody panel 2),
respectively, and geometric mean fluorescence intensity (gMFI)
was calculated.
Phagocytosis Assay
Assessment of Granularity of HMDMs
HMDMs were kept untreated or treated with CC, CC-C1q or
CC-C1q-vWF complexes as described above. After 18 h, HMDMs
were harvested with PBS/10mM EDTA and resuspended at a cell
concentration of 5 × 105 cells/100 µl in FACS buffer. HMDMs
were stained with anti-CD11c-APC (Biolegend) for 30min at
4◦C in the dark. Data were aquired using a BD LSRFortessa (BD
Biosciences) and analyzed with FlowJo10. For the quantification
of phagocytosis the percentage of CD11c+ cells with high cell
granularity, indicated by a shift into the side scatter (SSC) high
gate (gate set according to shift in SSC from CD11c+ untreated
to CC treated cells), was determined.
Assessment of Phagocytosed pHrodo-Dyed CC
Complexes
HMDMs were harvested with PBS/10mM EDTA and
resuspended in phagocytosis buffer (DMEM+/12.5mM
HEPES (Sigma Aldrich)/5mM MgCl2) at a density of 5 × 10
5
cells/100 µl. For pHrodo-dyed CC complexes, 1 mg/ml CC were
suspended in 0.1M NaHCO3 buffer (pH 8.3) and incubated with
10µg/ml pHrodo Red Ester (Thermo Fisher Scientific) for 1 h
in the dark before the addition of C1q or C1q-vWF as described
above. After a final wash, pHrodo-dyed CC complexes were
added to HMDMs at a concentration of 0.5 mg/ml and incubated
at 37◦C for 30min. Unphagocytosed CC complexes were
washed away and HMDMs were stained with anti-CD11c-FITC
(Bio-Rad, Hercules, CA, USA) for 30min at 4◦C in the dark and
resuspended in FACS buffer. Data were aquired using a Beckman
Coulter CytoFLEX (Beckman Coulter, Brea, CA, USA) and
analyzed with FlowJo10. For the quantification of phagocytosis,
the percentage of CD11c+ cells with a shift into the pHrodo
Red Ester+ gate (gate set according to shift in pHrodo Red Ester
from CD11c+ untreated to CC treated cells) was determined.
Quantification of Secreted Cytokine Levels
HMDMs were stimulated with LPS and treated with CC, CC-
C1q, or CC-C1q-vWF complexes as described above. After 18 h,
supernatants were collected, centrifuged to remove cellular debris
and CC and stored at −80◦C until measurement. Analyses of
cytokine secretion were carried out in duplicates with ELISA
kits according to the manufacturer’s instructions. IL-1ß, IL-1α,
IL-6, and IL-10 were measured using Biolegend ELISA kits, IL-
18 and IL-1RA using Abcam ELISA kits and TNFα using a BD
Bioscience ELISA kit.
Caspase-1 Activity Assay
HMDMs were kept untreated or treated with CC, CC-
C1q, or CC-C1q-vWF complexes as described above. After
18 h, HMDMs were harvested with PBS/10mM EDTA and
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resuspended at a cell concentration of 5 × 105 cells/ml. Cells
were incubated for 1 h with fluorochrome-labeled inhibitors of
caspases (FLICA) probes for caspase-1 detection according to
the manufacturer’s instruction (FAM FLICA Caspase-1 Assay
Kit, Immunochemistry Technology, Bloomington, MN, USA).
HMDMs were stained with anti-CD11c-APC (Biolegend) for
30min at 4◦C in the dark. Data were aquired using a BD
LSRFortessa (BD Biosciences) and analyzed with FlowJo10.
Quantification of caspase-1 activity was determined by the
percentage of CD11c+ cells in the FLICA+ gate.
Statistical Analysis
Data are expressed as median ± interquartile range (IQR), if not
stated otherwise. Wilcoxon matched pairs signed rank test was
used to compare two groups of paired data. When more than 2
groups of unpaired data were compared, Kruskal-Wallis test was
performed and if significant followed by Mann-Whitney U-test
for comparison of two specified groups as indicated. Data were
analyzed with a statistical package program (GraphPad Prism
8, La Jolla, CA, USA). Differences were considered statistically
significant when the p < 0.05.
RESULTS
vWF Binds to CC in a C1q-Dependent
Manner
Whereas, C1q is described as a classical opsonin for a variety
of DAMPs (10), the molecule has been also shown to adhere
to oxidized LDL (6). In addition, Samstad et al. demonstrated
C1q binding on CC after incubation with human plasma (7).
Therefore, we first analyzed whether surface-bound C1q on CC
secondarily enables the binding of vWF. We characterized the
binding of vWF to C1q on the surface of CC by flow cytometry
(Figures 1A–C), confocal microscopy (Figure 1D), and imaging
flow cytometry (Figure 1E). C1q deposition on the surface of CC
is shown in Figure 1A. The incubation of CC with vWF in the
absence of C1q showed no vWF deposition on the CC surface
(orange histogram in Figures 1B,C). Only in the presence of
surface-bound C1q, vWF was enabled to bind (green histogram
in Figures 1B,C). The gMFI for vWF binding in the presence of
C1q was 50-fold higher compared to CC without C1q [median
gMFI (IQR) of C1q+vWF: 115,000 (102,000–175,000) vs. vWF:
2,300 (1,500–2,400), p = 0.0079]. Furthermore, we analyzed the
localization of vWF binding to CC-C1q complex. Using confocal
microscopy, C1q and vWF could be visualized on CC. C1q and
vWF stainings co-localized (Figure 1D). Finally, we used imaging
flow cytometry to analyze a larger CC population as CC have
a heterogenous structure. Again, we observed a similar staining
pattern for C1q and vWF on CC (Figure 1E).
Taken together, our results demonstrate that bound C1q
mediates the binding of vWF to CC, and vWF alone is not able to
bind to the surface of CC.
CC-C1q-vWF Complexes Upregulate the
Surface Receptor Expression of HMDMs
Macrophages have a high degree of plasticity, enabling these
cells to change their phenotype according to the environmental
stimuli (32). In this context, C1q has been shown to elicit
upregulated expression of MerTK receptor, which is involved
in the process of dead cell removal, termed efferocytosis (33).
Moreover, it has been described that stimulation of macrophages
with C1q leads to a polarization of these cells toward an anti-
inflammatory state (34). Therefore, we aimed to investigate the
phenotype of HMDMs in our in vitro model. For this purpose,
HMDMs were kept untreated or treated with CC, CC-C1q, or
CC-C1q-vWF complexes for 18 h. To mimic the inflammatory
milieu present in, e.g., atherosclerotic plaques (35), HMDMs
were simultaneously exposed to 100 ng/ml LPS for 18 h. The
phenotype was studied by analyzing the expression of surface
CD14, CD86, LAIR1, LRP-1, MerTK,MHC II, PD-L1, and SR-A1
(Figures 2A–H). HMDMs treated with CC-C1q-vWF complexes
significantly upregulated the expression of CD14 (p = 0.0312),
LAIR1 (p = 0.0312), LRP-1 (p = 0.0312), MerTK (p = 0.0312),
PD-L1 (p = 0.0312), and SR-A1 (p = 0.0312) as compared to
CC-C1q complexes without vWF. In four out of six donors,
CD86 expression was upregulated, while MHC II expression was
downregulated in five out of six donors. Neither the median
receptor expression of CD86 nor of MHC II was significantly
affected. Also, CC treatment did not induce any significant
changes in surface receptor expression as compared to untreated
HMDMs (data not shown).
Our results demonstrate that CC-C1q-vWF complexes
uniquely affect the expression of surface receptors, namely
an upregulation of efferocytosis receptor MerTK, scavenger
receptors LRP-1 and SR-A1 as well as CD14, LAIR1, and PD-L1.
Phagocytosis of CC-C1q-vWF Complexes
by HMDMs Is Hampered
Since C1q is involved in the processes of efferocytosis (36) as
well as phagocytosis (9) and as the additional presence of vWF
upregulates efferocytosis and scavenger receptors (Figure 2), we
next investigated the role of C1q-vWF binding in the uptake of
CC complexes by HMDMs (Figure 3). Therefore, HMDMs were
kept untreated or treated with CC, CC-C1q, or CC-C1q-vWF
complexes for 18 h. The phagocytosis of CC led to an increase
in cell granularity, which could be determined by a shift in SSC
using flow cytometry. Analyzed as control, untreated CD11c+
HMDMs did not express a SSChigh population. When HDMDs
were treated with CC, CC-C1q, or CC-C1-vWF complexes,
the cells exhibited a SSChigh population (Figure 3A). HMDMs
showed a significant decrease in cells positive for phagocytosis
after the treatment with CC-C1q-vWF complexes compared
to CC-C1q complexes [median phagocytosis (IQR) in six
independent donors of CC-C1q-vWF: 13.65% (5.83–16.35%) vs.
CC-C1q: 24.05% (22.55–34.60%), p = 0.0312] (Figure 3B). To
exploit the effect on early phagocytosis, we incubated CC with
the pH-dependent pHrodo Red dye (Figures 3C,D). Analyzed
as control, unstimulated CD11c+ HMDMs only exhibited a
dim fluorescent signal for pHrodo Red. Fluorescent signal for
pHrodo Red increased strongly when HMDMs were treated with
pHrodo-dyed CC complexes for 30min, due to the fusion of
phagocytosed CC with the acidic lysosome of HMDMs. For
the early phagocytosis, HMDMs had phagocytosed significantly
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FIGURE 1 | vWF binds to CC in a C1q-dependent manner. Binding of C1q and vWF to surface-bound C1q on CC was determined by (A–C) flow cytometry, (D)
confocal microscopy, and (E) ImageStreamX. Representative flow cytometry diagrams show the binding of (A) C1q or (B) C1q-dependent binding of vWF on the
surface of CC. Controls (ctrl) represent the presence of secondary antibodies only. (C) Flow cytometry data are shown as median gMFI with IQR (n = 5, Mann-Whitney
U-test, **p < 0.01). (D) Confocal microscopy depicting a representative CC in brightfield, with C1q (red) or vWF (blue) in the presence of C1q bound to its surface. The
merged staining patterns visualize the C1q-vWF interaction. One of three independent experiments is shown. Scale bar = 50µm. (E) Fluorescent staining of CC
captured by ImageStreamX for C1q (yellow) or C1q-vWF (red). One of two independent experiments is shown. Scale bar = 10µm.
less CC-C1q-vWF complexes than CC-C1q complexes [median
phagocytosis (IQR) in six independent donors of CC-C1q-vWF:
54.55% (40.05–60.03%) vs. CC-C1q: 62, 40% (49.05–68.78%), p
= 0.0312] (Figure 3D).
In summary, late as well as early phagocytosis, by HMDMs,
of CC-C1q-vWF complexes is reduced as compared to CC-
C1q complexes.
CC-C1q-vWF Complexes Reduce IL-1
Cytokine Secretion of HMDMs
CC have been repeatedly described as capable inducers of IL-
1ß secretion in human monocytes and macrophages (23). On
the contrary, C1q has been shown to dampen pro-inflammatory
cytokine secretion for the same cell types (34). Consequently,
we next examined the effect of CC-C1q-vWF complexes on
the cytokine profile of HMDMs. For this purpose, HMDMs
kept untreated or treated with CC, CC-C1q, or CC-C1q-vWF
complexes were stimulated with 100 ng/ml LPS for 18 h and
supernatants were analyzed for the secretion of IL-1ß, IL-1α, IL-
1RA, IL-18, IL-6, IL-10, and TNFα cytokine levels (Figure 4).
The CC treatment induced a strong IL-1ß and IL-1α secretion
by HMDMs and a moderate increase in IL-18 secretion as
compared to untreated HMDMs. A robust decrease in pro-
inflammatory cytokines for IL-1ß and IL-1α was observed with
CC-C1q complexes, and a decreasing trend for IL-6 and TNFα
secretion. The additional presence of vWF on CC-C1q complexes
significantly enhanced reduction of IL-1ß secretion (p= 0.0078),
IL-1ß/IL-1RA ratio (p = 0.0078), and IL-1α/IL-1RA ratio (p
= 0.0234) compared to CC-C1q complexes alone. No other
cytokines were significantly changed by vWF bound to CC-
C1q complexes. Differences in cytokine secretion of HMDMs
according to the treatment added were not due to differences in
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FIGURE 2 | CC-C1q-vWF complexes upregulate the surface receptor expression of HMDMs. LPS-stimulated HMDMs were treated with CC, CC-C1q or
CC-C1q-vWF complexes for 18 h and analyzed by flow cytometry for surface marker expression of (A) CD14, (B) CD86, (C) LAIR1, (D) LRP-1, (E) MerTK, (F) MHC II,
(G) PD-L1, and (H) SR-A1. Pooled flow cytometry data are shown as gMFI with horizontal lines denoting median. Data points represent independent experiments
analyzing six different healthy donors used to obtain HMDMs (Wilcoxon matched pairs signed rank test, *p < 0.05; ns, not significant).
cell death as assessed by quantification of early and late apoptosis
or necrosis (data not shown).
Taken together, our data show that IL-1ß cytokine secretion
and IL-1ß/IL-1RA and IL-1α/IL-1RA ratio by HMDMs after
exposure to CC-C1q complexes are diminished further in the
presence of vWF. This reduction appears to be IL-1 specific.
CC-C1q-vWF Complexes Suppress
Caspase-1 Activity of HMDMs
It is well-known that IL-1 maturation, cleavage and secretion
is regulated transcriptionally as well as post-transcriptionally.
While a priming signal through pattern recognition receptors
is required for pro-IL-1β transcription, the maturation is
dependent on the formation of the NLRP3 inflammasome and
subsequent caspase-1 activation (37). Therefore, we aimed to
examine whether the observed change in IL-1 cytokine secretion
was the result of a preceding NLRP3 inflammasome assembly.
To address this point, HMDMs were kept untreated or treated
with CC, CC-C1q, or CC-C1q-vWF complexes for 18 h and
the effect on caspase-1 activation was quantified with FLICA
probes. Upon CC treatment, HMDMs showed a marked increase
in FLICA signal, demonstrating caspase-1 activity (Figure 5A).
While the presence of C1q on CC exhibited only a delicate
reduction in caspase-1 activity, the additional presence of vWF
significantly suppressed caspase-1 activity in HMDMs [median
FLICA+ cells (IQR) in six independent donors of CC-C1q:
11.54% (7.29–28.38%) vs. CC-C1q-vWF: 9.37% (5.92–22.73%),
p= 0.0312)] (Figure 5B).
Overall, our data show that HMDMs treated with CC-C1q-
vWF complexes exhibit decreased caspase-1 activity that impacts
on NLRP3 inflammasome dependent IL-1β secretion.
DISCUSSION
The cross-talk between the complement and the hemostatic
systems is extensive and can provide synergistic benefits for the
human body (38, 39). Yet, the role of many of these interplays is
still unknown. In particular, even though an interplay between
bound complement C1q and vWF has been demonstrated
previously (17), its impact on the immune system has remained
unexplored until now. In our study, we can illustrate that CC
provide another physiological surface that allows a C1q-vWF
interaction. Moreover, we found that the binding of vWF to
bound C1q on CC is capable of modulating the immune response
of macrophages by an upregulated expression of phagocytosis-
mediating receptors and costimulatory receptors, a hampered
phagocytosis and an enhanced suppression of pro-inflammatory
cytokine secretion compared to C1q on CC alone.
Deposition of CC is described as a hallmark of atherosclerotic
plaques. After recognition as DAMPs and ingestion by
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FIGURE 3 | Phagocytosis of CC-C1q-vWF complexes by HMDMs is hampered. (A,B) HMDMs were kept untreated or treated with CC, CC-C1q or CC-C1q-vWF
complexes for 18 h and analyzed by flow cytometry for the degree of phagocytosis of CC complexes. Phagocytosis was determined by the percentage of CD11c+
cells with a shift into the SSChigh gate. (A) Flow cytometry dot plots show one out of six independent experiments. (B) Quantification of phagocytosis for pooled data
is shown. (C,D) HMDMs were treated with CC, CC-C1q or CC-C1q-vWF pHrodo-dyed complexes for 30min and analyzed by flow cytometry for the degree of
phagocytosis of CC complexes. Phagocytosis was determined by the percentage of CD11c+ cells with a shift into pHrodo Red Ester+ gate. (C) Flow cytometry dot
plots show one out of six independent experiments. (D) Quantification of phagocytosis for pooled data is shown. Columns denote median while error bars indicate
interquartile range. Data points represent independent experiments analyzing six different healthy donors used to obtain HMDMs (Wilcoxon matched pairs signed rank
test, *p < 0.05).
phagocytes, CC trigger ROS formation and lysosomal leakage
with consecutive NLRP3 inflammasome assembly, caspase-1
generation and IL-1β secretion (24). IL-1β secretion leads to
further recruitment of phagocytes by an amplification loop in
a concerted action with other pro-inflammatory cytokines and
chemokines (40). Phagocytes, in particular macrophages, also
are responsible for the essential function of recycling LDL and
cholesterol in the periphery, but can develop into lipid-laden
macrophage-derived foam cells during the course of the disease
when their recycling capacity is overwhelmed. First, those foam
cells can become apoptotic due to various stimuli, such as
prolonged endoplasmic reticulum stress. Second, apoptotic cells
that are insufficiently cleared (as occurring in advanced lesions
due to defective efferocytosis), advance into cellular necrosis,
in turn contributing to the formation of the necrotic core (41).
Consequently, enhanced ingestion of LDL and CC fuels foam cell
development, which is thought to be detrimental in later stages
of atherosclerosis (42). Hence, the conclusion that CC induce
arterial inflammation and destabilization of atherosclerotic
plaques seems to be plausible (43). The complement molecule
C1q can be considered as a double-edged sword in the context
of atherosclerosis. Previous studies showed that the clearance
of oxidized LDL and modified LDL is enhanced by binding
of C1q (6), but simultaneously leads to a polarization of
macrophages toward an anti-inflammatory phenotype through
a reduction in pro-inflammatory cytokine secretion (44). In
addition, C1q induces mRNA transcription of cholesterol efflux
transporters (6). In contrast to these atheroprotective traits, C1q
was demonstrated to be present on CC from human plasma (45)
and found to be complexed to ApoE in human arteries (46),
where it enables complement activation and thus contributes to
atheroprogression (47, 48).
With regard to vWF, a number of studies in vWF-deficient
animals and in patients suffering from Von Willebrand disease
have been performed. Several of those animal studies (29) as
well as human studies (49, 50) suggest atheroprogressive effects
of vWF. Therefore, one could hypothesize disadvantageous
consequences for the additional presence of vWF on CC-C1q
complexes on macrophages. However, our findings unexpectedly
point to a beneficial effect of vWF in the context of
phagocytosis of CC by macrophages, and suggest that the
role of vWF in atherosclerosis might be intricate and requires
further investigation.
Previously, C1q and vWF have been regarded as separately
acting molecules. Here, we identified not only a complex
formation of C1q bound to the surface of CC but also
the subsequent binding of vWF. Moreover, the treatment of
HMDMs with CC-C1q-vWF complexes results in an upregulated
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FIGURE 4 | CC-C1q-vWF complexes diminish LPS-induced IL-1 secretion of HMDMs. LPS-induced HMDMs were kept untreated or treated with CC, CC-C1q, or
CC-C1q-vWF complexes for 18 h. Supernatants were analyzed by ELISA for cytokine secretion. Data show median cytokine concentrations of (A) IL-1β, (B) IL-1α,
(C) IL-1RA, (F) IL-18, (G) IL-6, (H) IL-10, and (I) TNFα levels or median ratios of (D) IL-1β/IL-1RA and (E) IL-1α/IL-1RA of pooled donors. Data points represent
independent experiments analyzing eight different healthy donors used to obtain HMDMs (Wilcoxon matched pairs signed rank test, *p < 0.05; **p < 0.01; ns,
not significant).
expression of surface receptors of efferocytosis (MerTK),
scavenger receptors (LRP-1 and SR-A1) as well as CD14, LAIR1,
and PD-L1 compared to CC-C1q complexes alone. Studies
investigating the role of the phagocytosis-mediating receptors
MerTK and LRP-1 indicate atheroprotective features (51, 52),
whereas the role of SR-A1 in cardiovascular disease is still
controversial [reviewed by Ben et al. (53)]. Additionally, LAIR1
was described to have beneficial effects on foam cell formation
(54). Therefore, we next sought to determine the effect on the
phagocytic capacity of HMDMs. Interestingly, the presence of
vWF on CC-C1q complexes strongly diminished the late as well
as early phagocytosis of CC by HMDMs, hereby reversing the
effect of C1q alone. A possible explanation for this unexpected
finding could be that the upregulated expression of phagocytosis-
mediating receptors is representing a reinforcing feedback loop
that is triggered in order to compensate for the decreased
ingestion of CC-C1q-vWF complexes. Last, our data illustrate a
significant decrease in IL-1 cytokine secretion by HMDMs when
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FIGURE 5 | CC-C1q-vWF complexes lead to a reduced caspase-1 activity in HMDMs. HMDMs were kept untreated or treated with CC, CC-C1q, or CC-C1q-vWF
complexes for 18 h and analyzed for caspase-1 activity by flow cytometry. Activity of caspase-1 was determined by the percentage of CD11c+ cells in the FLICA+
gate. (A) Flow cytometry dot plots show one out of six independent experiments. (B) Quantification of caspase-1 activity for pooled data is shown. Horizontal lines in
the box plots denote median while the boxes indicate interquartile range and whiskers minimum and maximum values. Data points represent independent
experiments analyzing six different healthy donors used to obtain HMDMs (Wilcoxon matched pairs signed rank test, *p < 0.05).
treated with CC-C1q-vWF complexes compared to CC-C1q
complexes without vWF. The clinical significance of IL-1 in
cardiovascular disease was demonstrated by the anti-IL-1beta
antibody CanakinumabAntiinflammatory Thrombosis Outcome
Study (CANTOS) (55). Thus, a reduction in phagocytosis and
inflammation could retard plaque progression (56, 57).
One limitation of our study is its in vitro character,
since the in vivo situation in humans is likely to be more
complex. C1q’s role in human atherosclerosis is supported
by studies that have shown C1q expression in atherosclerotic
carotid arteries of patients (58–60) and therefore underlines
the relevance of our results. Whereas the majority of C1q is
non-covalently bound with serine proteases C1r and C1s to
form the C1 complex in plasma and whole blood, free C1q
is more prevalent in tissues where it is locally synthesized
mainly by macrophages and dendritic cells (61). Furthermore,
it has been demonstrated that vWF binds to a cryptic
epitope of C1q, which is only exposed when C1q is surface-
bound, while binding of vWF to surface-bound C1 was much
weaker (17). Hence, we assume that the C1q-vWF interaction,
especially on CC, primarily occurs in tissue, such as arteries
of atherosclerotic patients. Nevertheless, further investigation
on the occurrence of CC-C1q-vWF complexes in human
atherosclerosis is needed.
Second, in vivo, shear stress is necessary to unfold the
full functional potential of vWF (62). In our study however,
permanent shear stress was not applied, since the physiological
occurrence of shear stress would rather reflect the situation
during plaque rupture resulting from continuous blood flow but
not that inside the plaque itself.
Lastly, alternative ways can be envisaged by which the C1q-
vWF interaction, in the form of CC-C1q-vWF complexes,
might exert its effect on HMDMs. One of the ways could be
partial steric shielding of the C1q molecule by vWF, weakening
the effects of C1q (e.g., Figure 3). Another way could be an
intrinsic effect of vWF (e.g., Figures 2, 4). Future studies will
have to explore the potential ways responsible for the overall
impact of CC-C1q-vWF complexes. In addition, since the mutual
interactions between complement and hemostatic systems in vivo
are likely to be more complex, our in vitro model will have
to be developed further in order to approach a physiological
setting. Recently, Gravastrand et al. have described that CC
induce complement-dependent activation of hemostasis (63).
In our group, we have observed that complement activation
remains unaffected by the presence of vWF (64). Hence,
downstream complement components, such as C4 and C3,
shall be implemented into our system and its effect on
HMDMs in the additional presence of platelets addressed in
the future.
In conclusion, with this study, we provide new insights into
an emerging cross-talk between C1q and hemostasis-initiating
vWF. Our findings reveal that binding of vWF to C1q on CC
regulates the immune response of HMDMs. We show that CC-
C1q-vWF complexes provoke a hampered phagocytosis together
with an accompanied reduction of IL-1 cytokine secretion by
macrophages that could prove favorable for retarding foam cell
formation and decelerating plaque progression.
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The complement system bridges innate and adaptive immunity against microbial infec-
tions, with viral infection being a major trigger. Activation of the classical, alternative, 
and lectin pathways have been reported in chronic hepatitis C virus (HCV) infection and/
or cryoglobulinemia. HCV infection leads to dysregulation of complement-mediated 
immune responses. Clinical and experimental evidence support involvement of com-
plement in intra- and extrahepatic manifestations of HCV infection, such as liver fibrosis 
and type II cryoglobulinemia. In this review, we summarize studies that have investigated 
the interplay between HCV and the complement system to establish chronic infection 
and autoimmunity, as well as the association between HCV pathogenesis and abnormal 
complement profiles. Several unanswered questions are highlighted which suggest 
additional informative lines of investigation.
Keywords: liver, hepatitis C virus, complement, C1q, gC1qR, mixed cryoglobulinemia
iNTRODUCTiON
The complement system includes major host defense mechanisms that bridge innate and adaptive 
immunity against microbial infections. It is also a critical mediator of the clearance of immune 
complexes and injured cells (1–3). Dysregulation may be associated with chronic autoimmune 
inflammatory conditions, such as systemic lupus erythematosus, cryoglobulinemia, and rheumatoid 
arthritis. Viral infections may trigger dysregulation by direct effects on complement components 
for the purpose of immune evasion, by effects on specific receptors used for viral entrance into 
cells or by promoting a pathogenic antiglobulin [i.e., rheumatoid factor (RF)] response as part of 
chronic immune stimulation. In particular, hepatitis C virus (HCV) infection has been associated 
with a number of extrahepatic disorders, such as type II mixed cryoglobulinemia (MC) and B cell 
lymphoma that may be accompanied by complement dysregulation. The recent introduction of 
direct-acting antiviral (DAA) therapy for HCV allows most patients to achieve a sustained virologi-
cal response (SVR)/cure. Treatment reduces liver inflammation and improves extrahepatic disease 
manifestations, but cryoglobulinemia and liver dysfunction may persist (4–14).
The majority of HCV-infected patients with evidence of B cell clonality have abnormal comple-
ment profiles; a low serum level of C4 is a “signature” for type II MC patients (15, 16). However, 
only limited information is available regarding the mechanisms by which the complement system is 
involved in HCV-induced intra- and extrahepatic disease. Therefore, in this review, we aim to high-




El-Shamy et al. Complement System in HCV Infection 
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1001
PRODUCTiON SiTeS OF COMPLeMeNT 
PROTeiNS AND ReCePTORS
More than 40 complement-related proteins have been identified in 
the plasma and on cell surfaces, constituting more than 15% of the 
of plasma globulins (17, 18). The liver makes ~90% of the plasma 
components of classical, alternative, and lectin pathways. By 
contrast, whereas hepatocytes are the predominant source of C1r 
and C1s in blood, activated monocytes/macrophages and imma-
ture dendritic cells are the primary source of C1q, a recognition 
molecule for classical pathway activation that also has significant 
non-complement functions (19). Although the liver produces the 
majority of C4, multiple tissues may also produce this protein for 
local consumption, particularly in response to interferon-gamma 
(20). Several complement receptors, such as complement receptor 
type 1 (CR1), the complement receptor of the immunoglobulin 
superfamily (CRIg), the integrin complement receptors 3 (CR3) 
and 4 (CR4), and the complement component 5a receptor 1 (C5aR), 
are expressed on liver cells (hepatocytes, endothelial cells, Kupffer 
cells, and stellate cells), and contribute to a variety of functions, 
such as induction of gluconeogenesis, synthesis of acute-phase 
proteins, hepatocyte proliferation, and phagocytosis (21).
FiBROSiS AND ReGeNeRATiON
Increasing evidence implicates activation of the complement 
system in the pathogenesis and response to acute and chronic 
liver injury (22). In a clinical study investigating the relationship 
between complement activation and development of liver fibro-
sis, blood samples from 50 chronically infected HCV patients 
were compared to 35 patients with other various liver diseases 
and 50 healthy controls (23). Complement system activation, as 
indicated by a significant decrease in total plasma complement 
activity (CH50) and increase in SC5b-9 [a marker for generation 
of the membrane-attack complex (MAC)] was associated with 
high necroinflammatory activity in the HCV patients and 
patients with other liver diseases compared to controls. The level 
of SC5b-9 significantly correlated with liver fibrosis stage in HCV-
infected patients but not in patients with other liver injuries. In a 
proteomic survey of serum samples from HCV-infected patients, 
liver fibrosis stage was associated with a decrease in C3, C4, and 
Factor H-related protein-1, a regulatory C3b-binding protein 
(24). C4a, a cleavage product of C4 that contrasts with C3a and 
C5a with regard to biologic function, was reported to be nega-
tively correlated with the stage of liver fibrosis in children with 
chronic HCV infection, serum levels being significantly lower in 
HCV children with advanced fibrosis than those with no/mild 
fibrosis (25); the significance of this study, however, was limited 
by the low numbers of HCV-infected children, and the fact that 
C4a may increase as a function of classical pathway activation and 
C4 consumption. In a murine genomic study, the gene encoding 
C5 was identified as a quantitative trait locus associated with 
the development of liver fibrosis (26). Expression of C5aR1 was 
significantly upregulated on hepatic stellate cells during trans-
differentiation to myofibroblasts in culture. Since myofibroblasts 
synthesize collagens and other extracellular matrix proteins, 
elevated C5aR1 expression is consistent with the concept that 
C5 is a modifier of liver fibrogenesis. Indeed, blockade of C5aR1 
reduces hepatic fibrosis in mice (26). Critical roles for C3a and 
C5a for liver regeneration following carbon tetrachloride injury 
have been shown in C3, C5, and C3aR knock-out and double 
knock-out mice, reversible by restoration of C3a, C5, or C5a 
(27). Interestingly, in 277 patients with chronic HCV infection, 
two C5 single-nucleotide polymorphisms (SNPs), rs17611 and 
rs2300929, were associated with advanced fibrosis (26). However, 
in a study of 1,435 HCV-infected patients and 1,003 patients with 
other liver diseases, there was no significant association between 
these C5 SNPs and fibrosis in either patient group (28).
HePATOCeLLULAR CARCiNOMA (HCC)
Cancer growth is determined by intrinsic properties of malig-
nant cells as well as several modifiers, including the complement 
system, which may either reduce or increase progression (29). 
HCC is the second leading cause of organ-specific cancer-related 
death worldwide (30) and is the most rapidly increasing cause of 
cancer-related death in the United States, Europe, and Japan (31). 
Of note, C3a was identified by mass spectrometry and 2-dimen-
sional gel electrophoresis (2-DE) of serum samples obtained from 
HCV-HCC, chronic HCV, HBV-HCC, chronic HBV, and healthy 
subjects as a differentially expressed biomarker protein with 
significantly higher levels among HCV-HCC patients compared 
to the other groups (32).
TReATMeNT
Until recently, HCV treatment has centered on interferon-alpha 
(IFNα), a cytokine with both antiviral and immunologic effects. 
However, IFNα-based treatment failed to eliminate HCV in many 
patients and was often poorly tolerated, particularly because of 
its ability to induce, uncover and/or exacerbate autoimmune/
inflammatory disorders (33, 34). The CC genotype associated 
with the rs285009 SNP of the C4 gene closely correlated with 
decreased level of mRNA expression and C4 protein which was 
more striking at baseline in HCV patients compared to healthy 
controls. More importantly, the presence of this SNP was signifi-
cantly associated with a poor response to IFNα-based therapy as 
well as the development of a high degree of liver fibrosis (35). 
Interestingly, a significant reduction in C4 activity was also 
observed in relapsers after IFNα treatment compared to patients 
who achieved SVR (36). Polymorphism at the rs2230201 SNP 
of C3 was also associated with IFNα treatment outcome (37). 
The rs2230201 ‘C’ allele was associated with increased serum C3 
levels compared to the ‘T’ allele, which conferred an advantage 
in attaining SVR, especially in homozygotes. Patients with serum 
C3 value < 53 mg/dL and non-CC genotypes may not respond to 
IFNα treatment (37). Recently developed DAA therapies provide 
an opportunity for HCV patients with autoimmune/inflamma-
tory disorders to be cured with a low risk of side effects (38–40). 
In the era of DAA, how a patient’s complement profile contributes 
to the treatment response remains to be defined.
In summary, accumulating clinical observations support a role 
for the complement system in mediating liver inflammation and 
fibrosis in HCV infection (Table 1). However, the mechanisms 
58
TABLe 2 | HCV strategies to evade innate and adaptive immunity using complement system-related components.
Complement system-
related factor
HCv-induced immune evasion Reference
C3 Downregulation of C3 promotor activity by HCV-NS5A via inhibition of C/EBP-β (43)
C2 Impairment of C3 convertase function via inhibition of C2 (44)
C4 Inhibition of C4 activity through HCV core-induced inhibition of upstream stimulatory factor-1 and HCV-NS5A-induced inhibition 
of interferon regulatory factor-1
(45)
C9 Impairment of membrane-attack complex (MAC) formation through inhibition of C9 promotor activity by HCV-core (46)
C3 and C4 Downregulation of C3 and C4 hepatocyte synthesis through the inhibition of the hepatocyte MICA/B (47)
MAC Impairment of MAC formation through incorporation of CD59 in HCV envelope (55)
C3 convertase Upregulation of CD55 expression which accelerates the decay of C3 convertase (56)
gC1qR Impairment of T-cell immunity through the interaction of HCV core to gC1qR on T-cells and monocyte-derived dendritic cells (65–67)
TABLe 1 | Complement system abnormalities in HCV-induced liver injury.
Complement abnormality HCv-induced liver injury Reference
Low plasma CH50 High necroinflammatory activity (23)
High SC5b-9 High stage of necroinflammation and degree of liver fibrosis (23)
Low C3 High degree of liver fibrosis (24)
Low C4 High degree of liver fibrosis (24, 25)
CC genotype of rs285009 single nucleotide polymorphism (SNP) of the C4 gene High degree of liver fibrosis and poor response to IFNα-based therapy (35)
Low factor H-related protein-1 High degree of liver fibrosis (24)
High C5 High degree of liver fibrosis (26)
High C3a High risk of hepatocellular carcinoma (32)
Low serum C3 and non-CC genotype of rs2230201 SNP of the C3 gene Poor response to IFNα-based therapy (37)
3
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underlying these observations are still unclear. Thus, further 
experimental and molecular studies are required to dissect how the 
complement system contributes to intrahepatic HCV pathogen-
esis, including roles in innate and adaptive immunity, regulation 
of apoptosis, fibrosis, and regeneration.
HCv STRATeGieS TO OveRCOMe 
ANTiviRAL ReSPONSeS OF THe 
COMPLeMeNT SYSTeM
Hepatitis C virus lacks a DNA intermediate; thus, it is incapable 
of integrating into host chromosomal DNA. Despite this, unlike 
most RNA viruses, chronic infection is established in ~80% 
of cases (41) through multiple strategies to evade innate and 
adaptive antiviral responses (42). In part, this is accomplished 
directly by inhibition of complement components and/or 
indirectly by induction of regulators of complement activation 
(RCA) (Table  2). Mazumdar et  al. examined the relationship 
between HCV infection and C3 concentrations in blood. C3 has a 
central role in modulating all three pathways of the complement 
system. In matched serum and liver biopsy samples from HCV 
patients, both the levels of C3 in serum and the expression of 
mRNA in biopsies were significantly lower compared to serum 
and tissue obtained from healthy donors (43). Further in vitro 
studies showed that HCV-NS5A protein strongly downregulated 
C3 promoter activity at the basal level. In addition, expression of 
the transcription factor C/EBP-β, which induces C3 promoter 
activity, was reduced in immortalized human hepatocytes and 
human hepatoma cells (Huh7) that were either infected with 
cell culture-adapted HCV or transfected with HCV-NS5A (43). 
Moreover, HCV inhibited C3 convertase activity, which is criti-
cal in promoting the activity of classical and lectin pathways of 
complement system (44). Infection of a hepatoma cell line with 
HCV resulted in inhibition of C2 expression and hence impair-
ment of C3 convertase function. On the other hand, C3b deposi-
tion onto bacterial membrane was reduced by sera from HCV 
patients as compared to healthy controls, which further indicates 
impaired C3 convertase (44). C4 contributes to the eradication 
of several viral infections by its role as opsonin and by its central 
role in promoting the activity of the classical and lectin pathways 
(3). Notably, C4 protein levels in the serum and mRNA expres-
sion levels in liver tissue were lower in HCV patients compared to 
patients with unrelated liver diseases (45). In vitro studies showed 
that the expression levels of the two C4 isoforms (C4A and C4B) 
were significantly reduced in hepatocytes transfected with a full-
length HCV genome. In particular, among different HCV pro-
teins, only core and NS5A contributed to HCV’s inhibitory effect 
on C4 as shown by in vitro transfection experiments, using the 
Huh7 hepatoma cell line and plasmids containing different HCV 
proteins (45). Consistent with these in vitro results, the expres-
sion levels of C4 mRNA in liver tissue of HCV-core or NS5A 
transgenic mice were also significantly reduced. Mechanistic 
studies showed that HCV-core downregulated the expression of 
upstream stimulatory factor-1, a transcription factor critical for 
C4 expression, while NS5A inhibited the expression of interferon 
regulatory factor-1, which is required for IFN-γ-induced C4 
promoter activation (45).
Likewise, Kim et  al., showed that liver biopsies from HCV 
patients had lower expression of C9 mRNA compared to samples 
from unrelated diseases or healthy controls. This indicates that 
HCV regulates the MAC via C9. C9 mRNA was significantly 
downregulated in cultured hepatocytes infected with HCV (46). 
In particular, HCV-core protein had a critical role in regulating 
C9 promoter activity. Furthermore, in a subsequent in vitro study, 
HCV NS2 and NS5B proteins were found to be responsible for 
59
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HCV-associated inhibition of the hepatocyte protein major his-
tocompatibility complex class I-related chains A and B (MICA/B) 
which functions as a key receptor ligand for NKG2D on NK cells 
resulting in downregulation of C3 and C4 hepatocyte synthesis (47).
A general role for lectins and pattern recognition of viral 
glycoproteins has been identified for HIV and HCV (48). In vitro 
studies showed that mannan-binding lectin (MBL) bound to the 
HCV E2 ectodomain and E1/E2 heterodimers through its lectin 
domain, as well as activate complement through MBL-associated 
serine protease 2 (49). Ficolin-2, a known lectin pathway activa-
tor was found to inhibit attachment of HCV envelope E1 and E2 
N-glycans to their low-density lipoprotein (LDL) and scavenger 
B1 receptors (50), with elevated blood levels of L-ficolin or MBL 
being found in the serum of some patients, possibly correlating 
with MBL2 genetic variants and response to IFNα (51).
Host expression of RCAs, such as CD35, CD46, CD55, and 
CD59, serves to protect the cells from MAC lysis (52, 53). HCV 
has developed strategies to attenuate complement activation 
by regulating RCAs. Amet et al. first showed that CD59, a key 
member of RCA, associated with the external membrane of HCV 
particles obtained from infected patients and Huh7.5.1 cells and 
had a direct role in abrogating antibody-dependent complement-
mediated lysis (54). In vitro studies by Ejaz et al. indicated that 
HCV selectively incorporates CD59 in its envelope, which inhib-
its the formation of the MAC complex (55). Also, it was found 
that HCV infection upregulates the expression of CD55, which 
accelerates the decay of C3 convertase (56). Taken together, HCV 
has the capability to attenuate the complement system at multiple 
steps to weaken the innate immune response.
ROLe OF gC1q ReCePTOR (gC1qR)  
iN HCv PATHOGeNeSiS
gC1q receptor is an acidic multifunctional cellular protein ubiq-
uitously expressed on somatic cells (57). It binds to the globular 
heads of C1q and modulates complement activation (58). Apart 
from its interaction with C1q, gC1qR binds to several host cell-
surface ligands, such as vitronectin and high molecular weight 
kininogen (59). Interaction of these ligands with gC1qR leads 
to classical complement pathway activation with generation 
of inflammatory cytokines, cell adhesion, and activation of the 
intrinsic coagulation cascade leading to the production of brady-
kinin, increased vascular permeability, and infiltration of vascular 
tissue with proinflammatory cells (60). In addition to cellular 
proteins, gC1qR interacts with several microbial proteins, such 
as adenovirus core protein (61), HIV rev (62), and protein A of 
Staphylococcus aureus (63), suggesting its role in the pathogenesis 
of these infections. Interestingly, by using HCV-core protein as 
bait in yeast two-hybrid assay, Kittlesen et  al. was the first to 
report the interaction between gC1qR and HCV-core (64). The 
interaction of HCV-core to gC1qR on T-lymphocytes resulted in 
inhibition of T-cell proliferation and function through impair-
ment of ERK/MEK phosphorylation (65) and Lck/Akt activation 
(66). Also, engagement of gC1qR on monocyte-derived dendritic 
cells with HCV-core resulted in an impaired capacity to gener-
ate type 1 CD4+ T cell immunity via inhibition of TLR-induced 
IL-12 production (67). Therefore, HCV might utilize the direct 
interaction of its core protein with gC1qR on T  cells as a tool 
to suppress cellular immunity which might imply an important 
role in persistent infection, an observation that might extend to 
minicore isoforms of this protein, which lack the RNA binding 
domain of the p21 core (68).
By contrast to the inhibitory influence of HCV-core protein 
and gC1qR interaction on T cell responses, this interaction on 
B  cells resulted in hyper-activation and proliferation indicated 
by upregulation of CD69, overexpression of costimulatory and 
chemokine receptors, and increased production of IgM and 
IgG (69). This might partially explain the link between chronic 
HCV infection, B-cell lymphoproliferative disorders, and several 
autoimmune-related diseases (70–72). In support of this, the 
level of circulating gC1qR and gC1qR mRNA of PBMC in HCV 
patients with MC, one of the major B-cell disorders associated 
HCV infection, is significantly increased compared to HCV 
patients without MC or healthy controls (73). Interestingly, there 
was also a positive correlation between circulating gC1qR with 
RF activity and C1q concentrations in HCV patients with MC 
(73). Taken together, these observations suggest the involvement 
of gC1qR in the pathogenesis of HCV-induced autoimmunity.
ROLe OF C1q iN HCv-iNDUCeD MC
Mixed cryoglobulins are cold-precipitable complexes of mono-
clonal or polyclonal IgM RF with polyclonal or oligoclonal IgG 
(15). Type II MCs, which are composed of monoclonal IgMκ RF 
and polyclonal IgG, are heavily represented among cryoglobulins 
associated with chronic HCV infection, and those found in 
patients with primary Sjogrens syndrome, both of which may be 
complicated by clonal B-cell proliferations and specific types of 
non-Hodgkin’s lymphoma (15). HCV patients with symptomatic 
type II MC suffer from various extrahepatic manifestations, 
including vascular, renal, and neurological lesions (74), i.e., cryo-
globulinemic vasculitis (CryoVas) (75).
In type III MCs, both the IgM and IgG components appear to 
be polyclonal; extrahepatic disease manifestations may occur, but 
cryoglobulin levels are lower than type II, and an association with 
asymptomatic disease is more frequent. In addition, intermediate 
types characterized by oligoclonality or mixed IgM clonality with 
polyclonal IgM (type IIa) have also been described (76). Type III 
MCs may be found in HCV infection, as well as associated with 
rheumatic diseases [e.g., systemic lupus erythematosus (SLE)] in 
which complement activation may occur (16). The significance 
of Type IIa and related intermediate forms with regard to the 
progression to clonality that may occur in cirrhosis associated 
with HCV, and in primary Sjogrens syndrome, remains to be fully 
defined (77, 78).
As noted, a low serum level of C4 is a significant “signature” 
of type II MC patients (15, 16). This selective depression of C4 
strongly implicates classical pathway activation of the complement 
in cryoglobulin formation. However, the level and function of C4 
may be significantly influenced by inter-individual copy-number 
variation of C4A or C4B genes, charge variation, or isotype 
deficiency of these genes (79). Incorporation of C1q into isolated 
cryoprecipitates was first demonstrated as an 11S peak on density 
gradient ultracentrifugation in patients with lupus nephritis (80). 
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More recent studies have confirmed that cryoprecipitates from 
patients with HCV-associated CryoVas are enriched in C1q 
(81), antibodies to HCV antigens (82), and may contain HCV-
core protein as indicated by results obtained using an enhanced 
highly sensitive chemiluminescent microparticle immunoassay 
(81). Based on evidence that C1q and HCV-core bind to gC1qR, 
gC1qR/HCV-core complexes might provide a platform for com-
plement activation and deposition of C4D at sites of vasculopathy 
(83). Additional factors that might be reflected in depletion of C4/
C1q and localization to cryocomplexes include the ability of C1q 
to bind promiscuously to >100 known ligands, including both 
IgG- and IgM-containing immune complexes, surface-bound 
C-reactive protein, and molecules exposed at the surface of apop-
totic cells, with binding through charged residues on the apex of 
the gC1q heterotrimer (19, 84), acquired C1-inhibitor deficiency 
(85), regulation of activation by C4-binding protein (86, 87), and 
antibodies to C1q and/or potentially to other components of the 
C1 complex (88).
ROLe OF RF iN MC PATHOGeNeSiS
Although MC may be associated with a rheumatoid-like arthritis, 
it is distinct from RA in that antiglobulin activity is restricted to 
the IgM isotype; although it is presumed that the antigen specific-
ity is directed primarily to determinants in the Fc portion of IgG 
uncovered by aggregation or complexing to antigen, there have 
been some suggestions of F(ab)′2 anti-hinge or anti-idiotypic 
specificity. Low-affinity RFs (Kd~10−5M) are natural antibodies 
cross reactive with other autoantigens, whereas high-affinity RFs 
(Kd~10−7M) have undergone affinity maturation and are hyper-
mutated (89). The RF response is broadly represented in a number 
of infectious etiologies, either as a response to immune complexes 
formed by the infecting microbe and antibodies or as a function 
of direct infection and polyclonal B-cell stimulation. In Type II 
cryoglobulins, the contribution of IgM and IgM RF to total pro-
tein content presents a spectrum of concentrations and clonality, 
ranging from cryocomplexes with RF activity greatly exceeding 
serum levels and enhanced representation of IgM cross-reactive 
idiotypes (notably the Wa idiotype first described 45 years ago) 
(90). This allows for the observation of RF in mixed cryoglobulins 
in patients with apparently negative RFs, and mixed cryoglobulins 
that are composed almost entirely of IgM with kappa light chains. 
It has also been reported that HCV virion in fractionated mixed 
cryoglobulins is complexed with VLDL, providing a mechanism 
for localization of virus to sites of pathology via the LDL receptor 
(91), and the potential for LDL receptor genetic polymorphisms 
to influence disease outcome (92). RFs studied from B-cell clusters 
isolated by microdissection of liver biopsies from HCV-infected 
patients were hypermutated and overlapped in regard to variable 
region gene usage with blood and bone marrow (93).
APOPTOTiC ROLe OF C1q iN SLe
Activation of complement is a central feature of SLE, intimately 
related to the pathogenesis of lupus nephritis, and a marker for 
disease activity and relapse; deficiencies or polymorphisms of 
molecules central to the classical, alternative, and lectin pathways 
have been linked to disease susceptibility, immune-complex 
nephritis, and severity (94). In particular, a central role for C1q 
and C1q receptors, both with regard to deficiency and as molecular 
cell-surface sensors for innate and acquired immune responses, 
has been reviewed (95). The observation that SLE develops in 
~90% patients genetically deficient in C1q highlighted a func-
tion of C1q as “protector” against autoimmunity that may be 
independent of its classical role ion complement activation (96). 
In SLE, C1q deficiency may result either from genetic disorders 
or anti-C1q autoantibodies (97). The contributions of C1q defi-
ciency in the development of SLE can be related to abrogation 
of binding to molecules (phosphatidylserine, double-stranded 
DNA, glyceraldehyde-3-posphate dehydrogenase, annexins 2 
and 5, calreticulin) expressed on the surface of dying cells (17) 
and resultant lack of generation of activated C1s to cleave these 
apoptotic autoantigens (19). In addition, all three pathways 
of complement can be activated on the surface of apoptotic 
cells without further activation of innate or adaptive immune 
components (17); impaired clearance of dying cells and immune 
complexes in absolute or functional C1q deficiency is linked 
to the development of self-reactive B  cells with affinity toward 
multiple autoantigens, and effects on monocyte and dendritic cell 
differentiation (98, 99).
Anti-C1q autoantibodies have been reported in 30–50% of SLE 
patients, most commonly correlating with antibodies to double-
stranded DNA, nephritis, and low levels of C3 and C4 (100, 101). 
While antibodies with unique specificities for the globular head 
and collagen tail of C1q have been identified, the impact of blocking 
C1q domains on biological activity remains uncertain compared 
to a number of other (e.g., calreticulin) known inhibitors (17). 
Although the C1q is a major component of HCV-induced cryo-
precipitate, to the best of our knowledge there are no published 
studies addressing this issue. Low levels of C1q and a significant 
prevalence of anti-C1q autoantibodies are shared features of SLE 
and HCV-induced cryoglobulinemia (36, 73, 102, 103).
Interferon-alpha is well-known to have both antiviral and 
inflammatory effects (104). Plasmacytoid dendritic cells (pCD) 
are the major producers of IFNα (105). Interestingly, C1q col-
lagen tail interacts with LAIR-1 (CD305), an inhibitory receptor 
for C1q (106), on pCDs and restricts the production of IFNα 
(107). Therefore, anti-C1q autoantibodies might contribute to 
HCV-induced cryoglobulinemia by blocking the interaction 
between the C1q tail and its inhibitory receptor, LAIR-1, on pDCs 
resulting in uncontrolled overproduction of IFNα, which may in 
turn drive the inflammation associated with progression of MC in 
HCV patients. Alternatively, elevated levels of IFNα produced by 
uncontrolled pCDs might promote differentiation of B cells into 
plasma cells resulting in production of pathogenic autoantibodies 
reported in SLE (108).
CONCLUSiON
The complement system plays a central role in rheumatic and 
autoimmune diseases, several of which are associated with the 
presence in blood of cold-perceptible immune complexes enriched 
in IgM RF, specific antibody activities, putative antigens and C1q as 
part of a cascade capable of activating the classical pathway, leading 
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in turn to the generation of anaphylatoxins, chemotactic factors, 
and inflammatory mediators. Both C1q and its globular receptor 
are promiscuous with regard to ligand specificity, allowing for 
alternative functions that include binding to specific intracellular 
antigens expressed on the surface of apoptotic cells, as well as to 
specific domains of HCV. A research agenda includes the map-
ping of C1q epitopes responsible for binding to diverse ligands, 
anti-C1q antibodies, heterotrimeric formation, and C4/C2 serine 
protease generation that might in turn be targets for therapy. Similar 
therapeutic strategies might be targeted to gC1qR binding to C1q 
and High Molecular Weight Kininogen in plasma, on the surface 
of endothelial cells as a mechanism for vasculopathy, and the 
regulation of danger sensors on mononuclear cells and immature 
dendritic cells. A second line of investigation is the delineation of 
factors responsible for the strikingly low C4 levels in sera of patients 
with Type II MC and some patients with SLE with regard to mecha-
nisms such as copy-number variation, polymorphisms, cleavage 
and deposition in tissue, and specific inhibitors. With regard to 
HCV, a focus on liver pathology would provide an arena to identify 
complement-defined mechanisms of disease, including immune 
activation in lymphoid follicles, steatosis, fibrosis, and regeneration.
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C1q is the first recognition subcomponent of the complement classical pathway, which 
acts toward the clearance of pathogens and apoptotic cells. C1q is also known to mod-
ulate a range of functions of immune and non-immune cells, and has been shown to 
be involved in placental development and sensorial synaptic pruning. We have recently 
shown that C1q can promote tumor by encouraging their adhesion, migration, and pro-
liferation in addition to angiogenesis and metastasis. In this study, we have examined the 
role of human C1q in the microenvironment of malignant pleural mesothelioma (MPM), 
a rare form of cancer commonly associated with exposure to asbestos. We found that 
C1q was highly expressed in all MPM histotypes, particularly in epithelioid rather than in 
sarcomatoid histotype. C1q avidly bound high and low molecular weight hyaluronic acid 
(HA) via its globular domain. C1q bound to HA was able to induce adhesion and prolif-
eration of mesothelioma cells (MES) via enhancement of ERK1/2, SAPK/JNK, and p38 
phosphorylation; however, it did not activate the complement cascade. Consistent with 
the modular organization of the globular domain, we demonstrated that C1q may bind 
to HA through ghA module, whereas it may interact with human MES through the ghC. 
In conclusion, C1q highly expressed in MPM binds to HA and enhances the tumor 
growth promoting cell adhesion and proliferation. These data can help develop novel 
diagnostic markers and molecular targets for MPM.
Keywords: complement system, malignant pleural mesothelioma, hyaluronic acid, mesothelioma cells, c1q, 
cancer
Abbreviations: MPM, malignant pleural mesothelioma; MES, mesothelioma cells; ECM, extracellular matrix; HA, hyaluronic 
acid; ghA, ghB and ghC: globular head region of human C1q A, B and C chain, respectively; MBP, maltose-binding protein; 
HMW, high molecular weight; LMW, low molecular weight.
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inTrODUcTiOn
Malignant pleural mesothelioma (MPM) is a rare form of 
cancer that develops from cells of the pleural mesothelium 
and is most commonly associated with exposure to asbestos 
(1). MPM typically develops after a long latency period, which 
averages 30–40 years, and the average age of patients is 60 years 
(2). MPM is highly invasive to surrounding tissues leading to 
the failure of the organs underlying the serosal membranes (3). 
Although low in metastatic potential, metastasis in MPM are 
more frequent postsurgery; at the autopsy, metastatic diffusion 
is observed in 50% of patients (3). Microscopically, MPM shows 
mainly one of the three patterns: epithelioid, sarcomatoid, or 
biphasic (4).
MPM is an aggressive malignancy; most patients succumb 
within 2 years of being diagnosed (5). Treating MPM remains 
a challenge. There are two main treatment alternatives: pallia-
tive chemotherapy or multimodal treatment including surgical 
resection combined with chemotherapy or radiotherapy, or 
both (6). The resistance of MPM to conventional treatment and 
poor prognosis has renewed interest in basic research in order 
to understand the MPM biology fully with the aim of identify-
ing possible new molecular therapeutic targets.
The local microenvironment, which encourages survival, 
growth, and invasion of cancer cells, plays a critical role in 
cancer development; the extracellular matrix (ECM) is an 
essential constituent of such microenvironment (7). Hyaluronic 
acid (HA), a member of the glycosaminoglycan family, is an 
abundant and ubiquitous component of the ECM (8). HA is a 
negatively charged high-molecular-weight (HMW) polysaccha-
ride (4–800 kDa) which is made up of the repeating disaccharide 
(glucuronic acid and N-acetylglucosamine) (9). In the tumor 
microenvironment, HA offers a molecular 3D-scaffold for cells 
via the assembly of ECM, thus modulating stromal as well as 
tumor cells (10). HA, whose multiple functions are dictated by 
its molecular size and tissue concentration, relies on balanced 
biosynthetic and degradation processes. Increased HA synthesis 
has been associated with cancer progression and metastasis (11). 
In patients with MPM, large quantities of HA are found in the 
tumor tissue although both malignant and benign mesothelial 
cells have been found positive for intracytoplasmic HA (12).
The complement system also constitutes the local environ-
ment for cancer as an immune surveillance against malignant 
cells due to its ability to promote inflammation and causes direct 
cell killing (13). We focused our investigation on C1q, which is 
the first recognition subcomponent of the complement classi-
cal pathway. C1q is a potent link between innate and adaptive 
immunity by virtue of its ability to bind IgG- and IgM-containing 
immune complexes (14). In addition to being involved in the 
clearance of apoptotic cells, and thus maintenance of immune 
tolerance, C1q also has the ability to directly impact upon cell 
differentiation and proliferation, dendritic cell maturation, and 
synaptic pruning; functions that are not reliant on comple-
ment activation by C1q (15). Recently, involvement of C1q in 
pregnancy via its ability to modulate the endovascular (16) and 
interstitial invasion (17) of trophoblast cells in placenta has 
also been demonstrated. In addition, we have recently showed 
that C1q is present in several solid human tumor tissues and 
is involved in tumor progression (18).
The present study focused on the involvement of C1q in the 
proliferation and invasiveness of MPM. We found that C1q can 
bind to HA and acquires protumorigenic properties, leading 




Hyaluronic acid was a kind gift from Prof. Ivan Donati, 
Department of Life Sciences, University of Trieste (19). C1q was 
either purified from fresh human serum following the procedure 
as described previously (20) or bought from Sigma-Aldrich 
(Milan, Italy). The recombinant globular head regions of the A, 
B, and C chains (ghA, ghB, and ghC, respectively) were expressed 
as fusion proteins linked to maltose-binding protein (MBP) in 
Escherichia coli BL21 and purified, as described previously (21). 
Poly-l-lysine, bovine serum albumin (BSA) and all reagents were 
from Sigma-Aldrich. The following antibodies were used: mono-
clonal antibody (mAb) mouse anti-human C1q was from Quidel 
(Quidel Corporation, San Diego, CA, USA), sheep anti-human 
C1q and anti-human C4 were purchased from The Binding Site 
(Bergamo, Italy). Mouse Monoclonal anti-C5b-9 antibody (aE11) 
was from AbCam. Mouse mAb anti-human von Willebrand fac-
tor (vWF), mouse mAb anti-human CD68, rabbit anti-human 
C1q, and goat anti-mouse-FITC F(ab)′ were purchased from 
Dako (Milan, Italy). Mouse mAb anti-human CD44-PE, mouse 
mAb anti-human CD45-PE-, or FITC-conjugated, unrelated 
mouse IgG1-PE- and FITC-conjugated were from Immunotools 
(Friesoythe, Germany). Cy3-conjugated F(ab′)2 goat anti-mouse 
IgG, and FITC-conjugated F(ab′)2 goat anti-rabbit IgG. Mouse 
mAb anti-human Mesothelin and rabbit anti-human Calretinin 
were from Santa Cruz Biotechnology (DBA, Milan, Italy). Mouse 
monoclonal anti-human Vimentin, goat anti-mouse IgG alkaline 
phosphatase (AP)-conjugated, anti-rabbit IgG-AP-conjugated, 
and anti-goat IgG-AP-conjugated were from Sigma-Aldrich.
Patients and specimens
MPM patients who were diagnosed and followed up at the 
Department of Pneumology, University Hospital of Cattinara, 
Trieste, Italy, were enrolled for this study. None of the patients 
received chemotherapy or radiotherapy prior to sampling.
Patients (five male) with reported asbestos exposure under-
went pleuroscopy for diagnosis of pleural effusion. All the pro-
cedures were performed under conscious sedation achieved by 
titration of intravenous midazolam and meperidine. Before the 
procedure, patients were placed in the lateral decubitus posi-
tion with the pleural effusion uppermost and a bedside chest 
ultrasonography was used to determine the entry site. After the 
creation of the sterile field and injection of 2% lidocaine in the 
intercostal space in order to obtain local anesthesia, a 2-cm skin 
incision was made with a scalpel, then blunt dissection of the 
chest wall was performed using curved Kelly forceps down to 
the parietal pleural. Finally, a trocar was placed into the pleural 
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space and the pleuroscope (Karl Storz GmbH, Tuttlingen, 
Germany) was inserted to examine parietal and visceral pleura 
to obtain parietal pleural specimens using dedicated forceps. 
At the end of the procedure, pleuroscope and trocar were 
removed and a chest tube was inserted trough the chest wall.
Tissue samples from patients were collected after informed 
consent following approval of the ethical considerations by the 
Institutional Board of the University Hospital of Trieste, Italy.
cell isolation and culture
Mesothelioma cells were isolated from pleural biopsy specimens. 
The tissue was finely minced with a cutter, incubated with a diges-
tion solution composed of 0.5% trypsin (Sigma-Aldrich, Milan, 
Italy) and 50  µg/ml DNase I (Roche, Milan, Italy) in Hanks’ 
Balanced Salt solution with Ca2+Mg2+ 0.5 mM (Sigma-Aldrich) 
overnight at 4°C. Next, the enzymatic solution was replaced 
with collagenase type 1 (3  mg/ml) (Worthington Biochemical 
Corporation, DBA) diluted in Medium 199 with Hank’s salts 
(Euroclone Spa, Milan, Italy) for 30 min at 37°C. The digestion 
was blocked with 10% fetal bovine serum (FBS, GIBCO, Life 
Technology) and the cell suspension was filtered through a 
100 µm pore filter (BD Biosciences, Italy).
The cells were seeded in a 12.5 cm2 flask and cultured using 
Roswell Park Memorial Institute (RPMI) medium 1640 with 
GlutaMAX (Life Technologies, Milan, Italy), 45% human 
endothelial cells serum-free medium (HESF, Life Technologies), 
10% heat-inactivated FBS supplemented with EGF (5  ng/ml), 
basic FGF (10  ng/ml), and penicillin–streptomycin (Sigma-
Aldrich). Fresh medium was replaced every 2–3 days. MES were 
used at their five to eight passages for all the in vitro experiments.
Met5A cells were purchased from ATCC. These cells were 
grown in DMEM supplemented with 10% FBS and 1% antibiotic 
mixture (Sigma-Aldrich) and maintained at 37°C in humidified 
atmosphere with 5% CO2.
Pleural effusions
Malignant pleural effusions (MPEs) were obtained from patients 
who underwent thoracentesis after diagnosis of MPM in order 
to remove the exudative liquid filling pleural space. The surgery 
was performed within the Department of Pathologic Anatomy 
of the Hospital of Monfalcone (Gorizia, Italy). MPEs were 
immediately stored at 4°C for a maximum of 24 h before being 
processed. Approximately 1 Liter of MPE was centrifuged twice 
at 250 g for 10 min to remove the cells.
Dose-Determination of soluble c1q
A 96-well plate (Corning Costar) was coated with sheep anti-
C1q (1:6.000) diluted in carbonate/bicarbonate buffer (100 mM, 
pH  >  9) and incubated overnight at 4°C. In order to avoid 
non-specific binding, the microtite wells were blocked with 
2% skimmed milk (SM) in PBS and incubated for 2 h at 37°C. 
In the meanwhile, samples to be dose-titrated were prepared 
and then added to the wells in triplicate. A standard curve was 
prepared using a serial dilution of purified C1q (Sigma-Aldrich) 
from 50 to 1.56 ng/ml and the plate was incubated overnight at 
4°C. Rabbit anti-human C1q (1:1,000) diluted in PBS  +  0.5% 
SM + 0.05% Tween was incubated for 1 h at 37°C, followed by 
secondary probing with anti-rabbit IgG-alkaline phosphatase 
(AP) conjugate (1:20,000) for 30  min at 37°C. p-nitrophenyl 
phosphate (pNPP) was used as substrate, as described above, and 
the developed color was measured at 405 nm using the Titertek 
Multiskan ELISA Reader (Flow Labs).
immunohistochemical analysis
Tissue samples of different MPM histotypes were fixed in 10% 
buffered formalin and paraffin embedded. Sections of 4 µm in 
thickness were fixed with xylene, 100% EtOH, and 95% EtOH and 
then microwaved three times in Tris–HCl/EDTA pH 9.0 buffer 
(Dako, Milan, Italy) for 5 min and washed in Tris-buffered saline. 
After neutralization of the endogenous peroxidase with H2O2 
(hydrogen peroxide) for 10 min, the sections were first incubated 
with PBS + 2% w/v BSA + 0.4% w/v Casein for 5 min in order 
to block the non-specific sites, and then probed with rabbit anti-
human C1q (1:500) overnight at 4°C. The bound antibodies were 
revealed using the Vectastain Elite ABC horseradish peroxidase 
(HRP) kit (Vector Laboratories, DBA, Italy). Secondary antibod-
ies were detected by 3-amino-9-ethylcarbazole (AEC)  +  high 
sensitivity Chromogen (Dako). The sections were counterstained 
with hematoxylin (Dako). Slides were examined under a Leica 
DM 3000 optical microscope and images were collected using 
a Leica DFC320 digital camera (Leica Microsystems, Wetzlar, 
Germany).
alcian Blue staining
After deparaffinizing and rehydrating, the sections were incu-
bated with a solution of 1% Alcian blue dissolved in 3% Acetic 
acid, pH 2.5, for 30 min at RT. After washing in tap water for 
10 min, the sections were dehydrated well in absolute alcohol and 
mounted. Images were acquired by the fluorescence microscope 
Leica DM 3000 using the Leica DFC320 camera.
immunofluorescence Microscopy of Mes
Mesothelioma cells cultured at confluence in an eight-chamber 
slide (BD Falcon) were fixed with FIX&PERM kit (Invitrogen, 
Life Technologies) for 15  min at RT. Incubation with primary 
antibodies (as listed earlier) was carried out for 1 h at RT. Cells 
were then washed and incubated with corresponding secondary 
antibodies (1:300) for 45  min at RT. The nuclei were stained 
with DAPI (Sigma-Aldrich). The glass was mounted with the 
Fluorescence Mounting Medium (Dako) and covered with a 
cover slip. Images were acquired by the fluorescence microscope 
Leica DM 3000 using the Leica DFC320 camera.
Flow cytometry
Mesothelioma cells (5 × 105) were fixed with the fixation reagent 
FIX&PERM kit for 15 min at RT in dark and incubated with pri-
mary antibodies for 1 h at 37°C in a thermomixer (Eppendorf) at 
800 rpm. Antibodies directed against intracellular antigens were 
diluted in permeabilization reagent of the FIX&PERM kit, while 
antibodies for cell surface antigens were diluted in PBS-1% w/v 
BSA. Incubation with secondary antibodies anti-mouse-FITC 
F(ab)′ (1:50) or anti-rabbit-FITC (1:300) was performed for 
30 min on ice. Cells were suspended in 1% paraformaldehyde, the 
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fluorescence was acquired with the FACScalibur (BD Bioscience), 
and data processed using the software CellQuest.
Binding of c1q to Mes
Mesothelioma cells were grown to confluence in 96-well tissue 
culture plates and incubated directly with increasing concentra-
tions of purified human C1q or preincubated with increasing 
concentrations of HA, for 1 h at room temperature. Bound C1q 
was revealed by ELISA using mAb anti-human C1q (10 µl/ml) 
and alkaline-phosphatase-conjugated secondary antibodies 
(Sigma-Aldrich). The color, developed using pNPP (Sigma-
Aldrich; 1  mg/ml) as a substrate, was read at 405  nm using a 
Titertek Multiskan ELISA reader (Flow Labs, Milano, Italy).
coating conditions
The microtiter wells were coated overnight at 4°C with HMW HA 
(50 µg/ml), C1q (20 µg/ml), ghA, ghB, ghC, or BSA (as a negative 
control; Sigma-Aldrich) diluted in 100  mM carbonate/bicarbo-
nate buffer, pH 9.6. C1q was allowed to bind (25 µg/ml) to HA 
in PBS + 0.5% BSA, 0.7 mM CaCl2, and 0.7 mM MgCl2, overnight 
at 4°C.
adhesion assay
1  ×  105 mesothelial cells or MES, labeled with the fluorescent 
dye FAST DiI (Molecular Probes, Invitrogen), were re-suspended 
in HESF (Life Technologies) containing 0.1% BSA (HESF + 0.1% 
BSA; Sigma), preincubated with 10  µM of ERK (#SCH772984, 
Selleckchem), JNK (#SP600125, SIGMA-Aldrich), or p38 
(#SB203580, Selleckchem) inhibitors for 30 min at RT and then 
added to a 96-well plate (wells were coated as described above) for 
35 min at 37°C in 5% v/v CO2 incubator. Then, the unbound cells 
were removed and the adherent cells were lysed with 10 mM Tris–
HCl, pH 7.4 + 0.1% v/v SDS. The plate was read via Infinite200 
(544 nm, emission 590 nm) (TECAN) using a calibration curve 
generated through an increasing number of labeled cells.
cell Proliferation
The cell proliferation assay was performed using Click-iT® Plus 
EdU Proliferation Kits (ThermoFisher). 5  ×  103 MES were re-
suspended in HESF + 0.1% BSA medium and seeded to a 96-well 
plate, which was earlier coated with C1q, HA or C1q + HA, as 
described above. Following adhesion, cells were incubated with 
15  µM analog EdU nucleotide (5-ethynyl-2-deoxyuridine) for 
DNA incorporation during replication. Cells were then incubated 
for 24 h at 37°C, fixed, and set up for a marking reaction by azide 
Oregon-Green 488. The signal amplification step included the 
incubation with antibody anti-Oregon-Green conjugated with 
HRP that reacts with the substrate, Amplx UtraRed, and pro-
duces a bright response that beams fluorescence around red. The 
fluorescence was analyzed by TECAN (Tecan, Milan, Italy) in the 
excitation/emission range of 535/595 nm.
apoptosis
Mesothelioma cells grown without serum, were suspended in 
0.1% w/v BSA in HEFS, and 2 × 104 cells/well were seeded on 
precoated plates. The cells were left to adhere for 1  h at 37°C, 
then incubated with 500  µM of H2O2 for 6  h, before adding 
5  µM of CellEvent™ Caspase-3/7 Green Detection Reagent 
(Life Technologies), a fluorogenic substrate for activated caspases 
3 and 7.
Migration assay
FAST DiI-labeled (Molecular Probes, Invitrogen, 1:100) MES 
(2 × 105 cells) were resuspended in 0.1% w/v BSA in HEFS and 
added to the upper chamber of a transwell system. The cells 
were allowed to migrate through HTS FluoroBlok systems with 
polycarbonate membranes of 8  µm pore size (Falcon) coated 
on the lower side, as described above. The plate was read using 
Infinite200, as described above.
scratch assay
Confluent monolayers of MES (2  ×  105) were seeded in 
HESF  +  0.1% BSA medium in 24-well plate. A scratch was 
placed in the middle of the well with a sterile 200 µl pipette tip. 
Subsequently, HA (50 µg/ml) or HA + C1q (20 µg/ml) were added 
to the wells. Cells incubated with 10% v/v FBS and as negative 
control MES were cultured in HESF/BSA (0.1%) medium with-
out stimuli. Images were acquired by phase-contrast microscope 
(Leica).
Phosphorylation of erK, saPK/JnK,  
and p38 in Mes
Pathway analysis was performed as per the manufacturer’s 
instructions of the PathScan® Intracellular Signaling Array 
Kit (Fluorescent Readout) (#7744; Cell Signaling Technology, 
EuroClone, Milan, Italy). Briefly, 24  h serum-starved MES 
(1.8 × 106 cells) were left to adhere to HA, or HA-bound-C1q, 
as described above for the indicated periods of time at 37°C. 
Then, the cells were washed with ice-cold 1× PBS and lysed 
in 1× ice-cold Cell Lysis buffer containing a cocktail of pro-
tease inhibitors (Roche Diagnostics). The Array Blocking 
Buffer was added to each well and incubated for 15 min at RT. 
Subsequently, an equal amount of total lysate (0.8 mg/ml) was 
added to each well and incubated for 2  h at RT. After wash-
ing, the biotinylated detection antibody cocktail was added to 
each well and incubated for 1 h at RT. Streptavidin-conjugated 
DyLight 680 was added to each well and incubated for 30 min 
at RT. Fluorescence readout was acquired using the LI-COR 
Biosciences Infrared Odyssey imaging system (Millennium 
science) and data processed by the software Image studio 5.0.
Detection of the interaction between 
human c1q (and its recombinant 
globular head Modules) and ha
The microtiter wells were coated overnight at 4°C with either 
50 µg/ml HA of different MWs diluted in carbonate/bicarbonate 
buffer (100 mM, pH 9.6). The blocking step with PBS + 1% BSA 
(2  h at 37°C) was followed by incubation with an increasing 
concentration of human C1q or the recombinant globular head 
modules (ghA, ghB, and ghC) of human C1q in PBS-Ca2+Mg2+ 
(0.7  mM) containing 0.5% BSA (PBS-CaMg-0.5% BSA) over-
night at 4°C. Bound C1q was detected with sheep anti-human 
C1q polyclonal antibodies whereas bound ghA, ghB, and ghC 
were detected with mouse anti-MBP (1 h at 37°C). The binding 
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of anti-C1q was detected using anti-goat IgG-AP conjugate, 
whereas the anti-MBP binding was detected using anti-mouse 
IgG-AP conjugate for 30 min at 37°C. The phosphatase substrate, 
pNPP (Sigma-Aldrich) was dissolved in 0.1 M glycine buffer con-
taining 1 mM MgCl2, 1 mM ZnCl2, pH 10.4 at a concentration of 
1.5  mg/ml. The absorbance was measured at 405  nm with the 
Titertek Multiskan ELISA Reader (Flow Labs).
evaluation of complement activation
Microtitre wells in a 96-well plate were coated with HA (50 µg/ml) 
or IgG (10 µg/ml), as described above. Non-specific binding sites 
were blocked with PBS-1%BSA for 1 h at 37°C, and then incu-
bated with 20 and 50 µg/ml C1q diluted in PBS-CaMg-0.5%BSA 
for 1  h at 37°C. Subsequently, the wells were incubated with 
pooled normal human serum (1:100) as a source of comple-
ment components in PBS-CaMg-0.5%BSA and incubated for 
30  min at 37°C with gentle shaking. C9 neoantigen detection 
was performed using the murine mAb aE11 against C9 neoan-
tigen (kindly provided by Prof. T. E. Mollnes, Oslo, Norway) 
and incubated for 1 h at 37°C. The AP-conjugated anti-goat IgG 
(Sigma-Aldrich) or anti-mouse IgG (Sigma-Aldrich), used as 
secondary antibodies, were incubated 30  min at 37°C. pNPP 
(Sigma) was dissolved in glycine buffer at the concentration of 
1.5 mg/ml. The absorbance was measured at 405 nm with the 
Titertek Multiskan ELISA Reader (Flow Labs).
statistical analysis
Data were analyzed using Two-way ANOVA, Tukey–Kramer 
test, and unpaired two-tailed Student’s t-test or one-way 
ANOVA with Bonferroni corrections. Results were expressed 
as mean ± SEM. Non-parametric data were assessed by Mann–
Whitney U tests and the results were expressed as median 
and interquartile range. p values  <  0.05 were considered sig-
nificant. All statistical analyses were performed using Prism 6 
software (GraphPad Software Inc., La Jolla, CA, USA).
resUlTs
c1q is Present in Malignant Pleural 
Mesothelioma specimens
We initially looked for the presence of C1q in a panel of invasive 
MPM specimens, including epithelioid, biphasic, and sarco-
matoid (Figure 1A) histotypes. As shown in Figure 1, a strong 
positivity for C1q was detected in all tumor specimen types 
examined, particularly in epithelioid histotype.
Within the mesothelioma microenvironment, C1q was mainly 
expressed by monocytoid cells suggestive of tumor-infiltrating 
myeloid elements (shown by arrows in the upper panels) and 
in the small vessels, as indicated by the black triangles of the 
lower panels in Figure  1B. C1q was also diffusely present in 
the tumor stroma and associated with the cell membrane of 
tumor cells. Immunohistochemical controls of C1q are shown 
in Figure 2. The presence of C1q was also detected in the three 
pleural exudate by a quantitative ELISA assay. We found out 
that the concentration of C1q was found to be about 76 µg/ml 
(±8  μg/ml), approximately two- or threefold lower than our 
control serum (about 200 µg/ml).
Binding of c1q to ha does not activate  
the complement classical Pathway
Having shown that C1q is abundantly present in the mesothe-
lioma microenvironment, we investigated the ability of C1q to 
interact with ECM components. We focused our attention to HA 
which is abundantly present in mesothelioma tissue (22). The 
presence of HA is clearly evident in Figure  3, where we show 
sections obtained from epithelioid and a biphasic mesothelioma 
tissue stained with Alcian blue.
We previously demonstrated that C1q is able to bind to a 
range of target ligands present in the ECM; this interaction 
is particularly strong with HA (17). We confirmed by ELISA 
the ability of C1q to bind to HA in a manner similar to IgG 
(Figure  4A). We also analyzed the binding of C1q to HA of 
different molecular weights (Figure 4B). Our results indicated 
that there were no statistically significant differences in C1q 
binding to low and high MW-HA. Furthermore, we evaluated 
the capability of HA-bound C1q to activate the complement 
classical pathway, by measuring the C4 and C9 (neoantigen) (C9 
neo) deposition by ELISA. As shown in Figures 4C,D, only C1q 
bound to IgG, and not HA-bound C1q, induced complement 
activation, and therefore, C4 deposition and C9-neoantigen 
formation. In order to localize the C1q interaction with HA, 
we analyzed the binding of recombinant forms of individual 
globular head modules (ghA, ghB, and ghC) to HA. Our results 
indicated that the globular head of C1q A chain (ghA) bound 
to HA better than ghB and ghC (Figure 4E), suggesting a dif-
ferential and modular nature of the interaction between the 
gC1q domains and HA.
isolation and characterization of Primary 
Tumor cells from MPM Biopsies
Having established that C1q is present in the MPM microen-
vironment and that it can bind to HA, we sought to investigate 
the implication of its presence in MPM biology. Therefore, we 
isolated MES from a portion of the resected malignant pleura, 
obtained during diagnostic pleuroscopy, from five patients 
with epithelioid MPM. We compared the MES morphology 
with Met5A, a commercial, immortalized mesothelial cell line, 
commonly used as a model of healthy cells. MES had mainly 
an elongated and filamentous shape and were very heterogene-
ous and multishaped (Figure 5A). It is possible to notice that 
there are also some polygonal and more regular cells in culture, 
which seem to resemble the epithelial phenotype of Met5A. 
Generally, they had an abundant cytoplasm in which vacuoles 
or granules were often present, transforming themselves in 
signet-ring cells.
We characterized MES for the expression of typical mesothe-
lial markers, such as mesothelin, calretinin, CK8-18, and CD44 
by immunofluorescence microscopy. The cells were also positive 
for vimentin, a marker of mesenchymal cells (Figure 5B). MES 
were positive for the above-mentioned markers. To assess the 
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FigUre 2 | Immunohistochemical controls for C1q. Representative microphotographs showing the immunohistochemistry controls: positive control tissue, lupus 
nephritis (a), scale bar, 100 µm; negative control tissue, pleural benign cyst (B), scale bar, 200 µm; negative control reaction, biphasic mesothelioma (c), scale bars, 
100 µm. Streptavidin–biotin–peroxidase complex system with 3-amino-9-ethylcarbazole (AEC) (red) chromogen.
FigUre 1 | Immunohistochemical analysis for C1q in human mesothelioma. (a) Representative microphotographs showing expression of C1q in different malignant 
pleural mesothelioma (MPM) histotypes: epithelioid (i), biphasic (ii), and desmoplastic (iii). Streptavidin–biotin–peroxidase complex system with 3-amino-9-
ethylcarbazole (AEC) (red) chromogen; scale bars, 50 µm. (B) Representative microphotographs showing the expression of C1q in tumor-associated stroma of 
mesothelioma. Highlighted are monocytoid cells suggestive of tumor-infiltrating myeloid elements (arrows) and neovascular endothelial cells (arrow heads). 
Streptavidin–biotin–peroxidase complex system with AEC (red) chromogen; scale bars, 100 µm.
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purity of isolated primary cells, we performed immunopheno-
typical staining against the classical leukocyte antigen CD45 to 
avoid the presence of contaminating leukocytes. Furthermore, 
we also found that MES cells were negative for vWF, a common 
marker used to detect endothelial cells. Interestingly, all MES 
were positive for CD68, a mature macrophage marker, although 
they were negative for CD14. Some of these markers were also 
analyzed by FACS (Figure 5C; Table 1).
IHC-positive staining for C1q in MPM tissues suggested that 
C1q may be produced locally. In this regard, C1q expression 
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FigUre 3 | Histochemistry of hyaluronic acid on malignant pleural mesothelioma (MPM). Alcian blue staining highlights hyaluronic acid of epithelioid (a) and 
biphasic (B) malignant mesothelioma sections. Scale bars, 100 µm.
FigUre 4 | Interaction of C1q with hyaluronic acid. (a) C1q interaction with high-molecular-weight (HMW) hyaluronic acid (HA) and IgG (positive control) by  
ELISA. Microtiter wells coated with 50 µg/ml HMW HA or 10 µg/ml IgG were incubated with an increasing concentration of C1q; HA-bound C1q was revealed  
with anti-C1q antibodies. C1q bound HA with an affinity similar to IgG. The data are expressed as mean of three independent experiments in triplicates ± SEM.  
(B) Binding of C1q to different MW HA. Microtiter wells coated with 50 µg/ml HMW-HA (or 5, 20, 800, or 1,500 kDa HA) were incubated with increasing 
concentration of C1q and bound C1q was revealed with anti-C1q antibodies. No statistically significant difference was observed between the binding of C1q to low 
and high MW-HA was observed. The data are expressed as mean of three independent experiments carried out in triplicates ± SEM. (c–D) Evaluation of the ability 
of C1q bound to HA to activate the classical pathway of the complement system. Microtiter wells coated with 50 µg/ml HMW HA, or 10 µg/ml IgG were incubated 
with 20 and 50 µg/ml C1q. Pool of normal human sera (1:100) was added as a source of complement components and the deposition of C4 (c) and the formation 
of C9-neoantigen (C9 neo) (D) were revealed by using specific antibodies against C4 and C9 neoantigen (mAb aE11) by ELISA. The data are expressed as mean of 
three independent experiments carried out in triplicates ± SEM. (e) Dose response curve of the binding of ghA, ghB, and ghC to HMW HA. Microtiter wells were 
coated with 50 µg/ml HMW HA. The wells were then incubated with increasing amounts (0–10 µg/ml) of recombinant C1q globular head modules (ghA, ghB, ghC). 
The binding was revealed using anti-MBP antibody. The data are expressed as mean of three independent experiments done in triplicates ± SEM.
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FigUre 5 | Continued
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FigUre 5 | Continued   
Characterization of mesothelioma cells (MES). (a) Morphological features of the three different populations of MES (MES7, MES9, and MES12) isolated from 
malignant pleural mesothelioma (MPM) biopsies. Images were acquired by phase-contrast microscope, Leica original magnification: 200×. (B) Mesothelial cells were 
characterized by immunofluorescence for the expression of mesothelin, CK 8/18, vimentin, CD9, CD68 (green), and CD44 (red). Mesothelioma cells were grown to 
confluence in eight-chamber culture slides. After fixation and permeabilization, the cells were stained with mAb anti-human mesothelin, CK 8/18, vimentin, CD9, von 
Willebrand factor (vWF), CD68, and CD14, followed by anti-mouse-FITC F(ab)′ secondary antibodies or mAb anti-human CD45 and mAb anti-human CD44-PE 
conjugate. Nuclei were stained blue by DAPI: original magnification 200×. (c) The expression of mesothelin, CD68, CK8/18, calretinin, and vimentin was confirmed 
by FACS. The expression of these markers (green lines) was compared with appropriate control antibodies (black lines). (D) Binding of C1q to MES. Tumor cells 
grown to confluence on 96-well tissue culture plates were incubated with increasing concentrations of purified C1q for 1 h at room temperature and the bound C1q 
was revealed by ELISA. (e) The binding of 25 µg/ml C1q to MES was detected preincubating the cells with increasing concentration of hyaluronic acid (HA). Bound 
C1q was revealed by ELISA as described above. The data are presented as mean ± SEM of three separate experiments.
TaBle 1 | Marker expression evaluated by FACS analysis on cells isolated from 
five different epithelioid mesothelioma tumors.
Marker Mes7 Mes9 Mes12 Mes13 Mes14
Mesothelin + + + + +
Vimentin ++ ++ + + +
CK 8/18 ++ Nd + + +
Calretinin + Nd − + +
vWF − − − Nd −
CD68 ++ + + + +
CD45 − − − − −
CD44 ++ + Nd Nd ++
Data refer to cells between the third and the fifth passage in culture. ++ = positivity 
(>50%), + = positivity (<50%), − = negativity, Nd = not done.
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was evaluated at both mRNA and protein levels in healthy 
(Met5A) and tumor MES. We performed qPCR for three C1q 
chains (C1qA, C1qB, and C1qC); none were positive in five 
different cell populations (data not shown). Interestingly, C1q 
was found to bind strongly to the surface of MES (Figure 5D) 
and the extent of binding increased in the presence of HA being 
highest at the concentration of 50  µg/ml of HA (Figure  5E). 
To investigate the role of bound C1q on complement activation, 
we incubated C1q-bearing cells with AB+ human serum and 
analyzed the cells for the presence of C4 and C9 neoantigen on 
their surface. We failed to detect both complement components 
suggesting that binding of C1q to MES is not associated with 
complement activation.
c1q Promotes Mes adhesion  
and spreading
To evaluate the ability of C1q to interact with MES, we per-
formed a cell adhesion assay using immobilized C1q. MES 
(four different populations) and Met5A cells were labeled with 
the fluorescent probe FAST DiI and seeded on to immobilised 
C1q, HA or HA-bound-C1q; BSA was used as a negative 
control protein. Met5A cells were able to adhere to HA, and 
to a less extent, to C1q or HA-bound-C1q (Figure 6A). In con-
trast, MES showed greater adherence to HA; HA-bound-C1q 
was able to enhance MES adhesion considerably compared to 
HA alone (Figure 6B). All four MES populations showed the 
same behavior on HA-bound-C1q, although MES adhesion 
to C1q alone varied considerably between patients’ samples 
(Figure 7).
The analysis of the adherent MES by phase-contrast optical 
microscopy revealed that a high proportion of the cells seeded 
on to C1q or HA-bound-C1q were spread out, in contrast to 
the round morphology exhibited by those attached to HA or 
BSA (Figure 6C). In order to understand which module of the 
globular domain of C1q was mainly involved in MES adhesion, 
MES were stained with Fast DI and allowed to adhere to C1q, 
HA or recombinant globular heads (ghA, ghB, ghC) for 30 min. 
As shown in Figure 6D, the interaction of the cells with C1q 
seems to be mediated by ghC, and to a lesser extent, ghB. The 
cells did not seem to interact with ghA.
Since both HMW-HA and LMW-HA are present in the tumor 
microenvironment, we investigated the adhesion of MES to 
LMW-HA alone or in combination with C1q and we compared 
the results with the adhesion to HMW-HA with or without 
C1q. We did not observe any statistical difference between the 
MES adhesion to LMW or HMW-HA (Figure 6E).
c1q Promotes MPM Tumor Progression by 
Favoring Mes Proliferation and Migration
We investigated whether C1q might contribute to tumor growth 
by stimulating the proliferation of MES. Thus, MES were seeded 
on to solid phase C1q, HA, or HA-bound-C1q and the number 
of proliferating cells were evaluated using the Click-iT® EdU 
Microplate Assay. Our results indicated that HA-bound C1q 
was able to enhance the proliferation rate of MES (Figure 8A), 
compared to HA or C1q alone.
C1q-induced migration of labeled MES was examined by 
monitoring cell migration from the upper chamber through an 
insert coated with C1q, or HA-bound-C1q. C1q (60%) was found 
to be more effective than HA (~20%), in effecting migration 
(Figure 8B). In this assay, we did not observe a synergistic effect 
of the double matrix (HA-bound-C1q). In fact, the percentage 
of the cell migration due to HA + C1q was comparable to that 
observed with C1q alone.
The effect of C1q on the cell migration was also analyzed using 
a scratch wound healing assay, monitoring the mobilization of 
MES toward the scratched area for 18 h. As shown in Figure 9, 
MES stimulated by C1q started to enter the scratched area 
and migrated farther than cells exposed to HA after 18 h.
In order to investigate whether C1q was able to protect MES 
from apoptosis, serum-starved MES were allowed to adhere on to 
the wells, coated with HA or HA-bound-C1q, and then incubated 
with 500 µM H2O2 for 6 h. Subsequently, the activation of caspases 
3 and 7 was detected using a fluorogenic substrate. As shown in 
the graph in Figure 8C, the fluorogenic units of the MES on HA 
treated with H2O2 was double, compared to the untreated cells. 
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FigUre 6 | Effect of C1q on mesothelioma cells (MES) adhesion. Mesothelial cells (Met5A) (a) and four different populations of MES (B) were labeled with the 
fluorescent dye FAST DiI and allowed to adhere to microtiter wells precoated with hyaluronic acid (HA), C1q, HA-bound-C1q, or bovine serum albumin (BSA).  
The data are expressed as mean of four independent experiments done in triplicates ± SEM. Cell adhesion was measured after 35 min. Results are expressed  
as percent of adhesion with reference to a standard curve established using an increasing number of labeled cells. (c) Morphological aspect of one representative 
primary cell line adhered to HA, C1q, HA-bound-C1q, or BSA. Images were acquired via phase-contrast microscopy, original magnification: 200×. (D) MES cells 
were labeled with the fluorescent dye FAST DiI and allowed to adhere to microtiter wells precoated with C1q, ghA, ghB, ghC, high molecular weight (HMW)-HA,  
or BSA. The data are expressed as mean of four independent experiments carried out in triplicates ± SEM. (e) MES were labeled with the fluorescent dye FAST DiI 
and allowed to adhere to microtiter wells precoated with HMW-HA, HMW-HA + C1q, low molecular weight (LMW)-HA, or LMW-HA + C1q. The data are expressed 
as mean of four independent experiments carried out in triplicates ± SEM.
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Surprisingly, MES adhering to C1q or HA-bound-C1q were not 
protected from apoptosis induced by oxidative stress (Figure 8C).
c1q enhances erK1/2, saPK/JnK, and 
p38 Phosphorylation in Mes cells
To further elucidate the mechanism of the cell activation, we 
analyzed the signaling pathways likely to be involved in tumor 
cell adhesion, migration and proliferation. We examined more 
specifically the activation of three members of the MAPK family, 
ERK1/2, SAPK/JNK, and P38 signaling molecules.
Serum-starved MES were allowed to adhere to wells coated 
with HA or HA-bound-C1q, for 5 or 20  min and the phos-
phorylation status of ERK1/2, SAPK/JNK, and P38 was 
evaluated by immunofluorescence using PathScan® Intracellular 
Signaling Array Kit (Cell Signaling Technology). As shown in 
Figures 10A–C, binding of MES to HA-bound-C1q resulted in 
the activation of all the signaling molecules, which was clearly 
seen at 20 min post stimulation for all pathways and the signal 
was significantly higher in the cells adhering to C1q bound to 
HA than in cells adherent to HA only. All three MAPK inhibitors 
tested in the adhesion assay proved to be effective in reducing 
significantly the cell adhesion to C1q bound to HA (Figure 10D).
DiscUssiOn
C1q is expressed in the stroma and vascular endothelium of a 
number of human malignant tumors, including adenocarcinomas 
of colon, lung, breast, and pancreas. In a murine model of 
melanoma, C1q was found to promote cancer cell adhesion, 
migration and proliferation (18). Thus, as a pro-tumorigenic 
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FigUre 7 | Effects of C1q on mesothelioma cells (MES) adhesion. Four different populations of MES were labeled with the fluorescent dye FAST DiI and allowed to 
adhere to microtiter wells precoated with hyaluronic acid (HA), C1q, HA-bound-C1q, or bovine serum albumin (BSA). The results of each independent experiment, 
done in triplicates ± SEM are shown in order to highlight differential behavior of these cells. Cell adhesion was measured after 35 min. The results are expressed as 
percent of adhesion with reference to a standard curve established using an increasing number of labeled cells.
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soluble factor, C1q can promote tumor progression by facilitat-
ing cancer cell seeding and angiogenesis. Here, we investigated 
the presence and the role of C1q in MPM for a number of 
reasons. MPM is an aggressive neoplasm with a poor progno-
sis, because it is resistant to chemotherapy and radiotherapy. 
Therefore, studying the microenvironment of this tumor can 
help devise novel therapeutic strategies. In this study, we par-
ticularly focused our attention on the interaction between C1q 
and HA and its implication on adhesion and proliferation of 
MPM cells. Understanding this C1q-HA interaction is of great 
importance given a unique expression pattern of C1q in meso-
thelioma tissues and a great relevance of HA in the biology of 
the MPM.
IHC revealed that C1q was present in all the histological 
variants examined and it seemed primarily associated with 
monocytoid cells, indicating that these cells might be the main 
source of C1q locally. C1q was also diffusely present in the tumor 
stroma and associated with the cell membrane of tumor cells 
mainly of the epithelioid histotype. This pattern of expression is 
similar to that in other solid tumors (18) and is reminiscent of 
its distribution in human decidua (17). There were also areas in 
which C1q could be found associated with small vessels, raising 
the possibility that C1q might exhibit a proangiogenic activity in 
this context, similar to that in wound healing (23).
We first investigated the interaction of purified human C1q 
with HA since MPM is associated with a high level of production 
of HA (24). HA is highly expressed in MPM because it is respon-
sible for the lubrication of the pleural membranes and is secreted 
by the mesothelial cells (25). Here, we demonstrated that HA is 
abundantly present in MPM tissues, confirming an earlier study 
(22). HA has previously been shown to promote proliferation and 
migration of MPM cells through its interaction with hyaluronan 
receptor (26). We have previously shown that C1q can interact 
with HA (17). Here, we showed that C1q can bind to HMW-HA, 
and as expected, this binding does not induce complement acti-
vation. The interaction between C1 and HA has been studied 
in the past mainly considering its anti-complement activity (27, 
28). The interaction of C1q with synovial HA in rheumatoid 
arthritis has been previously reported (29); however, C1q binds 
synovial antibodies that are covalently coupled to HA. Heated 
and then lyophilized HA binds C1q (and a range of complement 
components) better that native HA, probably via polyanionic 
charges (30). A comparable binding activity was also observed 
for LMW-HA, whose local accumulation can be detected in 
the tumor microenvironment as a consequence of enhanced 
synthesis and turnover of HMW-HA. Since LMW-HA, but not 
HMW-HA, can stimulate a number of biological processes (31, 
32), it is likely that C1q can interfere with several functions 
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FigUre 8 | Effects of C1q on mesothelioma cells (MES) migration, 
proliferation, and apoptosis. (a–c) The experiments of cell migration, 
proliferation and apoptosis were performed as detailed in Section “Materials 
and Methods.” (a) MES proliferation. MES were seeded in wells precoated 
with hyaluronic acid (HA), C1q, HA-bound-C1q, or bovine serum albumin 
(BSA) and the number of proliferating cells was evaluated using the Click-iT® 
EdU Microplate Assay. (B) FAST DiI-labeled MES were allowed to migrate 
through a trans-well system polycarbonate membranes coated on the lower 
side with HA, HA-bound-C1q, C1q, or BSA. (c) Serum-starved MES cells 
were seeded in the wells precoated with HA, C1q, HA-bound-C1q, or BSA 
and incubated with H2O2. Apoptotic cells were ascertained by CellEvent™ 
Caspase-3/7 (Life Technologies). Data from at least five independent 
experiments are presented as mean ± SEM.
FigUre 9 | Effects of C1q on mesothelioma cells (MES) migration. For 
wound healing assays MES (2 × 105) were seeded in HESF + 0.1% BSA 
medium in 24-well plate and grown to 90–95% confluence. A scratch  
was placed in the middle of the well with a sterile 200 µl pipette tip. 
Subsequently, hyaluronic acid (HA) (50 µg/ml) or HA + C1q (20 µg/ml)  
were added to the wells. The invasion was evaluated in three separate 
experiments performed independently. The results of a representative 
experiment are shown. Images were acquired by phase-contrast 
microscope, Leica original magnification: 200×.
mediated by HA, such as angiogenesis and inflammation. To 
dissect the functional contribution of each chain within the 
heterotrimeric globular domain of C1q, we investigated the 
binding properties of the recombinant ghA, ghB, and ghC mod-
ules. Our results demonstrated that the ghA module was the best 
binder of HA.
The proadhesive properties of C1q that we demonstrated in vitro 
for murine melanoma cells (18) were also evident for MES. In this 
study, we made a significant step forward since we were able to test 
several populations of MES isolated directly from human patients. 
Here, we demonstrated that the effects mediated by C1q-bound-HA 
were different from that observed for HA or C1q alone in terms of 
the number of adhering cells as well as morphology indicating that 
the presence of C1q can considerably modify the tumor microen-
vironment. The proadhesion effect of C1q seems to be restricted to 
the cells isolated from primary tumors while Met5A cells, which 
are representative of non-tumor mesothelium, adhere better to HA, 
compared to the adhesion on C1q-bound-HA or C1q alone. These 
data indicate that C1q can exert differential effects depending on 
the cell types and probably expression of putative receptors. Among 
various C1q receptors gC1qR, also called HA-binding protein-1, is 
an interesting molecule for its ability to bind both the gC1q domain 
of C1q and HA. Furthermore, CD44, the main receptor for HA, 
has been described as a possible docking signaling molecule for 
the interaction with gC1q (33). The nature and consequences of 
interaction between these cellular receptors and C1q-bound-HA 
is currently under investigation. Another interesting observation 
is that the adhesion of MES to C1q is predominantly mediated via 
the ghC module. Since ghA is the preferential binder to HA, the 
gC1q domain can act as a bridging molecule for anchoring the 
tumor cells to the ECM. C1q-bound-HA was able to promote the 
growth and the migration of MES in vitro confirming our previous 
results (18), obtained with B16/F10 murine cells and C1q bound to 
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FigUre 10 | Phosphorylation of ERK1/2, SAPK/JUNK, and p38 in 
mesothelioma cells (MES). (a–c) MES were allowed to adhere to hyaluronic 
acid (HA) or HA-bound-C1q and the phosphorylation status of ERK1/2, 
SAPK/JUNK, and p38 was evaluated using total cell lysates with PathScan 
Antibody Array Kit (Cell Signaling), as described in the Section “Materials and 
Methods.” Data from at least three independent experiments are presented 
as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).  
(D) Three different populations of MES were labeled with the fluorescent  
dye FAST DiI, preincubated for 30 min at 37°C with P38, ERK, or JNK 
inhibitors and then allowed to adhere to microtiter wells precoated with 
HA-bound-C1q. The data are expressed as mean of three independent 
experiments done in triplicates ± SEM. ***p < 0.001 vs. resting.
fibronectin. The finding that C1q alone did not exert a significant 
proliferating effect on MES seen previously on melanoma cells may 
be explained by differential response of cells derived from various 
tumors to C1q. It is also important to emphasize that this study 
was carried out on primary cells, which were freshly isolated from 
patients.
The activation of three members of the MAPK family, ERK1/2, 
SAPK/JNK, and p38 in this study is also consistent with the previ-
ously reported study (17).
That C1q can act as a tumor promoting factor in MPM 
confirms our recent data (18). In addition, Winslow et al. have 
observed that the three chains of C1q were highly expressed in the 
stroma of breast cancers with poor prognosis (34). On the con-
trary, Hong et al. reported that C1q is involved in the regulation 
of cancer cell survival and progression sustaining the activation 
of the tumor suppressor WW-domain containing oxidoreductase 
(WOX1). C1q downregulation enhanced prostate hyperplasia 
and tumorigenesis because of the lack of WOX1 activation (35). 
Recently, Kaur et al. have reported that C1q, via its gC1q domain, 
induced apoptosis in an ovarian cancer cell line SKOV3 via TNF-
α induced apoptosis pathway involving upregulation of Bax and 
Fas (36). These contrasting observations appear to suggest that 
the function of C1q in the biology of the tumor is complex and 
is strongly dependent on the microenvironment. Our hypothesis 
is that C1q can be locally produced by non-tumor cells and can 
interact differentially to the different ECM components present 
in the tumor microenvironment. The presence of C1q or C1 in 
soluble phase or bound to the ECM can provide different stimuli 
to the tumor cells present in the microenvironment.
In conclusion, C1q is abundantly present in mesothelioma 
tissue, interacts with HA, and interferes with adhesion, migra-
tion and proliferation of MES. The role of C1q is more complex 
than previously thought and is likely to be dependent on the 
tumor microenvironment. The availability of the recombinant 
globular domain of C1q may have implications for therapeutic 
approaches.
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The contribution of the complement system in the pathophysiology of brain cancers
has been recently considered in light of its well-known involvement in carcinogenesis.
Complement system represents an important component of the inflammatory response,
which acts as a functional bridge between the innate and adaptive immune response.
C1q, the first recognition subcomponent of the complement classical pathway, has
recently been shown to be involved in a range of pathophysiological functions that are
not dependent on complement activation. C1q is expressed in the microenvironment
of various types of human tumors, including melanoma, prostate, mesothelioma, and
ovarian cancers, where it can exert a protective or a harmful effect on cancer progression.
Despite local synthesis of C1q in the central nervous system, the involvement of
C1q in glioma pathogenesis has been poorly investigated. We, therefore, performed
a bioinformatics analysis, using Oncomine dataset and UALCAN database in order to
assess whether the expression of the genes encoding for the three chains of C1q
(C1qA, C1qB, and C1qC) could serve as a potential prognostic marker for gliomas.
The obtained results were then validated using an independent glioma cohort from
the Chinese Glioma Genome Atlas datasets. Our bioinformatics analysis, coupled with
immunohistochemistry and fluorescence microscopy, appears to suggest a positive
correlation between higher levels of C1q expression and unfavorable prognosis in a
diverse grade of gliomas.
Keywords: gliomas, C1q complement, bioinformatics analysis, survival probability, prognostic significance of C1q
INTRODUCTION
The complement protein C1q represents the recognition subcomponent of the complement
classical pathway, which is responsible for clearing immune complexes and invading pathogens.
Its association with C1r and C1s, following ligand recognition, triggers complement activation
(1, 2). C1q is characterized by a typical tulip-like overall structure, assembled from 18
polypeptide chains of three different types, A (28 kDa), B (25 kDa), and C (24 kDa),
each having an N-terminal collagen-like domain and a C-terminal globular (gC1q) domain
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(3, 4). The gC1q domain, which is the ligand recognition region
of C1q, has a heterotrimeric structure, being composed of C-
terminal ends of A, B, and C chains (5). In addition to binding
IgG and IgM containing immune complexes and activating the
complement classical pathway, there is emerging evidence to
suggest that C1q plays crucial roles in several processes that
are independent of complement activation, such as placentation
(6), angiogenesis (7), autoimmunity (8, 9), and carcinogenesis
(9, 10). C1q is highly expressed in the microenvironment of
various types of human tumors (10, 11) where it can exert
either a protective or a detrimental effect on the tumor growth.
In prostate cancer cells, C1q was recently shown to induce
apoptosis by activating the tumor suppressor WOX1 (12), thus
acting as an anti-tumor humoral factor. In ovarian cancer,
C1q has been shown to induce apoptosis in a representative
SKOV3 cell line via activation of TNF-α, upregulation of
Fas, and downregulation of mammalian target of rapamycin,
RICTOR, and RAPTOR survival pathways (13). In a BALB-
neuT mouse model of mammary carcinomas, C1q was shown to
have a protective role against cancer progression (14). However,
C1q can promote adhesion, migration, and proliferation of
primary cells derived from malignant pleural mesothelioma
patients, a relatively rare disease associated with exposure to
asbestos (11). This dichotomous role of C1q has been further
highlighted by a bioinformatics analysis involving several types
of carcinomas (15).
The importance of C1q in the pathophysiology of the central
nervous system (CNS) has been an area of intense research
in the last two decades. In a healthy brain, C1q promotes
synapse elimination required for fine circuitry refinement during
CNS development (16). C1q activities, unrelated to complement
activation, were shown to support neuronal survival and neurite
outgrowth in vitro and protect against β-amyloid-mediated
neurotoxicity (17). C1q can also interact with abnormal protein
aggregates, such as βA1-42, thus favoring neurodegenerative
diseases progression (18).
Since C1q and other complement components can be locally
produced within the CNS by microglia and astrocytes, it
is likely that C1q has involvement in primary brain tumor
pathophysiology (19). Brain malignancies arise from cells of the
CNS and are classified according to the tissue of phylogenetic
origin. Gliomas represent the most common and aggressive form
of brain tumors in adults; they are derived from glial or precursor
cells (20). These are a heterogeneous group of diseases with
multiple subtypes (20, 21). Glioblastoma multiforme (GBM) is
the most common and fatal form of the primary brain tumor,
accounting for approximately 60% of all glioma cases (22),
whereas low-grade gliomas (LGGs) are the secondmost common
type of glioma in adults (∼30%) (22).
In GBM tumor specimens, the presence of C1q does
not correlate with CD45 positive leukocytic infiltration (23).
Interestingly, C1q appeared to be highly concentrated around
the malignant cells and the necrotic debris. Moreover, the
serum concentration of C1q, together with critical components
of the lectin and alternative complement pathways, appeared
significantly increased in GBM patients as compared to healthy
controls (23), thus indicating a role for complement activation in
the pathogenesis of the GBM.
In the current study, we performed a bioinformatics analysis
aimed at investigating whether C1q can serve as a potential
prognostic marker for gliomas.
MATERIALS AND METHODS
Oncomine Database Analysis
The expression levels of C1qA, C1qB, and C1qC genes in gliomas
were analyzed using Oncomine (www.oncomine.org), a cancer
microarray database and web-based data mining platform for
new discovery from genome-wide expression analyses (24, 25).
We compared the differences in mRNA levels between normal
tissue and cancer. The mRNA expression level in neoplastic
tissues, compared to the healthy tissues, was obtained as the
parameters of P < 0.05, fold change > 2, and gene ranking in
the top 10%. Information about the datasets used in this study is
summarized in Table 1.
UALCAN and CGGA Database Analysis
UALCAN (http://ualcan.path.uab.edu) is a web resource for
analyzing cancer transcriptome data, which estimates the effect
of gene expression level on the patient survival (26). In addition
to the gene expression variation across tumor samples, gene-
level correlations with patient survival also feature in UALCAN.
Available genomics data from “The Cancer Genome Atlas”
(TCGA) project was used for Kaplan–Meier survival analysis
to generate survival probability plots (26). The prognostic
significance of C1qA, C1qB, and C1qC expression and survival
in gliomas were analyzed by UALCAN. The hazard ratio
with 95% confidence intervals and logrank p-value were
also computed.
The Chinese Glioma Genome Atlas (CGGA) (http://www.
cgga.org.cn) is a user-friendly web application for data storage
and analysis exploring brain tumors datasets from Chinese
cohorts (Table 1) (27). Analyze tool of CGGA was used to
browse C1qA, C1qB, and C1qC mRNA expression profile and to
perform survival analysis in specific glioma subtype. The hazard
ratio with 95% confidence intervals and logrank p-value were
also computed.
Statistical Analysis
Survival curves were generated by UALCAN and CGGA. All
results are displayed with p-values from a log-rank test. P-
values <0.05 were considered significant. Similarly, in the case
of Oncomine, the program provided the statistical significance of
data (P-values).
Immunostaining
Tissue samples, derived from the neuroepithelial tumors with
astrocytic differentiation, presenting different grades (grade-
II and -III to GBM, grade-IV), were collected from glioma
patients, after informed consent following approval of the ethical
considerations by the Institutional Board of the University
Hospital of Trieste, Italy.
Gliomas tissue specimens (five patients for each glioma grade,
Department of human pathology of the University Hospital of
Cattinara, Trieste, Italy) were fixed in 10% v/v buffered formalin
and paraffin embedded. For immunostaining, 4 µm-thick tissue
Frontiers in Immunology | www.frontiersin.org 2 October 2019 | Volume 10 | Article 236681
Mangogna et al. Prognostic Significance of C1q in Gliomas
TABLE 1 | Characteristics of the datasets used in bioinformatics analysis.
Datasets Study description Experiment type
Sun brain One hundred fifty-seven (157) brain and CNS tumors and 23 normal brain samples were analyzed on Affymetrix U133 Plus
2.0 microarrays. Sample data includes type, grade, and sample name. Corresponding DNA copy number data is available
in Kotliarov Brain
mRNA
French brain Twenty-three (23) anaplastic oligodendroglioma, 4 anaplastic oligoastrocytoma, and 6 normal brain samples were analyzed
on Affymetrix U133 Plus 2.0 microarrays. Sample data includes 10q loss of heterozygosity, 19q loss of heterozygosity, 1p
loss of heterozygosity, age, chemotherapy response, EGFR amplification, sex, survival after diagnosis, survival after surgical
resection, and therapy
mRNA
TCGA brain Five hundred forty-seven (547) glioblastoma and 10 normal brain samples were analyzed. Sample data includes age, sex,
survival, and others. This dataset consists of Level 2 (processed) data from the TCGA data portal. Corresponding DNA copy
number data is available in TCGA Brain 2
mRNA
CGGA brain The CGGA RNA sequence dataset consisted of 325 samples, including 109 grade-II samples, 72 grade-III samples and
144 grade-IV samples. Of the 144 GBM samples, 6 samples were lost to follow-up; therefore, 138 samples were included
in the survival analysis. The patients with GBM were followed up every 3 months
mRNA
Rickman brain Forty-five (45) astrocytoma and 6 normal temporal lobe samples were analyzed on Affymetrix HuGeneFL microarrays.
Sample data include type and grade
mRNA
Bredel brain 2 Fifty (50) brain CNS carcinoma samples and 4 normal brain samples were analyzed on cDNA microarrays. Sample data
includes disease type
mRNA
Liang brain Thirty (29) glioblastoma, 3 mixed astrocytoma-oligodendroglioma, 2 oligodendroglioma, 2 normal brain, and 1 normal
cerebellum sample were analyzed on cDNA microarrays. Sample data includes type, age, location, primary/recurrent, sex,
and survival
mRNA
sections were de-waxed with two changes of xylene, 10min each.
Slides were then transferred to 100% alcohol, for two changes,
10min each, and once through 95 and 70% alcohol respectively,
for 5min each. Finally, they were rinsed in de-ionized water,
twice for 3min each. The antigen unmasking technique was
performed using Novocastra Epitope Retrieval Solutions pH9
EDTA-based buffer in thermostatic bath at 98◦C for 30min (28).
Sections were brought to room temperature and washed in PBS.
Subsequently, the neutralization of the endogenous peroxidase
with 3% v/v H2O2 and Fc blocking by a specific protein block
(Novocastra, Leica Biosystems) were performed.
For immunostaining, glioma sections were probed with the
following primary antibodies overnight at 4◦C: rabbit anti-
human C1q polyclonal antibody (1:500; Dako), rabbit anti-
human C3d polyclonal antibody (1:100; Cell Marque) and rabbit
anti-human C4d polyclonal antibody (1:100; Cell Marque).
Antibody-Antigen recognition was detected using Novolink
Polymer Detection Systems (Novocastra Leica Biosystems,
Newcastle) and employing the high sensitivity AEC (3-Amino-
9-Ethylcarbazole) as chromogen. Slides were counterstained
with Harris Haematoxylin (Novocastra, Ltd) and images
were collected using a Leica DFC320 digital camera (Leica
Microsystems, Wetzlar, Germany).
For double immunostaining experiments, tissue sections
were incubated overnight at 4◦C with the following primary
antibodies: rabbit anti-human C1q polyclonal antibody (1:500,
Dako), mouse anti-human CD68 (1:50, Clone KP1, Dako)
and anti-human CD163 monoclonal antibodies (1:100, Clone
10D6, Leica Biosystems). The following secondary antibodies
were used: goat anti-rabbit conjugated to Alexa Fluor 488,
and goat anti-mouse conjugated to Alexa Fluor 568 (Life
Technologies). Nuclei were counter-stained with DAPI (4′,6-
diamidin-2-fenilindolo). All the sections were analyzed under
Zeiss Axio Scope A1 optical microscope (Zeiss, Germany) and
microphotographs were collected using an Axiocam 503 Color
digital camera with the ZEN2 imaging software (Zeiss Germany).
RESULTS
Bioinformatics Analysis Reveals Higher
mRNA Levels of C1q A, B, and C Chains in
Gliomas
We initially compared the mRNA levels of the three chains
of human C1q (A, B, and C) in normal brain and gliomas
using the Oncomine platform. From the analysis performed on
several datasets such as Sun’s, French’s, TCGA’s, Rickman’s, Bredel
2’s, and Liang’s, a significantly higher mRNA expression levels
for C1qA, C1qB, and C1qC chains were detected in gliomas
(different histotypes and grades) as compared to normal brain
tissue (Figure 1, P < 0.05; Table 2).
We then took advantage of the UALCAN tool to carry
out bioinformatics analysis on C1qA, C1qB, and C1qC mRNA
expression levels according to TCGA database. UALCAN tool
considers LLGs, grade-II and -III, and high-grade gliomas
(HGGs) only grade-IV (or GBM) while the World Health
Organization (WHO) considers as LLGs, grade-I and -II, and
HGGs as grade-III and -IV. Based on this analysis, as shown in
Figure 2, a positive correlation between the mRNA expression
of the three chains and the unfavorable prognosis only in LGGs
(grade-II and -III) was evident, where the survival probability
is indeed reduced (P < 0.05). By contrast, no correlation was
observed between C1qA, C1qB, and C1qCmRNA expression and
the survival probability in GBMs (grade-IV) (Figure 2).
To further validate these results, we used the CGGA tool to
inquire an independent glioma database. Based on this analysis,
a positive correlation was found between the mRNA expression
of the three C1q chains and the unfavorable prognosis in
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FIGURE 1 | C1qA, C1qB, and C1qC expression in gliomas. Sun’s dataset was used for bioinformatics analysis to explore C1qA and C1qB mRNAs expression in the
glioblastoma multiforme, whereas Bredel 2’s dataset was used for bioinformatics analysis to evaluate C1qC mRNA. A higher expression of the three chains was
detectable in glioblastoma multiforme compared to normal brain tissue. GBM, glioblastoma multiforme.
TABLE 2 | C1qA, C1qB, and C1qC expression in gliomas in the datasets used in
the current study with Oncomine.
Datasets C1q
chains
Brain vs. tumor P-value
Sun C1qA
C1qB
Brain (23) vs. Anaplastic astrocytoma (grade-III) (19)
Brain (23) vs. Glioblastoma multiforme (grade-IV)
(81)
Brain (23) vs. Anaplastic astrocytoma (grade-III) (19)








Brain (6) vs. Anaplastic oligoastrocytoma (grade-III)
(4)
Brain (6) vs. Anaplastic oligodendroglioma (grade-III)
(23)





TCGA C1qA Brain (10) vs. Glioblastoma multiforme (grade-IV)
(542)
1.63E-8
C1qB Brain (10) vs. Glioblastoma multiforme (grade-IV)
(542)
3.45E-4
Richman C1qB Temporal lobe (10) vs. Astrocytoma (different grade)
(45)
7.87E-4
Bredel 2 C1qC Brain (4) vs. Glioblastoma multiforme (grade-IV) (28) 5.23E-13
Liang C1qC Brain (2) vs. Glioblastoma multiforme (grade-IV) (30) 2.12E-4
n, samples number.
all WHO grade of gliomas, where the survival probability is
indeed reduced (P < 0.05) (Figure 3, lowest panels). A similar
unfavorable prognostic effect was detected in grade-III gliomas
(P <0.05) while no correlation was observed between C1qA,
C1qB, and C1qC mRNA expression and the survival probability
in gliomas grade-II (Figure 3). In contrast to UALCAN analysis,
a negative prognostic effect was underscored in GBMs (P < 0.05)
(Figure 3).
Low- and High-Grade Gliomas Abundantly
Express C1q Protein
We investigated the presence and the distribution of C1q in
several glioma samples of different grades. As shown in Figure 4,
a high expression level of C1q was observed both in LGGs as well
as GBM.
Within the tumor-associated microenvironment, C1q was
mainly expressed by monocytoid cells, suggestive of tumor
associated macrophages (arrow heads) scattered among the
neoplastic cells, which show an increased density around the
intra-tumoral necrotic foci (Figure 4C). Moreover, the presence
of C1q was detected in association with the vascular stroma;
in GBM, it was also expressed in the vascular endothelial
cells (Figures 4E,F). C1q deposition was not associated with
complement activation, occurring either via the classical or the
other pathways, since we failed to observe any C3d and C4d
immunoreactivity in our glioma’s specimens (Figure 5).
Infiltrating M2 Macrophages Are Likely
Source of C1q in Gliomas
To further characterize the cell type infiltrating the tumor
and actively involved in C1q synthesis, immunocytochemical
experiments were performed on gliomas specimens via staining
for C1q and CD68, a specific marker for monocyte/macrophage
cell types. A clear co-localization of C1q/CD68 immunoreactivity
was detected in both low- and high-grade gliomas (Figure 6),
thus identifying the macrophages infiltrating glioma tumor as the
main source of local C1q synthesis and secretion. Double labeling
experiments were also performed using an anti-CD163, a specific
marker for the tumor-promoting M2-polarized macrophages
(Figure 7). Under these conditions, it appeared that not only the
number of CD163 positive cells, but also the CD163 expression
level itself, were increased in high-grade gliomas as compared to
low-grade ones. Most of the C1q labeled cells colocalized with
CD163, even though a small fraction of infiltrating cells were
solely expressing C1q, suggesting that theymay correspond to the
CD68/C1q co-expressing M1-type of macrophages.
DISCUSSION
Glial tumors, also called gliomas, are the most prevalent form
of adult brain tumor, accounting for nearly 80% of all brain
malignancies (22). Based on their histological features and
expression of lineage markers, gliomas can be classified into
astrocytomas, oligodendrogliomas, ependymomas, and choroid
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FIGURE 2 | Pathological significance of C1q expression in gliomas. According to the UALCAN database analysis, C1qA, C1qB, and C1qC mRNAs expression were
negatively linked to a survival probability in patients with LGGs (grade-II and -III) (A), whereas no correlation in patients with GBM (grade-IV) (B). LGGs, low-grade
gliomas; GBM, glioblastoma multiforme.
plexus tumors (29). Astrocytomas, which represent almost half
of all primary brain and spinal cord tumors, may occur in the
brain with a preferential localization in the cerebrum and affect
mostly adults, particularly middle-aged men. In 2016, the WHO
has redefined this classification scheme by introducing molecular
parameters in addition to the well-established histopathological
features (20, 21). These new guidelines have allowed classification
of all pathological glial entities in four grades, according
to histological parameters including nuclear atypia, mitoses,
vascular proliferation, and necrosis. According to the grading
system, astrocytic neoplasm can be divided into low and
high-grade astrocytomas. Low-grade astrocytomas are the least
malignant tumors characterized by slow growth and good
prognosis being the pilocytic astrocytomas (grade-I) and diffuse
astrocytomas (grade-II), the most frequent types. High-grade
astrocytomas are glial tumors presenting a rapid growth with
a tendency to infiltrate nearby brain tissues. They are divided
into astrocytomas grade-III (anaplastic astrocytoma) and grade-
IV (glioblastoma multiforme, GBM). GBM is the most aggressive
and fast-growing malignancy characterized by poor clinical
outcome. It can arise in the brain de novo, or it can evolve from
lower-grade astrocytomas or oligodendrogliomas (29). Recent
studies have begun to address the immune signature of the
glioma microenvironment and its relationship with prognosis
(30). The fact that C1q can be locally synthesized within the
CNS and that it is involved in tumor immunology, we wanted
to interrogate its relevance in the pathogenesis and prognosis
of gliomas.
In the current study, we performed a bioinformatics analysis
to unveil whether C1q could serve as a potential prognostic
marker for these devastating malignancies. UALCAN queries of
the TCGA and the CGGA datasets were analyzed to validate
our initial result. It highlighted a significant correlation between
high expression level of the three chains of the C1q and
poor prognosis in gliomas of diverse grade of malignancy
(Figures 2, 3). In particular, while interrogating the CGGA
dataset, which allowed distinction between grade-II and grade-
III gliomas, a significant correlation was established only for
grade-III gliomas (Figure 3). In the TCGA dataset, significance
was achieved for the so-called LGGs, which combines grade-II
and -III cases (Figure 2). The main contradiction was noticed
in GBMs (grade-IV gliomas), where opposite prognostic effects
were underscored in relation to the dataset used (Figures 2, 3).
One possible explanation for these contradictory observations
may originate from the algorithm utilized by the bioinformatics
web resources to define high and low expression profile of
the genes. Another aspect to take into account is potential
differences in the genetic and epigenetic signatures characterizing
the two datasets, the TGCA mostly relying on Caucasian
patients while CGGA relying on Chinese cohorts. Indeed, it
has been proven that substantial variation in glioma incidence
and survival are connected, to some extent, to race and
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FIGURE 3 | Pathological significance of C1q expression in gliomas. According to the CGGA database analysis, C1qA, C1qB, and C1qC mRNAs expression were
negatively linked to a survival probability in patients with grade-III and GBM. H, high expression; L, low expression.
ethnicity (31). Finally, it is worth mentioning that GBM
exists in two forms, primary and secondary, indistinguishable
histologically, but clearly discernible clinically and in terms
of molecular signatures (29, 32). Primary GBM is the most
common form that occurs mainly in adults over 50 years of
age. The genetic profile is characterized by epidermal growth
factor receptor (EGFR) overexpression, phosphatase and tensin
homolog (PTEN) mutation, p16 deletion, and chromosome
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FIGURE 4 | Representative immunohistochemical analysis of C1q in low (A,B) and high grade (C,D) gliomas showing a high expression in both histotypes regardless
of grade. C1q results mainly expressed by macrophages and the vascular stroma (see arrows). C1q expression in the endothelial cells is shown in panels (E,F) (see
arrows, low, and high magnification). Polymer detection system with AEC (red) chromogen; scale bars, 50µm.
10 loss (32). Secondary GBM derives from a malignant
progression of diffuse or anaplastic astrocytomas (grade-II and -
III, respectively), and occurs in younger patients, characterized by
p53 mutation and a reduced state of heterozygosity in tumor cells
(loss of heterozygosity) on chromosome 10q (32). Both datasets
used in our bioinformatics analysis did not discriminate between
de novo and secondary GBM, possibly masking a significant
correlation, indeed expected, in those tumors progressing from
grade-III gliomas.
There is emerging evidence to confirm that C1q is involved
in cancer pathophysiology, being an important modulator of
inflammation and cytokine/chemokine/growth factor secretion.
What is still quite puzzling is whether and when C1q is
protective against or supportive of cancer progression. On
one hand, C1q can be detrimental to cancer cell viability via
its cell lytic, anaphylatoxin, and opsonin effector mechanisms
(33). Alternatively, C1q can exert tumor-promoting functions
which are independent of the classical pathway activation. As
observed for other types of cancers (10, 15), C1q deposition in
gliomas seems not to be correlated with complement activation
as we were unable to detect the complement split products
C3d and C4d in the cohort of tumor specimens tested (n =
5). It is worth noting that our conclusions are based on the
use of only five patients’ tissue samples that were subjected
to immunohistochemistry. This is in contrast to other cancers
such as renal and lung cancers, where C4d deposition has
been reported (34, 35). The mechanisms underlying such binary
features of C1q are likely to be shaped by the type of cancer
cells, nature and extent of infiltrating immune cells and their
ability to synthesize locally C1q (and/or other complement
components), and most crucially, the biochemical nature of the
tumor microenvironment.
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FIGURE 5 | Representative immunohistochemical analysis of C3d and C4d complement activation products in low grade (A,D) and high grade (B,E) gliomas. C3d
and C4d specific staining is segregated in the blood vessels, while the tumor tissues are negative. Liver staining (C,F) represents the antigen (tissue) control. Polymer
detection system with AEC (red) chromogen; scale bars, 50µm.
FIGURE 6 | Representative microphotographs of double immunofluorescence for C1q (green signal) and CD68 (red signal) in FFPE sections of low (A) and high (B)
grade gliomas confirming the macrophage nature of C1q expressing monocytoid elements. The cell nuclei were stained with DAPI; scale bars, 10µm.
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FIGURE 7 | Representative microphotographs of double immunofluorescence for C1q (red signal) and CD163 (green signal) in FFPE sections of low (A) and high (B)
grade gliomas confirming the M2-polarization of macrophages expressing C1q. The cell nuclei were stained with DAPI; scale bars, 10µm.
In the brain, complement components, including C1q,
can be locally produced by resident neurons and glial
cells, microglia and astrocytes being the major producers
(19, 36). Our immunocytochemical data demonstrated that
CD68 and CD163 positive infiltrating cells represent the
cell types actively synthesizing C1q in the tumor micro-
environment (Figures 6, 7). CD68 expression is characteristic
of tumor-associated macrophages, whose enrichment in
glioma has been associated with poor prognosis (37). CD163
identify the M2-polarized macrophages, which are highly
versatile cells known to influence multiple steps in tumor
development and invasiveness along with angiogenesis and
immunosuppression (38).
These cells in the brain are derived from two different
sources: resident microglia and monocytes/macrophages
that enter the brain from bone marrow. Even though it is
quite difficult to distinguish between these two different
cell types due to the lack of available definitive markers,
they are recruited by the tumor microenvironment via
several gliomas derived chemokines that also contribute to
their polarization from a tumor-suppressive to a tumor-
promoting phenotype (39). It is interesting to note that
C1q has been shown to enhance the secretion and action
of these chemokines (40, 41). Therefore, C1q produced and
released by microglia/macrophage cells, is expected to promote
immunosuppression, thus favoring glioma cell proliferation.
This is consistent with our observation linking the expression
of the three chains of human C1q with an unfavorable
prognosis in grade-II and -III gliomas (LGGs) in TCGA
dataset and in grade-III gliomas in CGGA dataset, respectively
(Figures 2, 3).
We also observed a high degree of deposition of C1q in the
perivascular stroma as well as on endothelial cells belonging to
the tumor vasculature. Developing gliomas require an increased
nutrient supply and hence trigger neovascularization via the
release of angiogenetic factors by cancer cells. C1q itself
promotes angiogenesis through its globular heads (7). Massive
angiogenesis is induced by regions of hypoxia within the tumor
that are not only loci generating damage-associated molecular
patterns (DAMPs), recognized by C1q but also privileged
sites for glioma stem-like cell (GSC) settlement (42). These
cells are quite dangerous since they maintain tumor growth
through self-renewal amidst a supportive microenvironment.
C1q, in this context, has been shown to participate in
GSC maintenance and expansion via the activation of the
canonical Wnt signaling cascade through its binding to
Frizzled-receptor (43).
Our bioinformatics study, based solely on mRNA expression
dataset and therefore further requiring a validation at the
protein level, underlines how complex, multifaceted and yet
feebly understood is the differential role of C1q in tumor
progression or suppression. In conclusion, C1q plays a
fundamental role in the pathogenesis of gliomas, but further
investigation is required for its use in the clinic as a
prognostic marker.
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